

Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Diseases

Authors:

Sepideh Louia

Islamic Azad University, Central Tehran Branch

Omid Fakharzadeh Moghadam

Mashhad University of Medical Sciences

Reza Judi Chelan

Yasuj University of Medical Sciences

Niloofar Taheri

Shahroud University of Medical Sciences

Fatemeh Amini

Sichuan University

Somayyeh Ahmadi

Mazandaran University of Medical Sciences

Oveis Ahmadzadeh

Kashan University of Medical Sciences

SeyedAshkan Mirzadeh Ahari

Zhengzhou University

Mohammad Eslami

Shahid Beheshti University of Medical Sciences

Saman Abdollahpour

Shahid Beheshti University of Medical Sciences

SEPIDEH LOUIA

Sanaz Amiri Marbini

University Medical Center Hamburg-Eppendorf

Atena Talebpoor Amirhandeh

Shahid Beheshti University of Medical Science

Amir Tahavvori

Northwell Health, The Feinstein Institutes for
Medical Research

Neda Gorjizadeh

Tehran University of Medical Sciences

ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNO...

SEPIDEH LOUIA

Book Details:

Publisher: Kindle

Publication Date: November 2025

Language: English

Dimensions: 5 x 0.39 x 8 inches

© Kindle and PreferPub 2025

ISBN-13: 979-8275085686

This peer-reviewed book is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specially the rights of translation, reprinting, result of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNO...

Contents

Chapter

1. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Renal Diseases
2. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Neurological Diseases
3. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Gastrointestinal Diseases
4. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Cardiac Diseases
5. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Dermatological Diseases
6. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Ophthalmological Diseases
7. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Oral Diseases
8. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of ENT Diseases
9. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Orthopedic Diseases
10. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Cancers
11. Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Other Diseases

1. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF RENAL DISEASES

Background

Renal diseases represent a major global health concern, affecting hundreds of millions of individuals across all age groups and contributing significantly to morbidity, mortality, and long term disability. These disorders comprise a wide spectrum of pathological conditions, ranging from acute kidney injury and glomerulonephritis to genetic cystic diseases, autoimmune conditions, and chronic kidney disease that progresses to end stage renal failure. Despite advances in diagnostic technologies and therapeutic approaches, the increasing prevalence of renal diseases underscores the need to expand understanding of their complex biological mechanisms. In recent decades, a substantial body of research has revealed that immune related genetic variations exert profound influence on susceptibility, progression, clinical manifestations, and treatment responses in many renal disorders. This perspective has ushered immunogenetics into a central position within nephrology research and clinical practice.

Immunogenetics is a field that investigates

how genetic variation within immune system pathways shapes individual immune responses and disease vulnerability. Its relevance to renal diseases arises from the essential role of the immune system in maintaining tissue integrity, responding to pathogens, regulating inflammation, and mediating tolerance to self antigens. The kidneys are uniquely sensitive to disturbances in immune system function because they are highly vascularized, constantly exposed to circulating immune cells and inflammatory mediators, and responsible for filtering immune complexes, cytokines, and metabolic byproducts. As a result, even subtle immune dysregulation can produce structural and functional damage to renal tissue. Genetic variants affecting innate immune pathways, antigen presentation, cytokine production, complement components, and regulatory T cell activity can therefore contribute directly to renal pathology.

Growing evidence demonstrates that the etiology of many renal diseases involves an interplay of environmental factors, infectious triggers, and hereditary genetic patterns that shape immune system behavior. Immunogenetic determinants influence how the kidney responds to injury, how immune cells interact with renal tissue, and how inflammation is controlled or perpetuated. Understanding these connections helps explain why some individuals develop renal failure after

minimal exposure to nephrotoxic agents, why certain populations show high prevalence of glomerular diseases, and why treatment responses differ widely among patients receiving standard therapies.

The significance of immunogenetics extends beyond theoretical interest, as it has become essential for advancing precision nephrology. Modern sequencing technologies, genome wide association studies, and molecular immunology have catalyzed remarkable progress in identifying genetic variants associated with renal disease risk. Moreover, insights from immunogenetics have guided the development of biomarkers used in diagnosis, helped refine disease classification schemes, and supported the creation of targeted biological therapies for conditions previously treated with broad immunosuppression. As nephrology moves toward individualized therapy, incorporating immunogenetic principles will be crucial in tailoring treatment to each patient's molecular and immunological profile.

The following sections explore the immunogenetic foundations of renal diseases, detailing their contributions to etiology, highlighting their growing role in early and precise diagnosis, and evaluating their influence on therapeutic strategies. These discussions underscore the importance of integrating immunogenetics into the contemporary study and

management of renal disorders.

Etiology of Renal Diseases from an Immunogenetic Perspective

The etiology of renal diseases is shaped by a complex interaction between genetic predisposition and immune system responses. Many renal pathologies develop as a result of inadequate control of inflammation, inappropriate activation of immune pathways, or a failure of tolerance mechanisms that normally prevent autoimmunity. Genetic variants influencing innate immunity, adaptive immunity, cytokine regulation, and complement activation can all contribute to renal injury.

Innate immune pathways play a critical role in the early defense against pathogens and in regulating inflammation. Toll like receptors represent one of the most studied groups of innate immune receptors involved in renal diseases. Variants in Toll like receptor genes have been associated with abnormal sensing of microbial or endogenous signals, resulting in excessive production of inflammatory cytokines. In the kidneys, persistent overactivation of these receptors contributes to tubular injury, interstitial fibrosis, and glomerular damage. Similar patterns have been observed for genes encoding inflammasome components, where certain variants lead to enhanced activation of caspase dependent pathways and promote

chronic renal inflammation.

The adaptive immune system also plays a significant role in the etiology of renal diseases. Genetic variation in HLA alleles influences susceptibility to many types of glomerulonephritis, particularly diseases mediated by autoantibodies or T cell driven inflammation. For example, specific HLA class II alleles are strongly associated with autoimmune kidney diseases such as IgA nephropathy, anti glomerular basement membrane disease, and lupus nephritis. These associations highlight the importance of antigen presentation in shaping immune responses that target renal tissues. When genetic variants modify how antigens are presented to T lymphocytes, they can create conditions that favor autoreactivity or insufficient immune tolerance.

The complement system represents another critical immunogenetic factor in renal disease etiology. Complement activation pathways support host defense but must be tightly regulated to prevent unintended tissue damage. Genetic mutations affecting complement components or regulatory proteins can lead to uncontrolled complement activation, causing severe renal damage. A well known example involves atypical hemolytic uremic syndrome, where mutations in complement factor H, complement factor I, or membrane cofactor protein result in excessive

complement activity that damages endothelial cells and leads to thrombotic microangiopathy. Similar mechanisms have been implicated in C3 glomerulopathy, where complement dysregulation produces chronic deposition of complement proteins in the glomeruli.

Immunogenetic contributions to renal diseases also extend to genes controlling cytokine production and signaling pathways. Variants in genes encoding interleukins, tumor necrosis factor, interferons, and chemokines influence the intensity and duration of inflammatory responses in the kidney. Individuals with high expression variants of pro inflammatory cytokines may develop more severe or persistent renal inflammation after infections or environmental exposures. Gene polymorphisms that reduce anti inflammatory cytokine production can further contribute to chronic renal injury and fibrosis.

Another important immunogenetic factor involves genes regulating T cell differentiation. Regulatory T cells are essential for maintaining immune tolerance and preventing autoimmunity. Variants affecting the function or development of regulatory T cells increase the risk of immune mediated renal diseases. For instance, mutations affecting the transcription factor FOXP3 disrupt regulatory T cell function and lead to early onset chronic kidney inflammation. Similarly, variants in genes involved in Th17 cell differentiation are

associated with glomerular diseases characterized by neutrophil recruitment and tissue destruction.

Ethnic and population level differences in renal disease prevalence also highlight the importance of immunogenetic variation. Populations with high frequencies of specific immune related variants, such as APOL1 risk alleles in individuals of African descent, experience significantly increased risk of focal segmental glomerulosclerosis and other severe renal disorders. These examples illustrate how evolutionary pressures and environmental exposures have shaped population specific immunogenetic patterns that contribute to renal disease risk.

Overall, the immunogenetic basis of renal disease etiology demonstrates the intricate relationships among genetic predisposition, immune system regulation, environmental triggers, and kidney pathology. A deeper understanding of these mechanisms is essential for identifying individuals at high risk and for developing strategies aimed at disease prevention.

Diagnosis and Classification of Renal Diseases through Immunogenetics

Diagnosis of renal diseases has traditionally relied on clinical evaluation, biochemical markers, and histopathological examination of renal tissue.

Although these methods remain essential for clinical assessment, they often fail to precisely differentiate disease subtypes or predict future progression. Immunogenetics has emerged as a powerful tool that complements traditional diagnostic approaches by providing insights into molecular pathways that drive renal pathology.

Immunogenetic biomarkers have significantly improved early detection of renal diseases, particularly those involving immune mediated injury. For example, characterization of HLA alleles associated with autoimmune kidney diseases allows clinicians to identify individuals at increased risk and to monitor early symptoms more closely. In IgA nephropathy, genetic variants related to mucosal immunity and complement activation have helped refine diagnostic algorithms. Similarly, the discovery of genetic risk factors in lupus nephritis has aided in stratifying patients according to expected disease severity and treatment responsiveness.

Modern high throughput sequencing technologies have made it possible to detect genetic variants involved in complement regulation, cytokine signaling, and innate immune pathways. These findings support early recognition of diseases that previously required invasive biopsy for definitive diagnosis. In complement mediated renal disorders, identification of mutations in complement genes helps distinguish between

diseases with similar clinical manifestations but distinct underlying mechanisms. This distinction is crucial because different mutations confer different prognostic outcomes and treatment strategies.

In addition to improving diagnostic accuracy, immunogenetics plays a major role in refining the classification of renal diseases. Traditional classifications relied heavily on morphological patterns observed in kidney biopsies. While histology remains important, it cannot fully capture the molecular heterogeneity of renal diseases. Immunogenetic profiling offers a more nuanced classification system based on genetic drivers of disease rather than solely on pathological appearance. This shift supports a framework in which two patients with similar histological patterns might receive different classifications based on distinct immunogenetic abnormalities.

For instance, membranous nephropathy has long been classified based on idiopathic or secondary causes. Recent discoveries of autoantibodies targeting specific renal podocyte antigens, along with associated genetic variants, have transformed the classification and management of this disease. Patients with different autoantibody profiles exhibit different immunogenetic signatures, clinical courses, and treatment responses. A similar transformation is

occurring in vasculitis research, where genetic studies have revealed distinct immunogenetic clusters that correlate with prognosis and risk of relapse.

Furthermore, immunogenetic signatures can support non invasive diagnostic methods. Molecular imaging techniques that incorporate immunogenetic information are being developed to identify renal inflammation and immune involvement without the need for biopsy. This approach combines imaging modalities with molecular probes that target genetic or immune related markers, enabling visualization of immune cell infiltration or complement activation in renal tissue.

In summary, immunogenetics strengthens renal disease diagnosis and classification by providing molecular insight into disease mechanisms, improving risk prediction, enabling personalized classification frameworks, and complementing traditional diagnostic tools.

Treatment of Renal Diseases through Immunogenetic Insights

Advances in immunogenetics have significantly influenced the development of new therapies and improved the selection of appropriate treatments for renal diseases. Historically, many immune mediated renal disorders were treated with broad immunosuppression, which often

produced significant side effects and variable efficacy. Immunogenetics has enabled a shift toward precision therapy by identifying specific molecular targets that drive disease in individual patients.

Biological therapies that target cytokines, immune receptors, or complement components represent a major breakthrough in renal disease treatment. In complement mediated disorders, such as atypical hemolytic uremic syndrome and C3 glomerulopathy, the use of monoclonal antibodies that inhibit complement activation has dramatically improved patient outcomes. These treatments were developed based on immunogenetic evidence demonstrating that complement dysregulation is central to the pathogenesis of these diseases. Genetic testing also helps determine which patients are likely to benefit from complement inhibitors and which individuals require additional therapies.

Autoimmune renal diseases such as lupus nephritis have benefitted from therapies derived from immunogenetic research. Biological agents targeting B cell activation, T cell costimulation, and specific pro inflammatory cytokines have been introduced for patients identified as having genetic profiles associated with heightened immune activation. Immunogenetic biomarkers support the selection of biological agents that best correspond to a patient's molecular disease

subtype, improving therapeutic outcomes and reducing unnecessary immunosuppression.

Kidney transplantation also illustrates the profound importance of immunogenetics in renal disease treatment. HLA matching between donor and recipient is essential for minimizing immune rejection and improving graft survival. Advances in high resolution HLA typing have improved transplant outcomes by reducing mismatches that cannot be detected through traditional methods. Genetic variants impacting alloreactive immune responses, complement activation, and antibody formation are being integrated into transplant evaluation to predict the risk of acute and chronic rejection.

In addition, immunogenetics informs the development of therapies that aim to promote immune tolerance following transplantation. Understanding the genetic determinants of regulatory T cell function supports strategies designed to induce long term immune tolerance, thereby reducing the need for lifelong immunosuppressive therapy. These strategies include cellular therapies, peptide based immunomodulation, and the exploration of genetic factors that favor tolerance induction.

Future treatment strategies for renal diseases are likely to incorporate individualized immunogenetic profiles into therapeutic decision making. Personalized nephrology will involve

selecting drugs based on the patient's genetic variants, immune signatures, and predicted treatment response. This approach not only improves efficacy but also reduces the risk of drug toxicity, which remains a major challenge in renal disease management.

Conclusion

Immunogenetics has transformed the understanding, diagnosis, and treatment of renal diseases by providing a detailed view of how genetic variation shapes immune responses within the kidney. The kidneys are highly sensitive to disturbances in immune balance, and genetic variants affecting innate, adaptive, and complement pathways can significantly influence disease susceptibility. Immunogenetics enhances diagnostic accuracy by identifying biomarkers that support early detection, improving disease classification through molecular profiling, and reducing uncertainty in clinical decision making. In therapy, immunogenetics contributes to the development of targeted treatments, guides transplant compatibility assessment, and supports personalized approaches to patient care.

As nephrology continues to advance, the integration of immunogenetics into clinical practice will be essential for improving patient outcomes. The growing availability of sequencing technologies, bioinformatics tools,

SEPIDEH LOUIA

and immunological assays offers the potential for even greater progress in the near future. Bridging the gap between molecular research and clinical application requires collaboration across genetics, immunology, nephrology, and computational sciences. Through this collaboration, immunogenetics will continue to shape the future of renal medicine and contribute to more precise, effective, and individualized patient care.

ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNO...

2. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF NEUROLOGICAL DISEASES

Background

Neurological diseases represent some of the most complex conditions in modern medicine, affecting the central and peripheral nervous systems and leading to diverse clinical manifestations ranging from cognitive impairment and seizures to motor dysfunction, sensory disturbances, and neuropsychiatric symptoms. These disorders, which include neurodegenerative diseases, autoimmune neurological syndromes, neuroinflammatory disorders, neuromuscular diseases, and congenital neuroimmune conditions, contribute substantially to global morbidity, disability, and health care costs. The increasing burden of neurological diseases, combined with the limited availability of disease modifying treatments for many of these conditions, has heightened interest in uncovering their underlying biological mechanisms. Among the factors receiving growing attention, the role of immunogenetics has emerged as both influential and indispensable.

Immunogenetics refers to the study of genetic

variation that influences immune system development, function, and regulation. Its significance in neurological diseases arises from the central role the immune system plays in maintaining neural integrity, responding to infections, clearing toxic proteins, regulating inflammation, and preserving tolerance to self antigens expressed by neural tissues. The brain, once viewed as an immune privileged organ, is now understood to maintain robust communication with the immune system through microglia, astrocytes, complement proteins, cytokine signaling, meningeal lymphatics, and peripheral immune cells. As a result, genetic alterations in immune pathways can profoundly affect neural health and contribute to neurological disease development.

The etiology of many neurological disorders cannot be explained solely by environmental factors or neuronal pathology. A large body of research shows that genetic variation affecting immune pathways plays a central role in susceptibility to and progression of conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, autism spectrum disorders, myasthenia gravis, neuromyelitis optica, and many forms of peripheral neuropathy. Immunogenetic determinants shape how the nervous system responds to infection and injury, how immune tolerance is maintained, and

how neuroinflammatory responses are regulated. Dysregulation of immune signaling due to genetic variants can lead to chronic inflammation, autoimmunity, impaired protein clearance, and neurodegeneration.

Advances in whole genome sequencing, genome wide association studies, functional genomics, and single cell profiling have accelerated the identification of genes involved in neuroimmune interactions. These discoveries have transformed scientific understanding of neurological diseases and have provided crucial insight into molecular pathways that may serve as therapeutic targets. At the same time, improvements in immunogenetic analysis have strengthened diagnostic accuracy and made it possible to identify disease subtypes that require distinct treatment strategies.

This chapter explores the role of immunogenetics in the etiology, diagnosis, and treatment of neurological diseases. It highlights the mechanisms through which immune related genetic variation contributes to neural pathology and examines how these insights are reshaping modern neurology. Integrating immunogenetics into the study of neurological disorders is essential for understanding disease onset, predicting outcomes, improving diagnosis, and guiding individualized therapy.

Etiology of Neurological Diseases

from an Immunogenetic Perspective

The etiology of neurological diseases reflects a highly complex interplay between neural vulnerabilities, environmental triggers, and immune system behavior shaped by genetic predisposition. Neurological tissues are sensitive to immune mediated injury because immune signaling is closely integrated with neuronal survival, synaptic pruning, central nervous system development, and the clearance of metabolic waste products. Genetic variants that influence innate immunity, adaptive immunity, cytokine production, microglial reactivity, and complement activation can predispose individuals to neuroinflammation and neurodegeneration.

Innate immunity plays a central role in neurological disease etiology. Microglia, the resident immune cells of the central nervous system, rely on pattern recognition receptors to detect pathogens, tissue damage, or abnormal proteins. Genetic variations in these receptors can alter microglial activation and inflammatory responses. Studies have shown that variants in genes such as TREM2, which regulates microglial phagocytosis, significantly increase the risk of Alzheimer's disease by impairing the clearance of amyloid beta and other toxic proteins. Similarly, polymorphisms in Toll like receptors can amplify neuroinflammatory responses, contributing to increased susceptibility to infectious encephalitis,

epilepsy following infection, and autoimmune neurological diseases.

Complement system genes also play a critical role in immune mediated synaptic pruning and in maintaining central nervous system homeostasis. Genetic variants that lead to overactivation of the complement cascade have been linked to schizophrenia, atypical neurodevelopment, and neurodegenerative diseases. Excessive complement activity during development may result in aberrant elimination of synapses, potentially contributing to cognitive and behavioral abnormalities. In contrast, insufficient complement activity can reduce the clearance of neural debris, promoting chronic inflammation and tissue damage.

Adaptive immunity is another key contributor to neurological disease etiology. Variants in HLA genes strongly influence susceptibility to autoimmune neurological disorders. The association between specific HLA class II alleles and multiple sclerosis represents one of the strongest genetic links identified in human autoimmune disease. These alleles shape antigen presentation to T cells, influencing whether self antigens from neural tissues trigger inappropriate immune responses. Similar HLA associations exist for myasthenia gravis, autoimmune encephalitis, neuromyelitis optica spectrum disorders, and Guillain Barre syndrome. In these conditions,

genetic predisposition leads to the production of pathogenic autoantibodies or autoreactive T cells that target components of the neuromuscular junction, myelin, or neuronal receptors.

Cytokine related genetic variations also contribute to neurological disease susceptibility. Polymorphisms in genes encoding interleukins, interferons, and other cytokines regulate the intensity and duration of inflammation in the nervous system. For example, variants in the IL 1 gene cluster have been linked to increased risk of temporal lobe epilepsy, while polymorphisms affecting interferon signaling influence susceptibility to inflammatory demyelinating diseases. In neurodegenerative diseases, elevated levels of pro inflammatory cytokines driven by genetic predisposition can accelerate neuronal injury and protein aggregation.

Genetic control of T cell differentiation further shapes neurological disease vulnerability. Variants affecting regulatory T cell development can reduce immune tolerance to neural antigens, while variants influencing Th17 cell activity promote inflammatory responses that damage the central nervous system. These mechanisms contribute to disorders such as multiple sclerosis, neurosarcoidosis, and autoimmune encephalitis.

Increasing evidence also suggests that immunogenetic variation affects the gut brain axis. Because gut microbiota influence systemic

immune responses, genetic variation in immune related pathways can shape microbiome composition, which in turn affects central nervous system inflammation. This relationship has been implicated in autism spectrum disorders, Parkinson's disease, and multiple sclerosis, indicating that immunogenetic variation may influence neurological health through multiple physiological systems.

Population studies reveal significant ethnic variation in immunogenetic susceptibility to neurological diseases. For example, specific HLA patterns associated with neuromyelitis optica are more common in East Asian and Latin American populations, while genetic variants associated with multiple sclerosis risk are most prevalent among northern Europeans. These differences illustrate how evolutionary pressures have shaped immune genetics in ways that influence neurological disease epidemiology.

Overall, immunogenetics provides critical insight into the etiology of neurological diseases by revealing how genetically mediated immune responses can drive or escalate neural pathology. These discoveries enable the identification of individuals at high risk and support development of strategies aimed at disease prevention or early intervention.

Diagnosis and Classification

of Neurological Diseases through Immunogenetics

Traditional diagnostic approaches in neurology rely on clinical evaluation, imaging, electrophysiology, and laboratory tests. While these tools remain essential, many neurological diseases exhibit overlapping symptoms or prolonged diagnostic uncertainty. Immunogenetics has expanded diagnostic capabilities by providing molecular information that improves accuracy, clarifies disease mechanisms, and supports precise classification.

Immunogenetic biomarkers have become increasingly important for diagnosing autoimmune and inflammatory neurological diseases. Identification of genetic variants associated with HLA alleles, immune receptors, and cytokine pathways helps clinicians assess risk and interpret ambiguous clinical findings. For example, detection of specific HLA alleles can strengthen the diagnosis of multiple sclerosis in patients with atypical presentations. In myasthenia gravis, certain genetic patterns correlate with specific autoantibody subtypes, helping to define distinct clinical forms of the disease.

Advances in genetic analysis have supported the discovery of antibodies directed against neuronal receptors, intracellular proteins, and synaptic components. Although antibodies themselves are

not genetic markers, immunogenetic studies have helped identify genetic predispositions that favor their development. Disorders such as anti NMDA receptor encephalitis, anti LGI1 encephalitis, and anti MOG associated disease have been classified based on these immune biomarkers, improving diagnostic clarity and guiding treatment.

Complement mediated neurological diseases also benefit from immunogenetic diagnosis. Identification of mutations in complement regulatory genes supports diagnosis of rare conditions such as recurrent Guillain Barre syndrome or complement mediated neuropathies. These discoveries make it possible to distinguish between immune mediated neuropathies that appear clinically similar but require distinct treatment strategies.

Immunogenetics has also transformed the classification of neurodegenerative diseases. Variants in genes such as TREM2, CD33, and CR1 reveal the importance of immune pathways in the pathogenesis of Alzheimer's disease. These genetic markers help define subtypes of neurodegenerative conditions with differing prognoses. Similar immunogenetic signatures are emerging in Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis, reshaping traditional diagnostic categories.

In addition, immunogenetic advances support the development of non invasive diagnostic

technologies. Molecular imaging techniques that integrate immunogenetic information enable visualization of neuroinflammation and immune cell activity in vivo. Imaging of complement activation, microglial activation, or cytokine expression strengthens diagnostic accuracy and helps monitor disease progression.

By integrating immunogenetic markers with clinical, imaging, and biochemical data, clinicians can achieve earlier and more precise diagnoses, enabling timely intervention and improving prognostic assessment.

Treatment of Neurological Diseases through Immunogenetic Insights

Immunogenetics has profoundly influenced treatment strategies for neurological diseases by enabling the development of targeted therapies and personalized medicine approaches. In disorders driven by abnormal immune responses, immunogenetic understanding guides the selection of therapies that modulate specific molecular pathways rather than relying on broad immunosuppression.

One of the major successes of immunogenetic research is the introduction of targeted biological therapies in multiple sclerosis. Monoclonal antibodies that block specific immune receptors, inhibit lymphocyte trafficking, or modulate cytokine signaling have transformed disease

management. Genetic profiling helps predict which patients will respond favorably to particular agents and identify those at increased risk for adverse effects. In neuromyelitis optica spectrum disorders, therapies targeting interleukin 6 signaling were developed based on immunogenetic evidence showing that this cytokine plays a central role in disease pathogenesis.

Autoimmune encephalitis is another field transformed by immunogenetic discoveries. Identification of autoantibodies targeting neuronal receptors has guided the development of immunotherapies tailored to specific molecular targets. Patients with anti NMDA receptor encephalitis respond best to early immunomodulatory therapy, while those with anti LGI1 encephalitis require different treatment strategies. Immunogenetics helps predict disease severity, risk of relapse, and therapeutic response.

Neurodegenerative diseases also benefit from immunogenetic insights. In Alzheimer's disease, genetic variants affecting microglial activation and complement signaling serve as targets for emerging therapies designed to modulate neuroinflammation or enhance clearance of beta amyloid. Similar mechanisms guide therapeutic development in Parkinson's disease, where genetic variants associated with inflammation shape disease progression.

Neuromuscular disorders such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy benefit from therapies that target specific immune pathways. For example, complement inhibitors have been introduced for the treatment of certain forms of myasthenia gravis, based on immunogenetic evidence linking complement activation to neuromuscular junction injury. In Guillain Barre syndrome, research on immunogenetic susceptibility supports the design of future therapies aimed at modulating innate immune activation.

Infection triggered neurological diseases, such as post infectious encephalitis or immune mediated peripheral neuropathies, are also influenced by immunogenetics. Genetic variants regulating immune responses to infection shape susceptibility and severity, guiding treatment decisions such as the use of antiviral therapy combined with immunomodulation.

Drug response in neurology is highly variable, and immunogenetics helps predict which patients will benefit from specific therapies. For instance, certain HLA alleles predict severe hypersensitivity reactions to anticonvulsants, allowing clinicians to avoid dangerous medications and choose safer alternatives. By integrating immunogenetic information, treatment becomes more effective, safer, and more personalized.

Looking forward, immunogenetics is expected to

support novel therapeutic approaches including individualized vaccines for autoimmune neurological diseases, gene editing to correct immune dysregulation, and cell based therapies that restore immune tolerance or enhance neuronal survival. These opportunities highlight the transformative potential of immunogenetics in shaping future neurological treatments.

Conclusion

Immunogenetics has become a fundamental component of modern neuroscience, offering critical insight into the mechanisms underlying neurological diseases and transforming approaches to diagnosis and treatment. Genetic variation affecting innate and adaptive immune pathways plays an essential role in disease susceptibility, severity, and progression. By integrating immunogenetic findings into diagnostic processes, clinicians achieve earlier and more accurate identification of disease subtypes, improving prognostic predictions and guiding individualized therapeutic strategies.

In treatment, immunogenetics supports the development of targeted therapies that address the specific immune mechanisms driving neurological diseases. This shift from broad immunosuppression to precision medicine improves outcomes, reduces side effects, and opens the possibility of modifying or preventing

disease progression. As research advances, immunogenetics will continue to shape the future of neurology by enabling personalized prediction, prevention, and treatment of neurological disorders.

3. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF GASTROINTESTINAL DISEASES

Background

Gastrointestinal diseases encompass a wide range of disorders affecting the stomach, intestines, esophagus, pancreas, biliary system, and liver. These conditions vary from inflammatory and autoimmune diseases to infectious, functional, metabolic, and neoplastic disorders. Globally, gastrointestinal diseases represent one of the most significant contributors to morbidity, mortality, and health care burden. Their impact is far reaching, influencing nutrition, immunity, quality of life, and systemic health. While environmental triggers such as diet, pathogens, medications, and lifestyle factors play important roles, growing evidence indicates that the immune system and genetic predisposition are central to understanding the origins and progression of many gastrointestinal diseases.

The gastrointestinal system is uniquely positioned as a major interface between the external environment and the internal milieu. It is exposed to an immense array of antigens, including food components, commensal and pathogenic

microbes, and environmental toxins. Maintaining homeostasis in this complex environment requires tightly controlled interactions between the mucosal immune system, epithelial barrier, and microbial communities. Immunogenetics, the study of how genetic variation shapes immune responses, provides essential insights into why some individuals experience normal immune tolerance while others develop chronic inflammation, autoimmunity, or malignant transformation in the digestive tract.

Advances in molecular immunology, genomics, and bioinformatics have revealed that many gastrointestinal diseases result from the interplay between immune pathways and inherited genetic factors. These genetic variants affect antigen presentation, cytokine production, epithelial barrier function, innate immunity, response to microbial stimuli, and regulation of inflammation. Disruption of these processes can lead to chronic inflammatory conditions, such as inflammatory bowel disease, celiac disease, autoimmune hepatitis, primary biliary cholangitis, and eosinophilic gastrointestinal disorders. Furthermore, immunogenetic insights are crucial for understanding gastrointestinal cancers, viral hepatitis, pancreatitis, and metabolic liver diseases, where immune dysregulation contributes to pathogenesis and influences disease progression.

Modern research has shown that genetic susceptibility influences disease phenotype, progression, and response to treatment. Immunogenetics has also revolutionized diagnostic approaches by enabling the identification of biomarkers and the development of personalized medicine strategies. Through genome wide association studies, next generation sequencing, single cell transcriptomics, and microbiome analysis, researchers are uncovering specific genetic variants that determine how individuals respond to intestinal microbes, nutritional factors, and environmental stressors. This has revealed new therapeutic targets and supported the creation of precise biologic therapies for gastrointestinal diseases.

The role of immunogenetics is expanding rapidly as researchers continue to unravel the complex mechanisms underlying gastrointestinal pathology. Understanding these mechanisms will be essential for designing personalized treatment, improving early diagnosis, reducing disease burden, and preventing complications. This chapter examines how immunogenetics contributes to the etiology, diagnosis, and treatment of gastrointestinal diseases and highlights its emerging significance within modern gastroenterology.

Etiology of Gastrointestinal

Diseases from an Immunogenetic Perspective

The etiology of gastrointestinal diseases is multifactorial, involving intricate interactions among genetic predisposition, mucosal immune responses, intestinal microbial communities, and environmental factors. Immunogenetic variation plays a fundamental role in determining susceptibility to gastrointestinal diseases by influencing how the immune system perceives and responds to luminal antigens. These interactions determine whether the gut maintains immune tolerance or progresses toward chronic inflammation and tissue injury.

One of the most thoroughly studied conditions demonstrating immunogenetic influence is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Genome wide association studies have identified hundreds of genetic loci associated with inflammatory bowel disease. Many of these loci affect immune pathways, including innate immune receptors, autophagy genes, epithelial barrier proteins, cytokines, and transcription factors controlling T cell differentiation. For example, mutations in NOD2, an intracellular pattern recognition receptor, lead to impaired recognition of bacterial components and altered microbial responses. Variants in autophagy related genes influence bacterial clearance and epithelial cell function,

predisposing individuals to chronic intestinal inflammation. Polymorphisms in interleukin related genes result in increased production of pro inflammatory cytokines, further contributing to mucosal damage.

Celiac disease also provides a clear example of immunogenetic etiology. It is strongly associated with specific HLA class II genotypes that determine susceptibility to gluten related autoimmunity. Particular genetic variants allow gluten peptides to be presented more effectively to T lymphocytes, triggering an inflammatory cascade that damages the small intestinal mucosa. Additional genetic variants influence epithelial permeability and immune tolerance, contributing to disease onset and clinical variability.

Autoimmune liver diseases such as primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis also exhibit strong immunogenetic associations. Variants in HLA genes play a central role, suggesting that altered antigen presentation contributes to loss of immune tolerance to hepatobiliary tissues. Other variants affecting cytokine pathways, T cell activation, and innate immune signaling further enhance susceptibility to hepatic inflammation. Dysregulation of these pathways can lead to chronic liver injury, fibrosis, cirrhosis, and, in some cases, progression to cholangiocarcinoma or hepatocellular carcinoma.

Immunogenetic factors also contribute to gastrointestinal infectious diseases. Variants affecting innate immunity can influence susceptibility to *Helicobacter pylori* infection, which is linked to gastritis, peptic ulcer disease, and gastric cancer. Certain genetic polymorphisms regulate how the immune system responds to viral hepatitis, influencing the risk of chronic infection, cirrhosis, and hepatocellular carcinoma. Similarly, genetic predisposition influences susceptibility to infections caused by *Clostridioides difficile* and other enteric pathogens.

Genetic factors affecting cytokines and immune receptors play a vital role in pancreatitis, where immunogenetic predisposition may determine severity and risk of progression to chronic disease. Variants influencing the inflammatory response contribute to sustained injury of pancreatic tissue and may promote fibrosis.

The gut microbiome represents another route through which immunogenetics influences gastrointestinal disease etiology. Genetic variants regulate immune responses to microbial antigens and shape microbiome composition. Dysbiosis, resulting from altered host genetics, can promote inflammation and has been implicated in conditions such as inflammatory bowel disease, colorectal cancer, irritable bowel syndrome, and nonalcoholic fatty liver disease. Immunogenetic

variation also affects the integrity of epithelial barriers, influencing susceptibility to microbial translocation and systemic inflammation.

Ethnic and population level differences underscore the influence of immunogenetics on disease prevalence. For example, specific genetic risk alleles for Crohn's disease are more common in European populations, while genetic variants associated with ulcerative colitis are distributed more globally. Variations in immune related genes also contribute to differences in gastric cancer incidence across populations, reflecting interactions between genetics, microbial exposures, and environmental factors.

In summary, immunogenetics plays an essential role in the etiology of gastrointestinal diseases by influencing immune responses to luminal contents, regulating interactions with the microbiome, and affecting tolerance mechanisms. Understanding these genetic factors is vital for identifying at risk individuals and developing targeted prevention strategies.

Diagnosis and Classification of Gastrointestinal Diseases through Immunogenetics

The integration of immunogenetic information into diagnostic practice has transformed the evaluation and classification of gastrointestinal diseases. Traditional diagnostic

approaches, including endoscopy, imaging, and histopathology, remain fundamental. However, these methods often lack the ability to fully distinguish disease subtypes or predict outcomes. Immunogenetic markers provide valuable molecular insight that enhances diagnostic precision.

In inflammatory bowel disease, genetic testing supports differential diagnosis by identifying variants associated with Crohn's disease or ulcerative colitis. Although genetics alone cannot provide a definitive diagnosis, immunogenetic markers improve diagnostic confidence, especially in early or atypical cases. Identification of immune related biomarkers helps stratify patients according to disease severity, risk of complications, and likely treatment response.

Celiac disease diagnosis benefits significantly from immunogenetics. HLA genotyping is a powerful tool for excluding the disease because the absence of specific HLA risk alleles makes celiac disease highly unlikely. This approach reduces unnecessary biopsies and clarifies diagnosis in ambiguous clinical scenarios. Immunogenetic markers also help identify individuals at risk before clinical symptoms appear, supporting early intervention and improved outcomes.

Autoimmune liver diseases are also influenced by immunogenetic diagnostic tools. HLA association

studies have allowed clinicians to identify patients who are genetically predisposed to autoimmune hepatitis or primary biliary cholangitis. These markers support early diagnosis and help distinguish autoimmune liver disease from other forms of hepatic injury. Complementing traditional serological markers, immunogenetic information contributes to a more comprehensive picture of disease mechanisms.

In gastrointestinal oncology, immunogenetics helps classify tumors according to molecular features that predict prognosis and guide treatment selection. For example, colorectal cancers with microsatellite instability reflect defects in DNA mismatch repair pathways and are associated with specific immunogenetic signatures. These tumors exhibit a distinct immune microenvironment and respond differently to immunotherapy. Genetic testing also supports risk assessment for hereditary gastrointestinal cancers, such as those associated with inherited syndromes, which often involve immunogenetic pathways affecting inflammation and tumor surveillance.

In infectious gastrointestinal diseases, genetic markers influence diagnosis by identifying susceptibility patterns. For instance, polymorphisms affecting the immune response to viral hepatitis help predict which patients are likely to develop chronic infection. Tests

for these genetic markers complement viral load measurements and serology in determining disease stage and treatment strategies.

Noninvasive diagnostic technologies integrating immunogenetic data are emerging rapidly. Molecular imaging techniques that incorporate information on immune pathways are helping to identify inflammation and tissue damage without reliance on invasive biopsy. These methods combine antibody based imaging, RNA profiling, and genetic sequencing to detect immune activity in gastrointestinal tissues.

Overall, immunogenetics strengthens diagnostic accuracy, supports early intervention, guides disease classification, and enhances predictive value for gastrointestinal diseases. Its integration into clinical workflows represents a major advancement in gastroenterology.

Treatment of Gastrointestinal Diseases through Immunogenetic Insights

Immunogenetics has significantly influenced therapeutic strategies for gastrointestinal diseases by enabling the development of targeted therapies and personalized medicine. Traditional treatments often relied on broad immunosuppression or symptomatic management. In contrast, modern approaches focus on specific molecular pathways, immune

targets, and individualized treatment plans guided by genetic and immunologic profiles.

In inflammatory bowel disease, immunogenetic insights support the use of biologics that target cytokines, immune receptors, and signaling pathways. Tumor necrosis factor inhibitors, interleukin blockers, and agents targeting lymphocyte trafficking have transformed disease management. Genetic testing helps identify patients likely to respond to particular therapies, reducing the trial and error approach that characterized earlier treatment strategies. Identification of genetic variants associated with primary nonresponse or rapid loss of response informs treatment selection and adjustment.

Celiac disease treatment remains primarily dietary, yet immunogenetics is informing the development of new therapies aimed at restoring immune tolerance to gluten. Experimental therapies include peptide vaccines, enzyme based treatments, and modulators of antigen presentation. These novel approaches depend on understanding the immunogenetic mechanisms responsible for the disease.

Autoimmune liver diseases benefit from immunogenetically informed therapies that target immune pathways involved in hepatic inflammation. Agents modulating B cell activity, T cell signaling, and cytokine production are being explored to supplement or replace corticosteroids

and traditional immunosuppressants. Genetic markers also help predict which patients will respond favorably to specific immunotherapies and which individuals are at high risk for treatment failure.

In gastrointestinal oncology, immunotherapies represent one of the most significant advances of the past decade. The efficacy of immune checkpoint inhibitors in treating colorectal cancer depends heavily on immunogenetic factors. Tumors with high microsatellite instability and robust immune infiltration respond more favorably to these agents. Genetic profiling supports treatment planning by identifying patients who will benefit from immunotherapy. Similar approaches are being explored for gastric cancer, hepatocellular carcinoma, and pancreatic cancer.

Immunogenetics also informs treatment of viral hepatitis, where genetic variants affect response to antiviral therapy. For example, certain host genetic markers predict the likelihood of achieving sustained virologic response in hepatitis C, guiding treatment decisions and optimizing outcomes.

In pancreatitis, understanding immunogenetic predisposition may support the development of targeted therapies aimed at reducing inflammation, preventing fibrosis, and preserving pancreatic function. This remains an active area of

research with promising potential.

Additionally, immunogenetics contributes to personalized nutrition and microbiome targeted therapies. Individuals with genetic variants predisposing them to dysbiosis or impaired mucosal immunity may benefit from specific probiotics, prebiotics, or dietary interventions tailored to their immunogenetic profile. Approaches that restore microbial balance and immune homeostasis hold promise for inflammatory bowel disease, irritable bowel syndrome, nonalcoholic fatty liver disease, and colorectal cancer prevention.

As research progresses, emerging therapies include individualized vaccines for autoimmune gastrointestinal diseases, cell based therapies to restore immune tolerance, and gene editing strategies that target immune dysregulation. These innovative treatments hold potential for transforming the future of gastrointestinal medicine.

Conclusion

Immunogenetics plays a central role in understanding the etiology, diagnosis, and treatment of gastrointestinal diseases. Genetic variants that influence immune pathways contribute to disease susceptibility, clinical variability, and progression. Incorporating immunogenetics into diagnostic practice

enhances accuracy, supports early intervention, and improves disease classification. In treatment, immunogenetics enables precision medicine by guiding the selection of targeted therapies, predicting treatment response, and informing individualized care plans.

As the field continues to advance, collaboration among immunologists, geneticists, gastroenterologists, bioinformaticians, and clinicians will be essential for translating immunogenetic discoveries into clinical practice. The integration of immunogenetics into gastroenterology promises to improve outcomes, reduce disease burden, and usher in a new era of personalized digestive health care.

4. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF CARDIAC DISEASES

Background

Cardiac diseases remain one of the leading causes of morbidity and mortality worldwide, representing an enormous burden on public health systems and societies. These conditions encompass a broad range of disorders that affect cardiac structure, function, electrophysiology, and vascular physiology. They include coronary artery disease, myocarditis, cardiomyopathies, valvular disorders, arrhythmias, congenital heart disease, autoimmune mediated cardiac injury, and heart failure. Although traditional risk factors such as age, sex, hypertension, dyslipidemia, obesity, diabetes, and lifestyle behaviors remain important drivers of cardiovascular disease, a growing body of evidence has highlighted the essential role of the immune system and genetic predisposition in shaping disease susceptibility, progression, and clinical outcomes.

The heart, once considered an immune privileged organ, is now recognized as a dynamic immunological environment that constantly interacts with immune cells, inflammatory mediators, and circulating

signals. The cardiac microenvironment contains resident macrophages, dendritic cells, fibroblasts, endothelial cells, and cardiomyocytes that respond actively to injury, infection, and metabolic stress. Immune pathways are involved not only in defense against pathogens but also in tissue repair, homeostasis, and regulation of cardiac remodeling. When these pathways become dysregulated, they can contribute to myocardial inflammation, fibrosis, electrical abnormalities, and impaired contractile function.

Immunogenetics, the study of genetic variation that influences immune responses, has become a central component of modern cardiovascular research. It examines how inherited differences in genes involved in innate immunity, adaptive immunity, antigen presentation, cytokine production, complement activation, and immune tolerance shape cardiac health. These genetic variations can influence susceptibility to autoimmune myocarditis, viral myocarditis, atherosclerosis, cardiomyopathies, transplant rejection, and many forms of heart failure. Immunogenetics also explains why patients with similar environmental exposures or risk profiles often exhibit markedly different clinical outcomes. Furthermore, immunogenetic insights are crucial for understanding the mechanisms that determine responsiveness to vaccines, antiviral therapies, biological treatments, and

immunomodulatory agents used in cardiac care.

With the development of genome wide association studies, next generation sequencing, single cell RNA sequencing, multiomic profiling, and advanced computational tools, researchers have been able to uncover molecular pathways linking specific genetic variants with immune mediated cardiac injury. These discoveries have opened new avenues for precision diagnosis and targeted treatment. They have also challenged existing classifications of cardiac diseases and emphasized the importance of viewing cardiac pathology through an integrated immuno genetic lens.

This chapter explores the role of immunogenetics in the etiology, diagnosis, and treatment of cardiac diseases. It examines how immune related genetic variations contribute to cardiac pathology, how these discoveries have improved diagnostic accuracy and risk stratification, and how they are shaping new therapeutic strategies. Understanding these relationships is crucial for advancing personalized cardiology and improving patient outcomes.

Etiology of Cardiac Diseases from an Immunogenetic Perspective

Cardiac diseases arise through complex interactions between genetic predisposition, immune function, environmental exposures, and

physiological stress. Immunogenetic variation plays a significant role in determining how the immune system responds to pathogens, tissue injury, metabolic stress, and inflammatory signals that affect the heart. In many cases, these genetic variations contribute to disease onset, severity, and progression.

Innate immunity represents the first line of defense against pathogens and tissue damage. Genetic variants affecting innate immune receptors can significantly influence cardiac disease susceptibility. Toll like receptors are particularly important in the detection of viral and bacterial components. Variants in Toll like receptor genes can alter the inflammatory response to viral infections, contributing to the development of viral myocarditis. In some individuals, excessive activation of these receptors promotes chronic myocardial inflammation, fibrosis, and progression to dilated cardiomyopathy. Similar mechanisms apply to receptors involved in inflammasome activation. Genetic variation affecting inflammasome components can lead to heightened inflammatory responses that damage cardiomyocytes and contribute to heart failure.

Adaptive immunity also plays a major role in the etiology of cardiac diseases. Autoimmune myocarditis and inflammatory cardiomyopathies arise when adaptive immune responses

target cardiac antigens. These conditions are closely associated with specific HLA alleles that determine how antigens are presented to T lymphocytes. Certain HLA class II variants increase susceptibility to autoimmune myocarditis by influencing antigen presentation and T cell activation. These variants contribute to loss of immune tolerance and promote chronic myocardial inflammation, sometimes progressing to cardiomyopathy or heart failure.

Cytokine gene polymorphisms further contribute to cardiac disease susceptibility. Variants in genes encoding tumor necrosis factor, interleukins, interferons, and chemokines influence the magnitude of inflammatory responses in the heart. Individuals with high expression variants of pro inflammatory cytokines may experience more severe cardiac injury following viral infections, ischemia reperfusion events, or exposure to environmental toxins. In contrast, insufficient anti inflammatory cytokine production may impair cardiac repair processes, contributing to tissue fibrosis and ventricular dysfunction.

Atherosclerosis, one of the most significant contributors to cardiac morbidity, is now understood as a chronic inflammatory disease. Immunogenetic variation influences the balance between inflammatory and regulatory pathways involved in plaque formation. Variants

affecting macrophage activation, lipid antigen presentation, T cell differentiation, and cytokine regulation all contribute to atherosclerotic risk. For example, genetic predisposition to elevated pro inflammatory cytokine expression can accelerate plaque development and destabilization, increasing susceptibility to myocardial infarction.

Complement system genes play an important role in innate immunity and are increasingly recognized as contributors to cardiac pathophysiology. Variants affecting complement activation or its regulation have been associated with myocarditis, ischemic injury, and cardiomyopathies. Excessive complement activity may promote myocardial injury by increasing inflammatory cell recruitment, enhancing oxidative stress, and promoting tissue necrosis.

Genetic factors affecting immune cell recruitment and activation are also implicated in arrhythmogenic diseases. Inflammation can disrupt electrical conduction pathways, and certain immunogenetic variants predispose individuals to arrhythmias by modifying ion channel function through cytokine mediated mechanisms.

Cardiac involvement in systemic autoimmune diseases highlights the importance of immunogenetics. Diseases such as systemic lupus erythematosus, rheumatoid arthritis,

vasculitis, and systemic sclerosis often exhibit cardiac manifestations including pericarditis, myocarditis, coronary vasculitis, and conduction abnormalities. Genetic variants involved in autoimmunity contribute to the likelihood of cardiac involvement in these systemic disorders.

The gut microbiome represents another important factor in the immunogenetics of cardiac diseases. Genetic variations affecting immune responses to gut microbes can influence systemic inflammation, which in turn affects cardiac health. Dysbiosis resulting from immunogenetic predisposition may contribute to atherosclerosis, hypertension, metabolic syndrome, and heart failure. Variants affecting innate immune receptors can alter responses to microbial metabolites, influencing vascular inflammation and cardiac remodeling.

Ethnic differences in cardiac disease prevalence also reflect underlying immunogenetic variation. For example, specific HLA variants associated with autoimmune myocarditis are more common in certain populations. Genetic variants associated with inflammatory cardiomyopathy vary across ethnic groups, influencing differences in disease patterns and outcomes.

In summary, immunogenetics plays a central role in shaping the etiology of many cardiac diseases. Genetic variants affecting immune pathways influence how individuals respond to infection,

injury, and inflammatory stimuli. These insights help explain variations in susceptibility and progression across populations and individuals.

Diagnosis and Classification of Cardiac Diseases through Immunogenetics

Accurate diagnosis of cardiac diseases often requires integration of clinical examination, imaging, biomarkers, electrophysiologic testing, and laboratory evaluation. However, many cardiac diseases share overlapping symptoms, making diagnosis challenging. Immunogenetics contributes significantly to improving diagnostic accuracy, refining disease classification, and predicting clinical outcomes.

In myocarditis, immunogenetic markers help distinguish between viral, autoimmune, and idiopathic causes. Detection of HLA alleles associated with autoimmune myocarditis can guide clinicians toward immunomodulatory therapy, while genetic markers indicating susceptibility to viral myocarditis can prompt early antiviral treatment. Immunogenetics also helps identify individuals at high risk of progression from myocarditis to dilated cardiomyopathy.

In atherosclerosis and coronary artery disease, inflammatory biomarkers and genetic risk scores derived from immunogenetic studies provide

improved diagnostic precision. Genetic variants involved in immune regulation, lipid metabolism, and endothelial function are included in risk stratification models that complement traditional clinical factors. These models are particularly useful for individuals with intermediate risk profiles, where decisions regarding early prevention and intervention are challenging.

Cardiomyopathies benefit significantly from immunogenetic classification. Certain genetic variants predispose individuals to inflammatory cardiomyopathies characterized by chronic immune activation. Immunogenetic profiling helps distinguish these from genetic cardiomyopathies caused primarily by structural protein defects. This distinction is essential because treatment strategies differ significantly. Patients with immune mediated cardiomyopathy may respond favorably to immunosuppressive or biologic therapies, whereas those with structural cardiomyopathies require mechanical or genetic interventions.

In autoimmune cardiac diseases, immunogenetics supports early diagnosis by identifying HLA alleles and cytokine gene variants associated with autoimmunity. In systemic autoimmune diseases, immunogenetic markers help predict cardiac involvement and disease severity. For example, certain genetic variants in systemic lupus erythematosus correlate with increased risk

of myocarditis and pericarditis.

In heart failure, immunogenetic signatures are emerging as valuable diagnostic tools. Genetic variants affecting inflammatory pathways and immune responses influence the risk of progression from compensated cardiac function to decompensated heart failure. Identification of these markers can support earlier intervention and personalized treatment strategies.

In arrhythmias, immunogenetics contributes to diagnosis by identifying inflammation related genetic variants that predispose individuals to electrical disturbances. Inflammatory signaling can alter ion channel function, and certain genetic markers help predict susceptibility to arrhythmias in patients with myocarditis or autoimmune diseases.

Cardiac transplantation relies heavily on immunogenetics for diagnosis and monitoring. HLA matching remains essential for reducing the risk of rejection. Advanced immunogenetic profiling is used to predict the likelihood of acute or chronic rejection. Furthermore, genetic markers that influence immune tolerance help identify patients who may benefit from reduced immunosuppressive regimens.

Overall, immunogenetic information complements traditional diagnostic tools, providing a deeper understanding of disease

mechanisms and supporting early, accurate diagnosis.

Treatment of Cardiac Diseases through Immunogenetic Insights

Immunogenetics has transformed cardiac therapeutics by enabling precision medicine approaches. Traditional therapies often relied on broad immunosuppression, anti-inflammatory drugs, or symptomatic management. Modern approaches increasingly target specific immune pathways, genetic variants, and molecular disease mechanisms.

In myocarditis, immunogenetic markers help guide treatment decisions. Patients with autoimmune myocarditis often benefit from immunosuppressive therapy, including corticosteroids and cytotoxic agents, while those with viral myocarditis may require antiviral treatment combined with agents that modulate the immune response. Genetic biomarkers also help identify patients likely to progress to dilated cardiomyopathy, enabling early initiation of therapies aimed at preventing ventricular remodeling.

In atherosclerosis and coronary artery disease, therapies targeting inflammation have been developed based on immunogenetic insights. Agents that inhibit pro-inflammatory cytokines reduce cardiovascular risk in specific patient

populations. Genetic profiling helps identify individuals likely to respond to these treatments. Therapies targeting interleukin pathways, macrophage activation, and innate immune receptors are under investigation for their potential to modify atherosclerotic disease progression.

Cardiomyopathies characterized by immune activation may respond to immunomodulatory therapies. Immunogenetic markers guide selection of targeted treatments aimed at reducing inflammation, suppressing autoimmunity, and preventing fibrosis. For example, therapies targeting cytokine signaling may be beneficial in patients with cardiomyopathies associated with elevated inflammatory markers.

Cardiac transplantation has benefited extensively from immunogenetics. High resolution HLA matching and immunogenetic profiling have improved graft survival rates. Genetic markers help predict the risk of acute rejection, chronic rejection, and antibody mediated injury. Advances in immunogenetic understanding also support the development of therapies that promote immune tolerance, reducing dependence on long term immunosuppression.

In autoimmune cardiac diseases, therapies targeting T cell activation, B cell function, and cytokine pathways have emerged. Genetic markers identifying disease mechanisms help guide the

choice of biologic therapies such as agents targeting B cell depletion or modulation of co stimulatory pathways.

In heart failure, immunogenetics supports the development of therapies targeting inflammatory mediators that contribute to ventricular remodeling. Genetic variants influencing inflammation may determine individual responses to these therapies. Approaches targeting complement activation, innate immune receptors, and cytokine signaling are being evaluated in clinical trials.

Emerging therapies include gene editing technologies aimed at correcting immune related genetic defects, cell based therapies to promote immune tolerance, and personalized vaccines designed to modulate cardiac immune responses. Additionally, microbiome based therapies tailored to individual immunogenetic profiles hold promise for reducing systemic inflammation and improving cardiac health.

Immunogenetics continues to advance the development of targeted therapies that address the underlying immune mechanisms contributing to cardiac diseases. As research progresses, personalized treatment strategies will become increasingly central to cardiac care.

Conclusion

Immunogenetics has become an essential

component of modern cardiology, offering critical insights into the etiology, diagnosis, and treatment of cardiac diseases. Genetic variation influencing immune pathways shapes susceptibility to cardiac injury, modulates inflammation, and affects disease progression across a wide range of conditions. Incorporating immunogenetic markers into diagnostic practice enhances accuracy, improves disease classification, and supports early identification of high risk individuals. Immunogenetic discoveries have transformed therapeutic approaches by guiding the development of targeted treatments and informing personalized management strategies.

As the field continues to advance, the integration of immunogenetics into cardiology will play an increasingly important role in improving patient outcomes. Ongoing collaboration across disciplines such as genetics, immunology, cardiology, and computational biology will be essential for translating immunogenetic discoveries into clinical practice. Through these efforts, immunogenetics will continue to shape the future of cardiac medicine and support the development of precise, effective, and individualized care.

5. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF DERMATOLOGICAL DISEASES

Background

Dermatological diseases represent a major category of global health conditions that affect individuals of all ages, ethnicities, and socioeconomic backgrounds. These diseases range from acute inflammatory reactions and chronic autoimmune disorders to hereditary keratinization defects, pigmentary abnormalities, allergic reactions, and cutaneous malignancies. The skin is the largest organ of the human body and functions as a physical, immunological, and neuroendocrine barrier against environmental challenges. Because the skin continuously interacts with microbes, allergens, pollutants, ultraviolet radiation, and mechanical forces, it requires a diverse array of immune and genetic mechanisms to maintain homeostasis. When these mechanisms become disrupted due to inherited genetic variants or altered immune responses, a wide spectrum of dermatological diseases can arise.

The field of immunogenetics has become central to the scientific understanding of dermatological

diseases. Immunogenetics refers to the study of how genetic variation influences the development, activation, and regulation of the immune system. In the skin, immune cells such as keratinocytes, Langerhans cells, dermal dendritic cells, mast cells, macrophages, natural killer cells, and T lymphocytes interact continuously with structural cells and extracellular matrix components. These interactions are governed by signaling pathways controlled by numerous immune related genes. Variants in these genes can predispose individuals to maladaptive immune responses, which may manifest as chronic inflammation, hypersensitivity reactions, autoimmunity, or impaired host defense.

Advances in genomic technologies, including whole genome sequencing, genome wide association studies, transcriptomics, and single cell immunology, have revealed how specific genetic polymorphisms drive susceptibility to common dermatologic diseases such as psoriasis, atopic dermatitis, vitiligo, alopecia areata, hidradenitis suppurativa, cutaneous lupus erythematosus, autoimmune blistering disorders, and melanoma. These discoveries have reshaped traditional views of dermatological disease mechanisms and have enabled clinicians to understand disease at the molecular level, paving the way for precision dermatology.

In addition to pathogenesis, immunogenetics

provides essential insights for improving diagnosis, predicting prognosis, identifying disease subtypes, and tailoring therapeutic interventions. Diagnostic strategies increasingly incorporate immunogenetic biomarkers that identify patients at risk for severe disease or predict response to biologic therapy. Immunogenetics has also led to the development of targeted treatments that modulate specific cytokines, immune cells, or signaling pathways implicated in dermatological pathology.

The integration of immunogenetics into dermatology has transformed the field, making it possible to move beyond descriptive diagnosis and symptomatic management toward mechanisms based interventions and individualized care. The following sections explore the role of immunogenetics in the etiology, diagnosis, and treatment of dermatological diseases, highlighting current scientific understanding and emerging applications in clinical practice.

Etiology of Dermatological Diseases from an Immunogenetic Perspective

The etiology of dermatological diseases often reflects complex interactions among genetic predisposition, immune system behavior, environmental stimuli, and microbial factors. Immunogenetic research has shown that many skin diseases arise when inherited genetic

variants cause inappropriate immune activation, impaired immune tolerance, defective barrier function, or altered host microbial interactions.

One of the best studied immunogenetic dermatological conditions is psoriasis. Psoriasis is a chronic inflammatory disease characterized by hyperproliferation of keratinocytes and infiltration of immune cells. It is strongly associated with genetic variants in the HLA complex, particularly HLA Cw6, which influences antigen presentation and T cell activation. Additional genetic polymorphisms affect cytokine signaling, including variants in genes encoding interleukin 23, interleukin 12, interleukin 17, and tumor necrosis factor. These variants increase immune sensitivity to environmental triggers and promote a cytokine driven cycle of inflammation that results in psoriatic lesions. Genome wide association studies have identified more than 60 psoriasis associated loci, many of which control immune pathways. These findings illustrate how immunogenetics shapes disease susceptibility and influences clinical subtype variation.

Atopic dermatitis is another dermatological disease with strong immunogenetic foundations. Variants in the gene encoding filaggrin, a key protein involved in epidermal barrier function, predispose individuals to impaired skin barrier integrity. This impairment increases transepidermal water loss and facilitates

penetration of allergens, microbes, and irritants. Immunogenetic variations affecting Th2 cytokines, immunoglobulin E production, and innate immune receptors further contribute to the inflammatory response characteristic of atopic dermatitis. The interplay between barrier defects and immune dysregulation, driven by genetic predisposition, explains why some individuals develop severe chronic atopic dermatitis while others exhibit only mild disease despite similar environmental exposures.

Vitiligo is an autoimmune skin condition characterized by destruction of melanocytes. Immunogenetic studies have identified associations with HLA class I and class II alleles, as well as genes involved in antigen processing, interferon signaling, and innate immune pathways. These genetic variants contribute to heightened immune surveillance of melanocytes and increased susceptibility to autoimmune attack. Variants in genes controlling oxidative stress responses also play a role, illustrating how immunogenetics and cellular stress pathways interact to influence disease development.

Autoimmune blistering diseases such as pemphigus vulgaris and bullous pemphigoid demonstrate strong immunogenetic associations. Specific HLA alleles predispose individuals to autoantibody formation against structural proteins in the skin. These variants influence

immune tolerance and antigen presentation, increasing susceptibility to autoimmunity. Genetic predisposition is also influenced by polymorphisms in cytokine genes that regulate inflammatory responses and B cell activity.

Hidradenitis suppurativa, a chronic inflammatory condition of hair follicles and apocrine glands, has immunogenetic associations involving innate immune pathways. Variants affecting gamma secretase complex genes disrupt follicular homeostasis and promote inflammatory responses. Additional immunogenetic variants increase susceptibility to abnormal immune activation in affected areas.

Cutaneous lupus erythematosus and systemic lupus erythematosus exhibit numerous immunogenetic associations, including variants in genes regulating interferon responses, complement activation, immune tolerance, and antigen presentation. These genetic factors contribute to impaired clearance of apoptotic cells, increased autoantibody formation, and heightened inflammatory responses that affect the skin.

Alopecia areata, an autoimmune form of hair loss, is associated with numerous immunogenetic variants involving T cell activation, immune regulation, and antigen presentation. Variants in HLA alleles influence susceptibility to autoimmune attack of hair follicles. Genes

regulating cytotoxic T cell activity and interferon pathways are also implicated.

Cutaneous malignancies, including melanoma, arise through immunogenetic interaction between ultraviolet radiation, DNA repair pathways, immune surveillance, and inflammatory microenvironments. Genetic variants affecting tumor antigen recognition and immune regulation may influence melanoma risk and progression.

Across these conditions, immunogenetics reveals how inherited differences in immune pathways influence disease susceptibility. These mechanisms demonstrate why only certain individuals develop dermatological diseases despite similar environmental exposures and why disease manifestations vary widely across patients.

Diagnosis and Classification of Dermatological Diseases through Immunogenetics

Diagnostic approaches in dermatology traditionally rely on clinical evaluation, histopathology, imaging, and laboratory tests such as serology and patch testing. While these methods remain essential, they sometimes fail to distinguish disease subtypes, identify early stage disease, or predict clinical course. Immunogenetics has emerged as an important

complement to traditional diagnostic methods, offering molecular insights that improve accuracy, refine classification, and guide clinical decision making.

In psoriasis, immunogenetic markers help distinguish early onset psoriasis from late onset forms. HLA Cw6 positivity supports a diagnosis of type I psoriasis and indicates increased likelihood of family history, severe disease, and good response to specific therapies targeting interleukin 23 or interleukin 17. Genetic markers also assist in differentiating psoriasis from similar appearing conditions such as chronic eczema, tinea infections, and drug induced eruptions.

In atopic dermatitis, immunogenetic testing for filaggrin mutations can help identify individuals with severe barrier dysfunction who may be at higher risk of early onset disease, secondary infections, and progression to asthma or allergic rhinitis. These genetic markers also support risk stratification and patient counseling regarding prognosis.

Diagnosis of autoimmune blistering diseases benefits significantly from immunogenetic insights. HLA typing helps distinguish between subtypes of pemphigus and may predict disease severity. Immunogenetic markers also assist in differentiating autoimmune blistering disorders from inherited blistering diseases, which require distinct management strategies.

In vitiligo, genetic markers associated with immune regulation and oxidative stress pathways support early diagnosis and help identify individuals at risk of rapidly progressive disease. These markers can also distinguish vitiligo from pigmentary disorders such as post inflammatory hypopigmentation or chemical leukoderma.

In lupus erythematosus, immunogenetic markers help distinguish cutaneous dominant forms from systemic forms. Variants in genes regulating interferon signaling and complement activation correlate with specific disease phenotypes. Early detection of genetic susceptibility can prompt closer monitoring for systemic involvement.

In melanoma and other cutaneous malignancies, immunogenetics aids in identifying individuals at increased risk due to family history or inherited variants affecting immune surveillance or DNA repair. Genetic profiling of tumors also supports classification of melanoma into molecular subtypes with distinct immune landscapes. These classifications help guide immunotherapy selection and predict therapeutic response.

In allergic contact dermatitis, immunogenetic variants affecting cytokine production or antigen presentation may predict sensitivity to specific allergens. This information supports targeted avoidance strategies and improved diagnostic accuracy in patch testing.

In addition to improving diagnosis, immunogenetics contributes to the development of molecular classification systems for dermatological diseases. These systems incorporate genetic, immunologic, and clinical features to improve prognostic accuracy and guide personalized treatment.

Treatment of Dermatological Diseases through Immunogenetic Insights

The emergence of immunogenetic understanding has transformed therapeutic strategies for dermatological diseases. Historically, many conditions were treated with broad immunosuppression, topical corticosteroids, and symptom targeted interventions. While still valuable, these approaches often lack specificity and may not address underlying immunogenetic mechanisms. Modern therapies increasingly target specific immune pathways and incorporate genetic information to optimize treatment.

In psoriasis, immunogenetic discoveries have led to the development of targeted biologic therapies that inhibit interleukin 12, interleukin 23, interleukin 17, and tumor necrosis factor. These biologics have transformed psoriasis treatment by providing highly effective and specific immunomodulation. Genetic markers help predict which patients may respond best to particular

biologics, improving treatment outcomes and reducing unnecessary exposure to ineffective therapies.

Atopic dermatitis treatment has advanced through the development of biologics targeting interleukin 4 and interleukin 13 signaling pathways, which are central to Th2 mediated inflammation. Immunogenetic markers guide identification of patients likely to benefit from these therapies and may help distinguish disease phenotypes that require alternative approaches, such as JAK inhibitors, which target intracellular immune signaling.

In autoimmune blistering diseases, immunogenetic insights support the use of biologics targeting B cells or specific cytokines involved in autoantibody production. Rituximab, which targets CD20 positive B cells, has become a central therapy for pemphigus vulgaris, offering superior outcomes compared with traditional immunosuppression. Immunogenetic profiling helps identify candidate patients and predict risk of relapse.

In vitiligo, therapies targeting interferon gamma and Janus kinase pathways have shown promise. These treatments aim to modulate autoimmune attack on melanocytes. Genetic markers associated with interferon pathway activation may guide selection of these therapies.

Cutaneous lupus erythematosus benefits from therapies targeting type I interferon signaling, T cell activation, and B cell function. Immunogenetic markers help determine which pathways are activated in individual patients and guide therapy selection.

Alopecia areata has entered a new era of treatment with the introduction of JAK inhibitors. Immunogenetic studies showed that interferon signaling and cytotoxic T cell activity are central to disease pathogenesis, leading to the development of therapies that modulate these pathways.

Hidradenitis suppurativa treatment increasingly incorporates biologics targeting tumor necrosis factor and interleukin 17 pathways. Genetic markers may help identify patients likely to respond to these therapies and guide selection of combination treatments that account for individual immune profiles.

Cutaneous malignancies have seen major therapeutic advances through the development of immune checkpoint inhibitors. Immunogenetics helps predict patient response to these therapies by identifying genetic variants affecting tumor antigen presentation, immune surveillance, and tumor microenvironment. Personalized cancer vaccines and adoptive cell therapies also rely heavily on immunogenetic information.

Beyond biologics, immunogenetics supports the development of personalized skincare regimens, microbiome targeted therapies, and topical agents tailored to individual genetic profiles. For example, patients with filaggrin mutations may benefit from barrier enhancing treatments and early preventive care.

Future therapies may include gene editing to correct immune related genetic defects, cell based therapies to restore immune tolerance, and immunogenetically informed vaccines designed to modulate cutaneous immune responses.

Conclusion

Immunogenetics has reshaped the understanding, diagnosis, and treatment of dermatological diseases. Genetic variation affecting immune pathways plays a central role in disease susceptibility, severity, and progression. Immunogenetic markers enhance diagnostic accuracy, refine disease classification, and predict treatment response. Advances in immunogenetic research have led to the development of targeted therapies that modulate specific immune pathways and support personalized dermatological care.

As the field continues to advance, collaboration among dermatologists, immunologists, geneticists, and computational biologists will be essential for translating scientific discoveries

SEPIDEH LOUIA

into clinical practice. The integration of immunogenetics into dermatology promises significant improvements in patient outcomes, reduced disease burden, and a future in which dermatological care is increasingly precise, effective, and individualized.

ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNO...

6. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF OPHTHALMOLOGICAL DISEASES

Background

Ophthalmological diseases constitute a diverse group of disorders affecting the various structures of the eye, including the cornea, conjunctiva, uveal tract, retina, optic nerve, and orbit. These diseases range from chronic inflammatory conditions and autoimmune disorders to infectious diseases, genetic dystrophies, degenerative disorders, and neoplasms. Vision loss and ocular morbidity represent major global public health challenges, with millions of individuals affected by preventable or treatable blindness each year. While environmental factors, microbial pathogens, systemic diseases, and mechanical injuries contribute significantly to ocular pathology, the contributions of the immune system and underlying genetic predisposition are increasingly recognized as essential determinants of ocular health and disease.

The eye has traditionally been considered an immune privileged organ because of its physical barriers, anti-inflammatory environment, and mechanisms that limit immune mediated

damage. However, this concept has evolved substantially. Research over the past two decades has demonstrated that the eye maintains active communication with both innate and adaptive immune systems through resident microglia, dendritic cells, macrophages, complement components, cytokine networks, and neuroimmune pathways. Immune privilege relies not on absolute isolation but on carefully regulated immune tolerance mechanisms that protect sensitive ocular tissues from excessive inflammation. When these regulatory systems are disrupted due to genetic variation or environmental influences, pathological immune responses can target ocular tissues and initiate disease.

Immunogenetics, the study of how genetic variation influences immune function, has become central to understanding the mechanisms underlying ophthalmological diseases. Genetic variants affecting immune pathways may predispose individuals to inappropriate immune activation, impaired immune tolerance, abnormal cytokine responses, and dysregulated complement activity within the ocular microenvironment. These variations contribute to the pathogenesis of several ophthalmic disorders, including autoimmune uveitis, age related macular degeneration, retinitis pigmentosa with inflammatory features, keratoconus with

immune interactions, dry eye disease, ocular allergy, glaucoma, optic neuritis associated with demyelinating disorders, and inherited retinal diseases modulated by immune responses.

The development of advanced genomic tools such as whole genome sequencing, genome wide association studies, transcriptomic profiling, and single cell immunology has revealed numerous immunogenetic contributors to ophthalmic disease susceptibility. These discoveries have reshaped ophthalmological research and clinical practice by providing insights into molecular mechanisms, enabling earlier diagnosis, refining disease classification, and guiding the development of targeted therapies tailored to immunogenetic profiles. The integration of immunogenetics into ophthalmology is paving the way for precision medicine in the prevention, early recognition, and treatment of eye diseases.

The following sections explore the role of immunogenetics in the etiology, diagnosis, and treatment of ophthalmological diseases, highlighting the biological mechanisms that link immune genetic variation to clinical outcomes and the therapeutic innovations that arise from this understanding.

***Etiology of Ophthalmological
Diseases from an Immunogenetic
Perspective***

The etiology of ophthalmological diseases often reflects the interplay between genetic predisposition and immune responses. Because ocular tissues are highly specialized and sensitive to inflammation, even subtle dysregulation of immune pathways can initiate or exacerbate disease. Immunogenetic research has clarified how variations in genes governing innate immunity, adaptive immunity, complement activation, cytokine signaling, and tolerance influence susceptibility to ocular disorders.

Autoimmune uveitis provides one of the most striking examples of immunogenetic contribution. Uveitis refers to inflammation of the uveal tract, including the iris, ciliary body, and choroid, and can lead to severe vision loss. Immunogenetic studies have consistently linked uveitis to specific HLA haplotypes, particularly the association between HLA B27 and anterior uveitis. This genetic variant influences antigen presentation to T cells, increasing susceptibility to immune responses against intraocular antigens. The presence of HLA B27 does not guarantee disease but significantly increases the likelihood of uveitis in individuals experiencing environmental or microbial triggers. Additional genetic variants influence cytokine profiles, including those regulating interleukin 17 and tumor necrosis factor pathways, which contribute to chronic inflammation in uveitis.

Age related macular degeneration, one of the leading causes of irreversible blindness worldwide, is also strongly influenced by immunogenetic factors. Variants in complement factor H, complement factor B, complement C3, and related genes are among the most well established genetic risk factors for age related macular degeneration. These genes regulate complement activation and inflammation in the retina. Dysregulation of complement pathways results in chronic low grade inflammation and deposition of drusen, leading to progressive degeneration of retinal pigment epithelium and photoreceptors. Environmental factors such as smoking, diet, and ultraviolet exposure interact with these genetic variants to modulate risk, highlighting the complex interplay between genetic susceptibility and external triggers.

Keratoconus, a condition characterized by progressive thinning and protrusion of the cornea, has traditionally been viewed as a structural disorder. However, increasing evidence suggests that immune mechanisms contribute to its pathogenesis. Immunogenetic studies have identified associations between keratoconus and polymorphisms in genes regulating inflammatory responses, oxidative stress, and immune mediated tissue remodeling. These findings suggest that genetically driven dysregulation of immune processes may contribute to corneal weakening

and structural instability.

Dry eye disease, which involves tear film instability, ocular surface inflammation, and epithelial damage, is influenced by genetic variants affecting innate immunity, mucin production, and cytokine signaling. Variants in genes regulating interleukin 1, interleukin 6, and tumor necrosis factor influence susceptibility to chronic inflammation and severe dry eye symptoms. These immunogenetic factors may also contribute to the increased prevalence of dry eye disease in autoimmune conditions such as Sjogren syndrome.

Optic neuritis, a common manifestation of demyelinating diseases such as multiple sclerosis, provides another example of immunogenetic involvement. Genetic variants associated with multiple sclerosis, particularly those involving HLA class II alleles, influence susceptibility to optic neuritis. These variants affect antigen presentation and T cell activation, leading to immune mediated damage of myelin sheaths surrounding optic nerve fibers. Immunogenetic predisposition determines not only susceptibility but also risk of recurrence and progression to multiple sclerosis.

Ocular allergies such as allergic conjunctivitis are influenced by immunogenetic variants regulating IgE production, mast cell activation, and cytokine responses. Genetic predisposition affects

individual sensitivity to allergens and contributes to clinical variability in disease severity.

Inherited retinal diseases demonstrate a complex interaction between genetic defects in photoreceptors or supporting cells and immunogenetic modifiers that influence retinal inflammation or degeneration. Genetic variants affecting microglial activation and complement function may modulate the rate of disease progression in conditions such as retinitis pigmentosa.

In summary, immunogenetics plays a central role in the etiology of ophthalmological diseases. Genetic variants influencing immune pathways determine susceptibility to ocular inflammation, tissue damage, and degeneration. Understanding these mechanisms helps clarify why only certain individuals develop ophthalmological diseases despite similar environmental exposures and why disease manifestations vary widely among patients.

***Diagnosis and Classification
of Ophthalmological Diseases
through Immunogenetics***

Advances in immunogenetics have greatly improved the diagnostic and classification capabilities within ophthalmology. Traditional diagnostic tools such as slit lamp examination, ophthalmoscopy, optical coherence tomography,

fundus autofluorescence, angiography, electrophysiology, and laboratory testing remain crucial. However, these tools often struggle to distinguish disease subtypes, predict prognosis, or guide personalized treatment. Immunogenetic information provides molecular insight that enhances diagnostic accuracy and supports early detection.

In uveitis, HLA typing is routinely used to help identify individuals with HLA B27 associated anterior uveitis. The presence of this genetic marker supports diagnosis, clarifies disease etiology, and helps predict the likelihood of systemic associations such as spondyloarthropathies. Immunogenetic markers also help differentiate infectious uveitis from autoimmune forms by identifying genetic predispositions that favor one mechanism over another.

In age related macular degeneration, genetic testing for complement factor H and related genes assists in identifying individuals at high risk for disease development or progression. These markers help refine diagnosis, predict response to antioxidant supplementation, and guide patient counseling. Immunogenetic profiling also supports classification of age related macular degeneration into subtypes with distinct complement related mechanisms, improving prognostic accuracy.

In keratoconus, immunogenetic markers help identify individuals with early disease or those at high risk of progression. Early identification supports timely intervention with corneal crosslinking or other treatments. Immunogenetic profiling may also identify subtypes of keratoconus that require individualized management based on underlying inflammatory mechanisms.

In dry eye disease, immunogenetic markers related to Sjogren syndrome support early diagnosis and classification. Detection of specific cytokine related polymorphisms may also help identify patients with severe inflammatory disease who require advanced immunomodulatory therapy.

Optic neuritis diagnosis benefits from immunogenetic testing in patients suspected of having multiple sclerosis or neuromyelitis optica spectrum disorder. Variants in genes such as aquaporin 4 and myelin oligodendrocyte glycoprotein are not purely genetic markers but interact with immunogenetic predispositions that influence severity and recurrence. Incorporating immunogenetic insights enhances diagnostic specificity and supports risk stratification.

In allergic conjunctivitis, immunogenetic markers may support identification of individuals predisposed to severe allergic reactions or chronic inflammatory disease. Genetic differences in IgE

regulation and cytokine responses help categorize disease into phenotypes requiring different treatment approaches.

In ocular oncology, immunogenetics supports early detection of uveal melanoma by identifying individuals with genetic predispositions affecting immune surveillance. Tumor genomic profiling identifies immunogenetic markers associated with response to immunotherapy and helps classify tumors according to molecular signature.

Overall, immunogenetics enhances diagnostic precision, improves classification systems, predicts disease progression, and informs patient counseling and early intervention strategies.

Treatment of Ophthalmological Diseases through Immunogenetic Insights

The application of immunogenetics to treatment has transformed ophthalmological therapeutics. Traditional treatments such as corticosteroids, immunosuppressive drugs, antibiotic or antiviral therapy, and surgical interventions remain indispensable. However, many of these treatments lack specificity and may not address the underlying immunogenetic mechanisms driving disease. Immunogenetic insights have led to a new era of targeted therapy and personalized medicine in ophthalmology.

In autoimmune uveitis, biologic therapies

targeting specific cytokines such as tumor necrosis factor, interleukin 6, and interleukin 17 have been developed. Immunogenetic markers help identify patients who will respond best to these therapies and reduce reliance on broad corticosteroid therapy, which has substantial ocular and systemic side effects. Patients with HLA related disease often respond differently to immunomodulatory agents, making genetic information essential for personalized treatment.

In age related macular degeneration, therapies targeting complement activation have emerged from immunogenetic discoveries. Complement inhibitors designed to modulate complement factor H or complement C3 aim to reduce retinal inflammation and slow disease progression. Genetic markers help determine which patients are most likely to benefit from complement targeted therapies.

In keratoconus, immunogenetic discoveries have prompted exploration of anti inflammatory therapies that target early immune pathways contributing to corneal weakening. While corneal crosslinking remains the mainstay of treatment, immunogenetic insights may guide the development of adjunctive therapies that stabilize the cornea by reducing inflammation.

In dry eye disease, immunogenetic information supports the use of therapies targeting inflammatory cytokines and T cell activation.

Agents such as cyclosporine, lifitegrast, and emerging biologics targeting interleukin pathways are selected based on immunogenetic and inflammatory profiles. Patients with strong immunogenetic predisposition to autoimmune inflammation may require systemic therapy in addition to topical treatments.

In optic neuritis associated with multiple sclerosis, treatments targeting T cell and B cell activation are guided by immunogenetic markers. Therapies deployed early based on genetic risk can prevent recurrence and reduce optic nerve damage.

In allergic conjunctivitis, immunogenetic understanding of IgE related pathways supports the use of targeted therapies such as monoclonal antibodies against IgE or specific cytokines. These therapies are particularly useful in individuals with severe or refractory disease identified through genetic testing.

In ocular oncology, immunogenetics plays an essential role in the use of immune checkpoint inhibitors and melanoma vaccines. Genetic markers help identify individuals most likely to benefit from these treatments and guide selection of adjunctive therapies.

Future treatment directions include gene editing to correct immune related genetic variants, personalized ocular vaccines designed to

modulate immune tolerance, cell based therapies to restore immune balance in the eye, and regenerative medicine that uses immunogenetic profiles to optimize outcomes.

Conclusion

Immunogenetics has become a foundational component of modern ophthalmology, offering essential insights into the etiology, diagnosis, and treatment of ophthalmological diseases. Genetic variation influencing immune pathways plays a central role in determining susceptibility to ocular inflammation, degeneration, autoimmunity, and malignancy. Incorporating immunogenetic information into diagnostic practice enhances accuracy, allows early detection of disease, and refines classification systems. In treatment, immunogenetics has enabled the development of targeted therapies that modulate specific immune pathways and supports personalized treatment planning that improves outcomes and reduces unnecessary interventions.

Continued advances in immunogenetics, supported by interdisciplinary collaboration among ophthalmologists, geneticists, immunologists, and computational biologists, promise to further improve understanding of ocular diseases and expand therapeutic possibilities. As immunogenetic research progresses, ophthalmological care will continue to

evolve toward precision medicine, enabling highly individualized approaches that reduce vision loss and improve quality of life for patients worldwide.

7. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF ORAL DISEASES

Background

Oral diseases represent one of the most widespread groups of health conditions globally, affecting billions of individuals and contributing substantially to morbidity, reduced quality of life, and financial burden on health systems. These diseases include dental caries, periodontal diseases, oral mucosal disorders, autoimmune conditions, oral cancers, salivary gland diseases, and congenital or developmental abnormalities. The oral cavity is a highly complex anatomical and immunological environment that is exposed continuously to a wide range of external stimuli, including dietary components, microbiota, viruses, mechanical forces, environmental toxins, and allergens. The mouth also functions as a critical entry point for pathogens and environmental antigens, which require precise coordination between innate and adaptive immune responses. The maintenance of oral health depends not only on effective immune defense but also on the development and preservation of immune tolerance to commensal microbiota and self antigens.

Immunogenetics, which studies how genetic variation shapes immune responses, has emerged as an essential field for understanding the origins, diagnosis, and treatment of oral diseases. The oral cavity contains a wide variety of immune cells, such as neutrophils, macrophages, dendritic cells, T lymphocytes, B lymphocytes, natural killer cells, and specialized mucosal immune cells. These immune cells interact continuously with epithelial barriers, connective tissues, saliva, and a diverse microbial community. Genetic differences in immune system components can influence how the mouth responds to microbial challenges, inflammatory stimuli, or environmental insults. These variations may predispose individuals to chronic inflammation, autoimmunity, dysregulated healing, susceptibility to infections, and increased risk of malignancy.

Rapid progress in genomic technologies, including whole genome sequencing, genome wide association studies, transcriptomic analysis, epigenetic studies, and single cell immunology, has significantly deepened scientific understanding of oral immunogenetics. Research has uncovered numerous genetic polymorphisms and immune related genes that modulate susceptibility to oral conditions such as periodontitis, oral lichen planus, recurrent aphthous stomatitis, Sjogren syndrome, temporomandibular joint disorders with inflammatory components, cleft lip and palate,

oral squamous cell carcinoma, and salivary gland dysfunction. These discoveries are helping to redefine oral diseases as complex immune mediated or immune modulated conditions, rather than disorders purely caused by external factors or microbial exposure.

In addition to supporting etiological insights, immunogenetics plays an increasingly important role in early diagnosis, disease classification, prognosis, and the development of personalized treatment strategies. Identifying immunogenetic markers helps clinicians recognize individuals at elevated risk for severe disease, select appropriate immunomodulatory therapies, and design preventive strategies tailored to individual immune profiles. Immunogenetic research has also contributed to the discovery of targeted biologic therapies for immune mediated oral diseases, as well as novel approaches to oral cancer immunotherapy.

This chapter explores the central role of immunogenetics in the etiology, diagnosis, and treatment of oral diseases, providing an extensive review of the biological mechanisms that link genetic variation to oral immune responses and clinical outcomes. It demonstrates how immunogenetics is transforming modern oral medicine and shaping the future of personalized care.

Periodontitis is one of the periodontal diseases and is a common chronic inflammatory condition

affecting adults. Periodontal disease involves the supporting tissues and is influenced by genetics. The risk of periodontal diseases such as gingivitis or periodontitis has increased due to genetic alterations that affect the body's immune response to oral bacteria. Chronic periodontitis can lead to tooth loss and profoundly influence chewing function and the overall quality of life. The development of oral cancers can also be increased by genetic mutations. Various systemic diseases, including respiratory and cardiovascular diseases, Alzheimer's disease, cancer, and adverse pregnancy outcomes, are linked with periodontitis. The shape, size, and position of teeth, as well as their function, esthetics, and overall oral health, can be influenced by genetic factors. Genetic influences may become apparent at birth through craniofacial anomalies such as cleft lip with or without cleft palate. These malformations are generally attributed to the combined effects of genetic susceptibility and environmental factors. New studies have shown the importance of the relationship between periodontal pathogens and the host immune response in the pathogenesis of periodontal diseases. The relationships between different systemic diseases and periodontitis are very complicated. The relationship between systemic immune related diseases, particularly immune mediated inflammatory disorders, and periodontal disease continues to be emphasized.

However, somewhat curiously, oral diseases such as gingivitis, dental cavities, and oral cancer remain a hazard to public health at all stages of life expectancy.

According to the World Health Organization, more than 3.5 billion people worldwide suffer from oral diseases. This provides clear evidence that a preventive and comprehensive control system is urgently needed. Oral diseases depend on environmental conditions, while their onset and progression are influenced by extremely complex factors. The outcome is a host of interrelated conditions involving innumerable contributing agents that interact with individuals and their specific dispositions. Genetic predisposition is a major factor in a person's susceptibility to oral diseases.

Variations in genes involved in immune function, inflammation, and tissue repair have been associated with an increased risk of adverse effects for respiratory diseases and increased risks of endpoints for respiratory diseases such as periodontal disease and oral carcinoma. For example, certain polymorphisms in the interleukin-1 gene cluster are associated with other autoimmune diseases and an increased probability of severe periodontitis, which may indicate that the strength of the immune response contributes to the development of the disease in the body. Recently, researchers have employed Mendelian randomization to identify strong

associations between immune related cells and diseases including schizophrenia, type 2 diabetes, multiple sclerosis, systemic lupus erythematosus, atrial fibrillation, and chronic obstructive pulmonary disease. This strong observational evidence provides a solid basis for reinforcing the contributory role of immune responses in the development of multiple systemic disorders. At the junction between medicine and dentistry, the mouth functions as an indicator of the overall state of health. The ailments that affect this organ have a significant impact on systemic health, much more than many doctors and nurses realize.

Etiology of Oral Diseases from an Immunogenetic Perspective

The etiology of oral diseases involves a dynamic interplay among genetic predisposition, immune system regulation, environmental exposures, and microbial stimuli. Immunogenetic variation plays a significant role in determining how the oral cavity responds to these factors. When immune system genes are altered or dysregulated, oral tissues become susceptible to both excessive inflammatory responses and insufficient immune protection. This dual vulnerability contributes to the onset and progression of many oral diseases. Periodontitis is one of the most extensively studied oral diseases from an immunogenetic perspective. It is a chronic inflammatory condition characterized by destruction of supporting

structures of the teeth, including gingiva, periodontal ligament, and alveolar bone. While bacterial biofilm is a primary trigger, genetic and immune factors determine disease susceptibility and severity. Polymorphisms in genes encoding interleukin 1, interleukin 6, tumor necrosis factor, and other pro inflammatory cytokines influence the magnitude of the host inflammatory response to bacterial challenge. Some individuals exhibit hyperresponsive immune profiles due to these genetic variants, resulting in excessive cytokine production that leads to accelerated tissue destruction. Variants affecting neutrophil function, Toll like receptor signaling, and complement activation also contribute to immune dysregulation in periodontitis. Genetic variations in adaptive immunity, including T cell differentiation pathways, modulate the balance between Th1, Th2, Th17, and regulatory T cell responses, shaping the inflammatory environment within periodontal tissues. Dental caries, while traditionally viewed as a microbial and dietary disease, also shows immunogenetic influences. Genetic variations affecting immune responses to cariogenic bacteria, enamel formation, saliva composition, and sugar metabolism contribute to caries susceptibility. Polymorphisms in genes that regulate innate immunity, such as those encoding defensins and pattern recognition receptors, influence resistance or susceptibility to bacterial

colonization. Variants in immunoglobulin A production affect mucosal immunity and modulate the ability of saliva to neutralize acidogenic bacteria.

Oral mucosal diseases such as oral lichen planus are closely associated with immune system dysregulation. Oral lichen planus is an immune mediated condition characterized by T cell infiltration in oral mucosa. Genetic polymorphisms in cytokine genes including tumor necrosis factor and interleukin 6 influence disease susceptibility. Variants in genes regulating T cell activation and antigen presentation, particularly HLA class II alleles, contribute to autoimmune susceptibility.

Recurrent aphthous stomatitis, one of the most common ulcerative oral conditions, also exhibits immunogenetic associations. Variants in genes regulating mucosal immunity, inflammatory cytokines, and oxidative stress responses contribute to susceptibility. HLA haplotypes influence T cell recognition of self antigens, promoting inappropriate immune attacks on mucosal tissues.

Sjogren syndrome, a systemic autoimmune disease with prominent oral manifestations such as xerostomia, provides a clear example of immunogenetic mechanisms. Variants in HLA genes, interferon related genes, and genes regulating B cell activity contribute to autoantibody formation and salivary gland

destruction. These genetic factors create a predisposition to dysfunctional immune responses that attack lacrimal and salivary tissues. Oral cancer, particularly oral squamous cell carcinoma, has both environmental and immunogenetic determinants. While tobacco, alcohol, and human papillomavirus infection are major environmental risk factors, genetic variants affecting immune surveillance, inflammation, and DNA repair mechanisms influence susceptibility and progression. Variants in immune checkpoint genes, cytokine signaling pathways, and antigen processing mechanisms can impair immune recognition of malignant cells and contribute to tumor growth.

Cleft lip and palate involve interactions between developmental genetics and immune system influences. Although primarily considered congenital structural anomalies, recent research suggests that immune regulatory genes may influence abnormal tissue remodeling and inflammatory processes during embryological development.

Taken together, immunogenetic mechanisms provide essential insight into the etiological diversity of oral diseases. They explain why individuals exposed to similar environmental and microbial conditions may experience widely differing disease outcomes. Genetic predisposition influences immune sensitivity, inflammatory intensity, tissue repair mechanisms, and microbial

interactions within the oral cavity.

Diagnosis and Classification of Oral Diseases through Immunogenetics

Diagnosis in oral medicine traditionally relies on visual examination, palpation, radiographic analysis, histopathology, serological tests, microbiological studies, and clinical criteria. These tools remain indispensable for evaluating structural changes, microbial involvement, and clinical presentation. However, many oral diseases exhibit overlapping symptoms, variable progression, and complex immune mediated pathology that are not fully captured through traditional clinical methods. Immunogenetics has emerged as a valuable addition to diagnostic practice, allowing earlier identification of disease predisposition and more accurate classification of complex conditions.

In periodontitis, genetic markers related to cytokine production and innate immune responses support risk assessment and early diagnosis. For example, individuals with specific interleukin 1 polymorphisms are at higher risk of severe periodontitis. Identifying these risk alleles can guide early interventions, preventive strategies, and differentiated recalls in dental clinics. Immunogenetic information is also being explored to classify periodontitis into subtypes based on inflammatory profiles rather than purely clinical presentation. This offers potential for

personalized treatment approaches that account for underlying molecular mechanisms.

In dental caries, genetic testing for variants influencing enamel strength, saliva composition, and immune responses may identify children and adults at high risk for severe or early onset caries. Incorporating immunogenetic information into caries risk assessment supports preventive strategies such as fluoride therapy, sealants, and tailored dietary counseling.

In oral mucosal diseases such as oral lichen planus, detection of specific cytokine gene polymorphisms and HLA alleles can support diagnosis by distinguishing autoimmune mediated lesions from other white oral patches. Genetic markers may also help identify individuals at higher risk for malignant transformation of oral lichen planus.

In recurrent aphthous stomatitis, immunogenetic testing can assist in differentiating idiopathic disease from ulcerative lesions associated with systemic disorders such as Behcet disease. HLA markers help classify disease subtypes and support prognosis.

In Sjogren syndrome, which often presents initially with oral symptoms, immunogenetic markers such as HLA alleles associated with autoimmunity help support early diagnosis before full systemic manifestations appear. Genetic markers complement serological tests for anti Ro and anti La antibodies and contribute to disease

stratification.

In oral cancers, immunogenetic profiling of tumors supports early detection, risk classification, and prediction of response to immunotherapy. Genetic markers related to immune surveillance mechanisms, such as PD L1 expression and tumor infiltrating lymphocyte profiles, contribute to personalized oncology approaches that target immune evasion mechanisms in malignant cells. Somatic and germline immunogenetic alterations influence the expression of tumor antigens, which are important for immunotherapeutic targeting.

In salivary gland disorders, genetic markers related to inflammatory responses help distinguish autoimmune sialadenitis from infection or mechanical obstruction. Immunogenetic markers related to interferon pathway activation support the classification of salivary dysfunction in systemic autoimmune diseases.

In all of these conditions, immunogenetics enhances diagnostic accuracy by providing molecular context. It helps clinicians identify disease subtypes and understand individual variability in clinical course, thereby improving management strategies.

Treatment of Oral Diseases through Immunogenetic Insights

The application of immunogenetics to treatment

has transformed oral medicine by guiding the development of targeted therapies, improving treatment selection, and advancing personalized care. Many oral diseases have historically been treated using broad anti-inflammatory agents, corticosteroids, antibiotics, or surgical interventions. While these approaches remain important, they often fail to address immune dysregulation at the molecular level. Immunogenetics provides a pathway to more specific and effective therapies.

In periodontitis, understanding immunogenetic susceptibility has supported the development of immunomodulatory treatments aimed at reducing excessive inflammatory responses. Targeting cytokines such as interleukin 1, tumor necrosis factor, and interleukin 17 may help reduce tissue destruction in patients with hyperinflammatory phenotypes. New therapies aim to rebalance immune responses using host modulation strategies such as subantimicrobial dose doxycycline, anti-cytokine biologics, and modulators of bone metabolism. Genetic information may help identify patients who will benefit most from these targeted interventions.

In dental caries, immunogenetic understanding supports strategies that enhance host defense mechanisms, such as boosting salivary immunity or modulating innate immune responses. Treatments may include salivary stimulation, antimicrobial peptides, and probiotics

personalized to genetic immune profiles.

In oral mucosal diseases such as oral lichen planus, immunogenetic discoveries have led to the development of therapies targeting T cell activation and specific cytokines involved in mucosal inflammation. Agents that modulate interleukin pathways or reduce T cell mediated inflammation are being explored as alternatives to long term corticosteroid use.

In recurrent aphthous stomatitis, targeted therapies include agents modulating tumor necrosis factor or other cytokines implicated in genetic studies. Immunogenetics may guide the use of biologics in severe cases or those resistant to conventional therapy.

In Sjogren syndrome, immunogenetic insights have supported development of therapies targeting B cells, T cells, and interferon pathways. These therapies aim to reduce autoantibody production, restore salivary gland function, and alleviate xerostomia. Genetic markers may identify patients most likely to respond to these advanced therapies.

In oral cancer, immunogenetic discoveries have revolutionized treatment through the development of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Genetic profiling of tumors helps identify individuals most likely to respond to immunotherapy and guides selection among available agents. Targeting immune evasion

mechanisms has become a central component of oral cancer therapy.

In salivary gland disorders, therapies targeting interferon signaling or cytokine pathways may help reduce inflammation and restore glandular function in immune mediated disease.

Future therapeutic innovations based on immunogenetics include gene editing to correct immune related genetic defects, cell based therapies to restore immune balance, targeted antimicrobial therapies guided by immunogenetic susceptibility, and personalized oral vaccines designed to modulate immune tolerance. These approaches offer significant promise for improving outcomes in oral diseases with immune mediated etiologies.

Conclusion

Immunogenetics provides a powerful framework for understanding the etiology, diagnosis, and treatment of oral diseases. Genetic variation affecting immune pathways shapes susceptibility to oral conditions, influences disease progression, and affects treatment response. Integrating immunogenetics into diagnostic practice enhances precision, improves risk prediction, and refines disease classification. Immunogenetic insights have transformed treatment by supporting the development of targeted therapies that address underlying immune dysregulation rather than merely managing symptoms.

SEPIDEH LOUIA

As research continues to advance, immunogenetics will further shape the future of oral medicine by enabling highly individualized preventive strategies, early detection methods, and tailored therapeutic interventions. Collaboration among geneticists, immunologists, dental researchers, clinicians, and computational scientists will be essential for translating immunogenetic discoveries into improved patient care. Through these efforts, oral medicine is entering an era of precision health in which immunogenetics plays a central role in reducing disease burden, improving quality of life, and achieving optimal oral health outcomes.

ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNO...

8. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF ENT DISEASES

Background

Ear, nose, and throat diseases represent a diverse group of disorders affecting the upper aerodigestive tract and associated structures, including the external, middle, and inner ear, nasal passages, paranasal sinuses, pharynx, larynx, and regional lymphoid tissues. These diseases include infectious, inflammatory, autoimmune, allergic, neoplastic, congenital, and degenerative conditions. ENT diseases affect individuals of all ages and are among the most common reasons for medical consultations worldwide. Disorders such as allergic rhinitis, otitis media, chronic rhinosinusitis, tonsillitis, laryngitis, Meniere disease, autoimmune inner ear disease, thyroid disorders with ENT manifestations, head and neck cancers, and obstructive sleep apnea illustrate the broad clinical spectrum of ENT medicine.

While environmental exposures, microbial infections, lifestyle factors, and anatomical variations remain central contributors to ENT disorders, advances in immunology and genetics have revealed that immune system behavior and

inherited genetic factors significantly influence disease susceptibility, severity, and progression. The ENT region plays a crucial immunological role because it represents a primary interface between the external environment and internal tissues. The nasal and pharyngeal mucosa are constantly exposed to inhaled allergens, airborne pathogens, pollutants, and particulate matter. The tonsils and adenoids contain specialized lymphoid tissues that contribute to the development of mucosal immunity. The middle ear environment is influenced by immune responses to nasopharyngeal microbial colonization. The inner ear, although protected by the blood labyrinth barrier, expresses immune related genes that regulate inflammation and tissue homeostasis. Because the ENT system is embedded in such immunologically active sites, even subtle variations in immune genes can have significant clinical consequences.

Immunogenetics, the study of how genetic variation influences immune function, has emerged as a central discipline for understanding ENT diseases. Genetic differences in immune pathways can predispose individuals to inappropriate inflammatory responses, impaired immune tolerance, excessive mucosal reactivity, chronic tissue remodeling, susceptibility to infections, and increased risk for head and neck cancers. The involvement of immunogenetics

provides explanations for clinical observations such as why some individuals frequently develop otitis media while others remain resistant, why chronic rhinosinusitis varies so dramatically in severity and immune profile, why allergic responses differ widely among individuals, why certain populations show increased susceptibility to laryngeal diseases, and why immune checkpoint behaviors differ in head and neck cancer patients.

Modern genomic tools, including whole genome sequencing, genome wide association studies, single cell transcriptomic profiling, epigenetic analysis, and advanced computational immunology, have made it possible to identify numerous immunogenetic markers associated with ENT disorders. These discoveries have clarified disease mechanisms, refined diagnostic approaches, informed prognosis, and guided the development of targeted therapies. Immunogenetics has reshaped ENT clinical practice by enabling personalized treatment strategies that tailor interventions to immune profiles and genetic susceptibility.

The following sections explore the multifaceted role of immunogenetics in the etiology, diagnosis, and treatment of ENT diseases. They examine the immune genetic mechanisms contributing to disease development, the diagnostic utility of immunogenetic markers,

and the therapeutic advances arising from immunogenetic understanding. This chapter presents an integrated perspective on how immunogenetics is transforming ENT medicine and shaping future innovations.

Etiology of ENT Diseases from an Immunogenetic Perspective

The etiology of ENT diseases reflects a complex interplay among environmental exposures, infectious agents, immune responses, and genetic predisposition. Immunogenetic variation influences how the immune system recognizes antigens, responds to pathogens, regulates inflammation, and maintains tissue integrity in ENT structures. When immune related genetic pathways are dysfunctional, ENT tissues are prone to chronic inflammation, immune dysregulation, and disease.

Allergic rhinitis is one of the most common ENT disorders, affecting hundreds of millions globally. It results from IgE mediated hypersensitivity to inhaled allergens, as well as dysregulation of mucosal immunity. Immunogenetic studies have identified numerous polymorphisms in genes regulating cytokines such as interleukin 4, interleukin 5, and interleukin 13 that predispose individuals to heightened allergic responses. Variants in the IgE receptor gene complex and genes regulating T helper 2 cell differentiation

influence susceptibility to allergic rhinitis. These genetic variations contribute to an exaggerated immune response to environmental triggers such as pollen, animal dander, dust mites, and mold. Additional variants influencing epithelial barrier integrity may increase mucosal permeability and facilitate allergen penetration.

Chronic rhinosinusitis, especially the subtype with nasal polyps, has strong immunogenetic underpinnings. The condition is associated with dysregulated innate immunity, particularly in pathways involving Toll like receptors, nucleotide binding oligomerization domain proteins, and epithelial derived cytokines. Genetic variants influence the activity of interleukin 5, interleukin 33, thymic stromal lymphopoietin, and eosinophilic inflammation, all of which contribute to polyp formation. Variants affecting epithelial regeneration, mucociliary clearance, and microbial interactions further modify susceptibility.

Otitis media, especially recurrent acute otitis media and chronic otitis media with effusion, also demonstrates immunogenetic influences. Polymorphisms in genes regulating mucosal immunity, such as interleukin 6, interleukin 10, and surfactant proteins, influence the efficiency of immune responses within the middle ear. Genetic variants affecting Eustachian tube function, middle ear mucosal defense, and

nasopharyngeal colonization with pathogens such as *Streptococcus pneumoniae* or *Haemophilus influenzae* contribute to susceptibility.

Autoimmune inner ear disease is characterized by immune mediated damage to inner ear structures and progressive sensorineural hearing loss. Immunogenetic studies have identified associations with specific HLA class II alleles and genes regulating T cell activity. Variants affecting cytokine responses such as those involving interleukin 2 and interleukin 17 contribute to autoimmune susceptibility.

Meniere disease, which involves episodic vertigo, hearing loss, tinnitus, and aural fullness, may have immunogenetic origins in some patients. Genetic variants influencing autoimmune pathways, endothelial permeability, and inflammatory signaling may predispose individuals to endolymphatic hydrops and vestibular dysfunction.

Head and neck cancers, including cancers of the oral cavity, oropharynx, larynx, and thyroid, have multifactorial etiologies involving environmental exposures such as smoking and human papillomavirus infection. However, immunogenetic factors also play critical roles in determining susceptibility, tumor progression, and response to therapy. Variants in immune checkpoint genes such as PD CD274, CTLA4, and HLA alleles affecting antigen presentation

contribute to the ability of the immune system to detect and eliminate early malignant cells. Dysregulation in innate immune receptors and inflammatory cytokines can create a microenvironment conducive to tumor development.

Thyroid diseases affecting the ENT region, particularly autoimmune thyroiditis, exhibit strong immunogenetic associations. Variants in genes regulating immune tolerance, B cell activity, and thyroid specific antigen presentation contribute to autoimmune destruction of thyroid tissue.

In recurrent tonsillitis and adenoid hypertrophy, genetic differences in mucosal immunity, cytokine production, and lymphoid tissue development influence susceptibility to chronic infection and inflammation. Variants affecting innate immune receptors and antimicrobial peptides may reduce the ability of tonsillar tissue to control microbial load.

In summary, immunogenetic mechanisms play a critical role in determining susceptibility to ENT diseases by shaping immune responses within the upper aerodigestive tract. Genetic variation influences inflammatory intensity, immune tolerance, tissue repair, and microbial interactions, offering valuable insight into disease etiology.

Diagnosis and Classification of ENT Diseases through Immunogenetics

Diagnostic approaches in ENT medicine traditionally involve clinical examination, otoscopic and endoscopic evaluation, radiographic imaging, audiometry, vestibular tests, microbiological studies, and histopathology. While these methods are indispensable, they may not fully capture the immunological and genetic factors underlying ENT diseases. Immunogenetics provides an additional layer of diagnostic precision by identifying molecular markers that influence disease susceptibility, progression, and treatment response.

In allergic rhinitis, immunogenetic markers support the identification of individuals with strong predisposition to IgE mediated hypersensitivity. Variants in cytokine genes or IgE receptor gene clusters can help differentiate allergic rhinitis from non allergic chronic rhinitis. Genetic markers may also guide decisions regarding immunotherapy.

In chronic rhinosinusitis, immunogenetic profiles help distinguish subtypes such as eosinophilic chronic rhinosinusitis, aspirin exacerbated respiratory disease, and chronic rhinosinusitis without nasal polyposis. Genetic markers associated with interleukin 5 or eosinophilic inflammation help predict prognosis and guide

therapy selection, including the use of biologics.

In otitis media, identifying genetic predisposition to recurrent infections may guide early intervention in children. Genetic markers associated with immune deficiencies, cytokine dysregulation, or ciliary dysfunction may help differentiate otitis media susceptibility from anatomical factors alone.

In autoimmune inner ear disease, HLA typing supports diagnosis and helps distinguish immune mediated hearing loss from other causes of progressive sensorineural hearing loss. Immunogenetic markers also help identify candidates for immunosuppressive therapy.

In Meniere disease, genetic markers associated with inflammatory pathways may assist in differentiating immune mediated Meniere disease from other vestibular disorders. This supports personalized management strategies.

In head and neck cancers, immunogenetic profiling of tumors provides essential information for diagnosis and classification. Genetic markers related to immune checkpoint expression, tumor antigen presentation, and immune infiltration guide the selection of immunotherapy and predict response to treatment. Tumor mutational burden and immune gene signatures are increasingly used in diagnostic frameworks.

In thyroid disorders with ENT involvement,

immunogenetic markers contribute to the diagnosis of autoimmune thyroid conditions and help differentiate lymphocytic thyroiditis from infectious or neoplastic processes.

In recurrent tonsillitis and adenoid disease, immunogenetic insights help identify children at risk of persistent or severe disease. This diagnostic information may support decisions regarding surgical intervention.

Overall, immunogenetics enhances diagnostic precision in ENT diseases by revealing immune pathways and genetic vulnerabilities that are not apparent through traditional diagnostic tools. Incorporating immunogenetics into diagnostic practice refines disease classification and supports early intervention.

Treatment of ENT Diseases through Immunogenetic Insights

The application of immunogenetics to the treatment of ENT diseases has transformed therapeutic strategies by providing more precise, targeted, and personalized approaches. Traditional treatments include antibiotics, antihistamines, corticosteroids, surgical interventions, immunotherapy, and symptomatic management. While effective, these treatments often do not address immunogenetic mechanisms underlying disease susceptibility. Immunogenetics supports the development of

therapies that modulate specific immune pathways and optimize patient outcomes based on individual immune profiles.

In allergic rhinitis, immunogenetic understanding supports precision immunotherapy. Patients with genetic predisposition to IgE overproduction may benefit from monoclonal antibodies targeting IgE or interleukin pathways involved in allergic responses. Identifying genetic markers helps determine which patients will respond to biologics and which are better suited for conventional immunotherapy.

In chronic rhinosinusitis, targeted biologic therapies have emerged from immunogenetic discoveries. Biologics targeting interleukin 4, interleukin 5, or interleukin 13 pathways offer effective treatment for eosinophilic forms of chronic rhinosinusitis with nasal polyps. Immunogenetic profiling helps identify candidates for these therapies and predict treatment response.

In otitis media, therapies aimed at enhancing mucosal immunity or modulating cytokine responses are being investigated. Immunogenetic insights may guide personalized prophylactic strategies and identify individuals who require more aggressive interventions.

In autoimmune inner ear disease, immunosuppressive therapy is guided by HLA

typing and other immunogenetic markers. Early initiation of corticosteroids, methotrexate, or biologics targeting T cell pathways may preserve hearing when genetic markers indicate autoimmune susceptibility.

In Meniere disease, immunogenetic insights support the use of immunomodulatory therapy in patients with suspected immune mediated disease. Therapies targeting inflammatory pathways may slow disease progression and reduce vestibular symptoms.

In head and neck cancers, immunogenetics has revolutionized treatment through the introduction of immune checkpoint inhibitors targeting PD and CTLA4 pathways. Genetic profiling of tumors helps determine eligibility for immunotherapy and predict response. Personalized cancer vaccines and adoptive T cell therapies rely heavily on immunogenetic analysis to identify target antigens and optimize treatment.

In thyroid autoimmune diseases with ENT manifestations, treatments targeting B cells, T cells, or interferon signaling pathways are informed by immunogenetic markers that predict response and disease severity.

In recurrent tonsillitis and adenoid disease, immunogenetics may guide the use of targeted therapies aimed at modifying mucosal immunity,

potentially reducing the need for surgery in selected patients.

Future directions in immunogenetic treatment include gene therapy to correct immune related genetic defects, microbiome targeted therapies tailored to immunogenetic profiles, personalized vaccines for ENT autoimmune disorders, and regenerative medicine guided by immunogenetic markers. These innovations promise to transform ENT care over the next decade.

Conclusion

Immunogenetics plays an integral role in understanding the etiology, diagnosis, and treatment of ENT diseases. Genetic variation influencing immune responses contributes to disease susceptibility, severity, and clinical presentation across a wide spectrum of ENT disorders. The incorporation of immunogenetic insights into diagnostic practice enhances precision, improves classification, and supports earlier recognition of disease. Immunogenetics has also revolutionized treatment by enabling targeted biologic therapies, personalized immunomodulatory strategies, and customized interventions based on individual immune profiles.

As immunogenetic research advances, ENT medicine will increasingly adopt precision medicine approaches that integrate genomic,

immunologic, and clinical data. Collaboration among otolaryngologists, immunologists, geneticists, and data scientists will be essential for translating immunogenetic discoveries into practice. This ongoing transformation promises to improve outcomes for patients with ENT diseases, reduce disease burden, and create new opportunities for preventive and therapeutic innovation.

9. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF ORTHOPEDIC DISEASES

Background

Orthopedic diseases comprise a wide range of disorders affecting bones, joints, muscles, ligaments, tendons, cartilage, and connective tissues. These diseases include degenerative conditions, autoimmune and inflammatory disorders, infectious diseases, traumatic injuries with immune consequences, congenital skeletal anomalies, metabolic bone diseases, orthopedic cancers, and complications related to implants and prostheses. Orthopedic conditions are among the most common causes of disability worldwide, producing substantial economic burden, chronic pain, reduced mobility, and diminished quality of life. The conventional understanding of orthopedic diseases has traditionally focused on mechanical stress, aging, trauma, and metabolic deterioration. However, advances in immunology and genetics have reshaped this view by clarifying the powerful influence of immune responses and genetic variation on musculoskeletal health.

The musculoskeletal system is not simply a framework for movement; it is a highly dynamic

and immunologically active network of cells and tissues. Bones and joints contain resident immune cells, including macrophages, mast cells, dendritic cells, and lymphocytes, which regulate tissue homeostasis, inflammation, and repair. Synovial tissue contains specialized macrophage and fibroblast populations that coordinate responses to injury and infection. Bone remodeling depends heavily on the interplay between osteoclasts, osteoblasts, and immune mediators such as cytokines and chemokines. The immune system therefore plays a central role in the maintenance of skeletal integrity as well as in the pathogenesis of orthopedic diseases.

Immunogenetics, the study of how inherited genetic variation shapes immune responses, has become essential for understanding orthopedic disorders. Genetic differences influence cytokine production, antigen presentation, immune cell activation, tissue repair mechanisms, and susceptibility to chronic inflammation. These immunogenetic variations help explain why some individuals develop debilitating orthopedic conditions even under modest environmental stress, while others remain resistant despite significant mechanical or metabolic challenges. Conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, osteoarthritis with inflammatory components, osteoporosis,

avascular necrosis, intervertebral disc degeneration, complex regional pain syndrome, and orthopedic implant failure all exhibit immunogenetic influences. Genetic variation in immune pathways also affects susceptibility to orthopedic infections, bone healing after fractures, inflammatory complications of trauma, and tumor immune surveillance in orthopedic oncology.

Modern genomic technologies, including whole genome sequencing, genome wide association studies, single cell transcriptomics, and multiomic profiling, have revealed numerous immunogenetic markers associated with orthopedic diseases. These discoveries have improved the understanding of disease mechanisms and have led to breakthroughs in diagnostics, risk prediction, and the development of personalized therapeutic strategies. Immunogenetics has also contributed to the innovation of targeted biologic therapies, immunomodulatory drugs, and regenerative medicine approaches for orthopedic conditions.

The following sections examine the role of immunogenetics in the etiology, diagnosis, and treatment of orthopedic diseases. This chapter provides a comprehensive analysis of how genetically influenced immune pathways contribute to musculoskeletal disease development, how immunogenetic markers

enhance diagnostic accuracy and classification, and how immunogenetic insights guide modern orthopedic therapeutics.

Etiology of Orthopedic Diseases from an Immunogenetic Perspective

The etiology of orthopedic diseases is multifactorial and influenced by an intricate interplay between genetic predisposition, immune system behavior, mechanical stress, environmental factors, and systemic health conditions. Immunogenetic variation plays a critical role in determining how the musculoskeletal system responds to injury, infection, metabolic stress, and inflammatory stimuli. Genetic differences in immune pathways contribute to the onset and progression of many orthopedic diseases.

Rheumatoid arthritis provides one of the strongest examples of immunogenetic involvement in orthopedic pathology. It is a chronic autoimmune disease characterized by synovial inflammation, joint destruction, bone erosion, and systemic manifestations. The most significant genetic association is with specific HLA class II alleles that shape antigen presentation to T cells. These HLA variants alter immune tolerance and increase susceptibility to autoimmune responses against joint tissues. Additional genetic polymorphisms in cytokine pathways, including

tumor necrosis factor and interleukin 6, amplify inflammatory responses and promote chronic synovial proliferation. Variants in genes regulating T cell activation, B cell behavior, and innate immune receptors further contribute to susceptibility and disease severity.

Ankylosing spondylitis is another orthopedically significant autoimmune disease with strong immunogenetic determinants. The association with the HLA B27 allele is one of the most well established genetic relationships in medicine. HLA B27 influences antigen presentation and misfolding responses that promote chronic inflammation in the spine and sacroiliac joints. Additional genetic variants affecting interleukin 23 and interleukin 17 pathways contribute to the inflammatory processes that drive new bone formation and joint ankylosis.

Psoriatic arthritis, a musculoskeletal manifestation of psoriasis, demonstrates complex immunogenetic regulation involving HLA class I alleles and genetic variants affecting interleukin 12, interleukin 23, and interleukin 17 pathways. These immune pathways influence enthesitis, bone remodeling, and synovial inflammation. Genetic predisposition helps explain why only a subset of individuals with psoriasis develop psoriatic arthritis.

Osteoarthritis, once viewed solely as a degenerative disorder caused by mechanical

wear, is now recognized to have important immunogenetic components. Genetic variants affecting inflammatory mediators, matrix degradation enzymes, innate immune receptors, and cartilage homeostasis contribute to susceptibility and progression. Variants that regulate interleukin 1 signaling and Toll like receptor activation may predispose individuals to heightened inflammatory responses following mechanical joint stress, accelerating cartilage degeneration.

Osteoporosis is a metabolic bone disease influenced by both genetic and immunogenetic factors. The immune system plays a key role in bone remodeling through cytokines that regulate osteoclast and osteoblast activity. Variants in genes regulating interleukin 6, interleukin 1, and receptor activator of nuclear factor kappa beta pathways influence the balance between bone resorption and bone formation. Genetic predisposition may determine susceptibility to inflammation induced bone loss, including in postmenopausal osteoporosis.

Avascular necrosis of bone, characterized by ischemic bone death, can also involve immune mediated mechanisms. Variants affecting coagulation pathways, endothelial function, and inflammatory cytokines may increase susceptibility to vascular compromise and bone necrosis.

Intervertebral disc degeneration is associated with immunogenetic variants that influence inflammatory responses within the disc microenvironment. Variants in interleukin genes, matrix degrading enzymes, and immune receptors contribute to chronic inflammation, disc cell apoptosis, and extracellular matrix breakdown.

Complex regional pain syndrome is a chronic pain condition with neuro immune components. Immunogenetic studies have identified associations with HLA alleles and cytokine gene variants that influence susceptibility and severity.

Orthopedic infections, including osteomyelitis and prosthetic joint infections, demonstrate immunogenetic influences. Variants in innate immune genes such as Toll like receptors and cytokine genes affect susceptibility to infection and the severity of immune responses to bacterial invasion.

Orthopedic implant complications, such as aseptic loosening, involve immune reactions to wear particles and foreign materials. Genetic variants affecting macrophage activation and inflammatory responses may predispose individuals to exaggerated immune reactions that lead to bone resorption around implants.

Orthopedic cancers, including osteosarcoma and chondrosarcoma, involve interactions between tumor cells and the immune system. Genetic

variants influencing immune surveillance and tumor antigen recognition affect susceptibility to malignancy and progression.

Across these conditions, immunogenetic mechanisms contribute significantly to disease pathogenesis. Genetic variation influences antigen processing, cytokine signaling, immune cell activation, tissue repair, and inflammation resolution. Understanding these mechanisms provides essential insight into orthopedic disease etiology.

***Diagnosis and Classification
of Orthopedic Diseases
through Immunogenetics***

Diagnostic approaches in orthopedics traditionally rely on clinical examination, radiography, magnetic resonance imaging, computed tomography, bone density assessment, laboratory testing, histopathology, and arthroscopic evaluation. While these methods are essential, they often provide limited insight into the immunological and genetic mechanisms underlying disease. Immunogenetics enhances diagnostic accuracy and supports improved classification of orthopedic diseases by identifying molecular markers associated with immune dysregulation and genetic susceptibility.

In rheumatoid arthritis, genetic testing for specific HLA alleles can support early diagnosis,

particularly in seronegative patients without detectable autoantibodies. Immunogenetic markers help differentiate rheumatoid arthritis from other forms of inflammatory arthritis such as psoriatic arthritis or reactive arthritis. Genetic profiling may also predict disease severity and the likelihood of joint destruction.

In ankylosing spondylitis, detection of HLA B27 is widely used in diagnostic practice. Although not diagnostic on its own, its presence significantly increases the likelihood of spondyloarthropathy in patients with back pain or sacroiliitis. Immunogenetic markers also help identify early disease before radiographic changes become evident.

In psoriatic arthritis, immunogenetic markers help distinguish the disease from rheumatoid arthritis and other inflammatory arthropathies. HLA class I alleles and cytokine gene variants contribute to classification of disease subtypes, including those with axial involvement, peripheral arthritis, dactylitis, and enthesitis.

In osteoarthritis, immunogenetic studies are helping refine disease classification by identifying subtypes with inflammatory, metabolic, or biomechanical predominance. Genetic markers may help distinguish individuals who have predominantly immune mediated progression from those with primarily mechanical degeneration.

In osteoporosis, immunogenetic markers help identify individuals at risk for rapid bone loss due to inflammation driven mechanisms. Genetic profiling can complement bone density testing in predicting fracture risk.

In intervertebral disc degeneration, immunogenetic markers such as variants in interleukin genes help distinguish inflammatory phenotypes from mechanical or degenerative phenotypes. This refinement supports targeted treatment strategies.

In complex regional pain syndrome, HLA typing and cytokine gene polymorphisms contribute to diagnostic frameworks that help differentiate CRPS from other chronic pain disorders.

In orthopedic infections, immunogenetic markers help identify individuals predisposed to recurrent infections or severe inflammatory responses. Genetic testing may complement microbiological studies by identifying host susceptibility factors.

In orthopedic oncology, immunogenetic profiling supports diagnosis and classification by identifying genetic variants influencing tumor immunogenicity, immune microenvironment, and response to immunotherapy.

Overall, immunogenetics enhances diagnostic frameworks by revealing underlying immune mechanisms and genetic vulnerabilities. Incorporating immunogenetics into orthopedic

diagnostics supports earlier detection, more accurate classification, and personalized clinical decision making.

Treatment of Orthopedic Diseases through Immunogenetic Insights

Immunogenetics has profoundly influenced the treatment of orthopedic diseases by enabling the development of targeted therapies and personalized treatment strategies. Traditional orthopedic treatments include non steroidal anti inflammatory drugs, corticosteroids, physical therapy, surgery, joint replacement, bone grafting, antibiotics for infection, and symptomatic management. While these approaches are important, they do not address the immunogenetic mechanisms underlying many orthopedic conditions. Immunogenetic understanding supports the development of biological therapies, immunomodulatory strategies, regenerative medicine approaches, and personalized treatment plans.

In rheumatoid arthritis, biologic therapies that target specific immune pathways have revolutionized treatment. Tumor necrosis factor inhibitors, interleukin 6 receptor antagonists, B cell depletion therapies, and T cell costimulation inhibitors are used to suppress autoimmune inflammation and prevent joint destruction. Immunogenetic markers help predict which

patients are likely to respond to specific biologics. Pharmacogenomic testing may also guide the selection of targeted therapies and reduce adverse effects.

In ankylosing spondylitis, therapies targeting interleukin 17 and interleukin 23 pathways have significantly improved outcomes for patients. Genetic markers associated with cytokine dysregulation may help identify individuals who will benefit most from these biologics. Early initiation of therapy based on immunogenetic risk profiles can prevent severe spinal fusion.

In psoriatic arthritis, immunogenetic insights support the use of biologics targeting interleukin 12, interleukin 23, and interleukin 17 pathways. Genetic profiling helps identify patients with inflammatory phenotypes who require aggressive treatment.

In osteoarthritis, immunogenetic research supports the investigation of targeted anti-inflammatory therapies for individuals with immune mediated phenotypes. Therapies targeting interleukin 1 or other inflammatory mediators may benefit select patients. Regenerative medicine approaches, such as mesenchymal stem cell therapy or platelet rich plasma injections, may be optimized using immunogenetic profiles.

In osteoporosis, immunogenetics supports

treatment strategies aimed at modulating immune pathways that influence bone remodeling. Therapies targeting RANKL, sclerostin, and inflammatory cytokines may be tailored to genetic risk.

In intervertebral disc degeneration, therapies targeting inflammatory pathways may be informed by genetic susceptibility. Immunogenetic analysis may guide the use of biologics, stem cell therapy, or gene therapy for disc regeneration.

In avascular necrosis, immunogenetic markers may help identify individuals at risk for inflammatory vascular compromise and guide early intervention.

In complex regional pain syndrome, immunogenetic insights support the development of immune targeted therapies aimed at reducing inflammation and modulating neuro immune interactions.

Orthopedic infections may benefit from immunogenetic guidance in selecting immunomodulatory treatments that enhance host defense or reduce excessive inflammation.

In orthopedic oncology, immunogenetic profiling guides the use of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. These therapies rely on understanding tumor antigens and immune microenvironment characteristics.

Future directions in immunogenetic treatment of orthopedic diseases include gene editing to correct immune related genetic defects, personalized vaccines to modulate autoimmune responses, cell based therapies tailored to immunogenetic profiles, and microbiome modulation strategies to reduce inflammation and enhance bone health.

Conclusion

Immunogenetics plays a central role in understanding the etiology, diagnosis, and treatment of orthopedic diseases. Genetic variation in immune pathways shapes susceptibility to inflammation, bone remodeling, autoimmune responses, tumor development, and infection. Incorporating immunogenetic information into diagnosis enhances accuracy, supports personalized classification, and identifies individuals at risk for severe disease. In treatment, immunogenetic insights have revolutionized orthopedic practice by enabling targeted biologic therapies, personalized immunomodulatory strategies, and advanced regenerative approaches.

As research in immunogenetics continues to expand, orthopedic medicine will increasingly adopt precision approaches based on genomic, immune, and clinical integration. Collaboration among orthopedic specialists, immunologists, geneticists, and computational scientists will be essential for translating immunogenetic

discoveries into effective clinical practice. Through continued innovation, immunogenetics will shape the future of orthopedic care by improving patient outcomes, reducing disease burden, and advancing personalized musculoskeletal medicine.

10. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF CANCERS

Background

Cancer is one of the most significant health and social challenges in the world, affecting millions of people every year. According to the World Health Organization, cancers are the second leading cause of death globally and create a substantial economic and psychological burden on families and health systems. Recent scientific advances have shown that not only environmental and lifestyle factors but also the foundations of genetics and individual immunity play a key role in the incidence, progression, and response to cancer treatment.

Immunogenetics is a branch of the biological sciences that studies the effect of genetic diversity on immune system function. This field has become one of the main axes of cancer research in recent decades with tremendous advances in genomics and immunology technologies. The study of HLA (Human Leukocyte Antigen) genes, genetic polymorphisms associated with immune responses, and their effects on cancer cell identification has provided better access to understanding molecular and epidemiological

pathways related to cancer.

One of the important advances in this field is next generation sequencing and single cell methods, which allow the identification of neoantigens and the accurate profiling of tumor immune cells. These technologies are used not only in basic research but also in the development of personalized therapies. For example, the neoantigens identified through genetic analysis of tumors have made it possible to design anti cancer vaccines and have provided cell based therapies such as CAR T treatments.

Innate and adaptive immunity are the two main pillars of the body's defense against cancer cells. The innate immune system provides the first line of defense using NK cells, macrophages, and dendritic cells, while the adaptive immune system generates a targeted and long lasting response through T and B cells. Immunogenetic studies have shown that genetic variation in these pathways can determine an individual's susceptibility to cancer and can help predict the response to immunotherapy treatments.

Recent advances in immunotherapy, including immune checkpoint inhibitors and neoantigen based vaccines, have further emphasized the importance of understanding immune genetics in the design of treatment strategies. The combined study of the genome and the immune system allows researchers to identify biomarkers that

predict treatment response, disease recurrence, and drug tolerance.

Another critical aspect of immunogenetics is the connection between genetic factors and environmental or lifestyle influences in the incidence of cancer. For example, people with specific polymorphisms in HLA genes may be more sensitive to environmental factors such as air pollution, diet, or viruses and may therefore be more likely to develop lung, liver, or colorectal cancers. Recent epidemiological studies analyzing genome wide data have shown that the complex interaction between genetics and environment can modify immune pathways and contribute to tumor progression.

In addition, the gut microbiome and other resident microbial communities play a key role in regulating immune responses and even in the progression of cancer. Evidence suggests that the composition of the microbiota can affect antitumor T cell activity and the level of peripheral inflammation, and that these effects are influenced by host genetic polymorphisms. Therefore, the study of immunogenetics is not limited to classical immune genes, and the interaction between genetics, environment, and the microbiome is also highly important.

From a clinical perspective, immunogenetics has a vital role in identifying high risk patients, selecting the optimal treatment, and predicting

responses to immunotherapy. For example, some HLA alleles are associated with a better response to PD 1 inhibitors, while others may be associated with drug resistance. This information forms the basis for designing personalized and tailored treatments and can significantly increase clinical success rates.

The Role of Immunogenetics in Cancer Etiology

Cancers are complex diseases caused by a combination of genetic, environmental, and immune factors. During this process, the immune system plays a vital role in preventing tumors by recognizing and removing cancer cells. However, in some individuals, genetic defects in immune system pathways can lead to a failure to recognize or eliminate cancer cells, which results in the occurrence of cancer. The study that investigates the relationship between genetics and the immune system in the incidence of cancer is referred to as immunogenetics.

HLA genes and Cancer Risk

One of the major immunogenetic findings in cancer is the role of HLA genes in shaping the immune response to tumor cells. Different HLA alleles can increase or decrease the ability to present tumor antigens to T lymphocytes, thereby influencing the likelihood of developing cancer. For example, some population based studies have

found that certain HLA alleles are associated with an increased risk of lung cancer, while others may have a protective effect. These findings suggest that genetic variation in the HLA system can be a key factor in explaining individual differences in susceptibility to cancer.

Genetic Variation and Lung Cancer in Smokers and Non Smokers

Lung cancer is one of the most common and deadliest types of cancer. Immunogenetic research has shown that genetic differences between smokers and non smokers play an important role in the mechanisms leading to this disease. In smokers, certain genetic changes that weaken anti tumor immune responses are more common. This indicates that in addition to environmental factors such as tobacco use, genetic predisposition also plays a decisive role in the development of cancer.

Inverse Relationship Between Cancer and Alzheimer's Disease

Recent studies have shown that there is an inverse relationship between the incidence of cancer and Alzheimer's disease. This phenomenon, initially observed epidemiologically, has also been examined in immunogenetic research. Evidence suggests that genetic and immune pathways involved in cancer and Alzheimer's disease may function in opposite directions, where the activation of certain genes and immune pathways

increases the risk of cancer but simultaneously reduces the risk of developing Alzheimer's disease. These findings demonstrate the complexity of immunogenetic interactions across different diseases.

Molecular Immunogenetic Mechanisms in Cancer

Immunogenetics helps us better understand how genetic changes lead to alterations in immune responses and contribute to the development of cancer. Some of the key mechanisms include:

Creation of neoantigens: Gene mutations in cancer cells lead to the production of abnormal proteins that can be identified as novel antigens.

Impairment of innate and acquired immune pathways: Changes in genes involved in the production of cytokines and immune receptors can disrupt the balance of immune responses.

Immune evasion: Certain genetic changes allow cancer cells to evade detection and removal by the immune system.

Case Studies in Specific Cancers

Colorectal cancer: Genetic polymorphisms in genes that regulate immune responses, including PD 1 and CTLA 4, can be associated with a higher risk of colorectal cancer.

Breast cancer: The association between genetic variation in the genes of the interferon pathway

and the risk of breast cancer has been examined in several studies.

Liver cancer (HCC): In patients with hepatitis B or C, variation in HLA genes can increase the risk of chronic liver disease progressing into liver cancer.

The Role of Immunogenetics in the Diagnosis and Classification of Cancers

Early and accurate detection of cancer is one of the major challenges faced by modern medicine. Due to the molecular complexity and high diversity of cancers, traditional diagnostic methods still have many limitations. By providing detailed insights into the genetic profile and immune characteristics of patients, immunogenetics enables more accurate diagnosis and supports the personalization of cancer classification.

With the help of advanced techniques such as next generation sequencing and RNA sequencing, the genetic and immunologic profile of each tumor can be identified. This information helps clinicians determine not only the type of cancer but also its molecular subtypes based on immunogenetic biomarkers and allows them to select the most appropriate treatment options.

Immunogenomic Profile in Triple Negative Breast Cancer (TNBC)

Triple negative breast cancer is one of the most

difficult forms of breast cancer to treat because of the lack of hormonal and HER2 receptors. Immunogenomic studies have shown that this cancer consists of several molecular subtypes, each characterized by a specific immunogenetic signature. Identifying these signatures can help guide the selection of targeted therapies.

Cholangiocarcinoma and Immunogenetic Signature

Cholangiocarcinoma is one of the rare and aggressive cancers that is often diagnosed at advanced stages. Immunogenetic research has demonstrated that this cancer possesses a specific immunologic signature that can be applied to the design of targeted therapies and the development of improved diagnostic approaches.

Colorectal Cancer and Immunogenetic Mechanisms

Colorectal cancer is one of the clearest examples of a malignancy in which the role of immunogenetics has been extensively studied. Gene mutations in this cancer contribute to the production of tumor antigens that may serve as targets for immunotherapy treatments. Research has shown that genetic variation in colorectal cancer can influence the strength of the immune response, the effectiveness of therapy, and the overall prognosis of patients.

The Role of Immunogenetic Biomarkers in Early Detection

One important application of immunogenetics is the identification of biomarkers that can be used for the early detection of cancers. These biomarkers often include gene expression profiles related to the immune system that are capable of detecting early stage disease with high sensitivity and specificity. Some examples include:

PD L1 and PD 1: The expression levels of these proteins in cancer cells can help predict responses to immunotherapy.

Neoantigens: Genetic alterations lead to the formation of new proteins that can serve as targets for T cells.

HLA typing: Determining the pattern of HLA alleles can assist in predicting immune responses and cancer risk.

Molecular Imaging and Immunogenetics

Advances in molecular imaging technologies now allow the integration of imaging information with immunogenetic profiles. This combined approach can play a significant role in early tumor identification and in determining the aggressiveness of cancers. Molecular imaging techniques, along with genetic and immunologic data, provide a powerful set of tools for accurate

cancer diagnosis. Examples include:

PET or CT using molecular tracers, which have the ability to identify small tumors with high metabolic activity.

Imaging based on labeled antibodies, which makes it possible to trace cancer cells that express specific proteins.

DNA based imaging probes, which enable the tracking of genetic alterations and the expression of specific genes in tumors.

Application of Bioinformatics in Diagnosis and Classification

Macroanalysis of genetic and immune related data requires advanced bioinformatics methods. By using machine learning techniques and artificial intelligence algorithms, hidden patterns within the data can be identified, and patients can be categorized based on risk levels and expected treatment responses. These computational methods have improved the accuracy of diagnosis in several rare cancers such as cholangiocarcinoma and sarcomas, and they continue to enhance the precision of cancer classification.

The Role of Immunogenetics in Cancer Treatment

Cancer treatment has rapidly shifted from general therapeutic approaches such as

chemotherapy and radiation therapy to precision medicine and highly personalized treatment strategies. Immunogenetics, through its detailed understanding of genetic profiles and immune characteristics, makes it possible to design targeted therapies and personalized immunotherapy. This section reviews new methods and technologies in cancer treatment, with a focus on the influence and importance of immunogenetics.

Precision Medicine Based on Immunogenetics

Recent advances in high speed technologies such as next generation sequencing have enabled comprehensive analysis of genetic and immunogenic alterations in cancer. This approach allows clinicians to personalize treatments based on each patient's genetic and immune profile. As a result, treatment effectiveness can increase and adverse effects may be reduced. Immunogenetics also supports the identification of unique characteristics of tumors, including the patient's individual genetic profile, the identification of driver and passenger mutations in cancer related genes, the tumor immune profile such as PD L1 expression, the presence of neoantigens, and the type and activation state of T cells. By combining genetic and immunologic information, clinicians can predict treatment responses and select the most appropriate drugs and therapeutic

combinations.

Anti Cancer Vaccines Based on Neoantigens

One of the most promising developments in cancer therapy is the creation of personalized vaccines that target tumor specific neoantigens. These vaccines can generate a precise immune response against cancer cells and have produced encouraging results in early clinical studies. The general process includes the identification of neoantigens through next generation sequencing and RNA sequencing, the design of a personalized vaccine to stimulate T cell responses, and the evaluation of clinical effects on tumor reduction and enhanced immune activity.

The Role of Immunogenetics in Response to Immunotherapies

Responses to immunotherapies vary greatly among patients. Research has shown that specific genetic variations can predict stronger or weaker responses to immunotherapy. Patients who possess certain HLA alleles may demonstrate improved responses to immune checkpoint inhibitors. These inhibitors, which target PD 1, PD L1, and CTLA 4, are central components of modern cancer therapy. Their effectiveness is influenced by genetic and immune related factors such as the presence of active neoantigens, the abundance of functional T cells, and the combination

of immunotherapy with other treatments like chemotherapy or radiation therapy, which may increase therapeutic effectiveness.

Immunogenetic Perspective in Prostate Cancer

Although substantial progress has been made in understanding the immunogenetics of many cancers, the role of immunogenetics in prostate cancer has not been thoroughly investigated. Early studies indicate that examining immune and genetic pathways in prostate cancer may lead to the identification of new therapeutic targets and could contribute to more personalized treatment strategies.

Modern Cell Therapy and Immunogenetics

New cell based therapies, including CAR T cell therapy, rely directly on immunogenetic discoveries to design engineered receptors that target specific tumor antigens. These therapies have shown remarkable success in certain leukemias, and ongoing research aims to expand their use to solid tumors. In this approach, T cells are collected from the patient's blood, genetically modified to express synthetic receptors, and returned to the patient to attack tumor cells. Another promising method is TIL therapy, which uses tumor infiltrating lymphocytes to strengthen the body's natural immune response by enhancing

the activity of immune cells already present in the tumor environment.

The Role of Immunogenetics in Cancer Prevention and Predictive Medicine

Immunogenetics is not only essential for diagnosing and treating cancer but also plays an important role in prevention and early risk assessment. Advances in genetic analysis and immunology now make it possible to screen individuals for their genetic and immune profiles before cancer develops. Based on this information, preventive interventions, lifestyle recommendations, or closer clinical monitoring can be implemented.

HLA Based Screening and Genetic Polymorphisms

Research has shown that certain HLA alleles increase the risk of developing various cancers, including lung, breast, liver, and melanoma. Identifying these alleles in high risk populations allows for the development of targeted and more efficient screening programs. This type of approach may eventually become a standard predictive test, similar to how BRCA screening is used in breast cancer risk assessment.

The Role of Immunogenetics in Vaccine Prevention

The discovery of tumor related neoantigens and

other antigenic structures has opened the way for the development of preventive cancer vaccines. A leading example is the HPV vaccine, which has significantly reduced the incidence of cervical cancer and demonstrates how an immune based preventive intervention can dramatically change cancer outcomes. Current research is exploring the possibility of creating personalized preventive vaccines shaped by each individual's genetic profile, with the potential to prevent cancer before it develops.

Predictive Medicine with the Help of Bioinformatics and Artificial Intelligence

The large volume of genetic and immune related data generated from international projects such as TCGA and ICGC has created unique opportunities for predicting cancer incidence. Artificial intelligence models can estimate cancer risk at the individual level by integrating genomic data, HLA typing, microbiome information, and environmental factors. This approach can support the design of rigorous and highly personalized prevention plans that may include individualized diets, regular clinical monitoring, and targeted preventive treatments.

The Role of the Microbiome and Immunity in Prevention

Recent studies have shown that regulating

the gut microbiome may help reduce chronic inflammation and thereby lower the risk of cancer development. Immunogenetics contributes to understanding why certain individuals are more vulnerable to microbiome imbalances and why specific genetic differences in immune related genes make some people more prone to inflammation driven cancers.

In the near future, each person may have a personal immunogenetic profile that predicts their cancer risk level and guides the design of specific preventive measures tailored to their biology. These measures may include personalized vaccines, microbiome regulating supplements, regular genomic monitoring, and lifestyle interventions that are directly based on individual genetic characteristics.

Future Challenges and Prospects

Challenges

Separating causative mutations from associated mutations is difficult, since many genetic changes observed in cancer may coexist with the disease without playing a direct causal role.

The high diversity of cancers, each with its own unique immunogenetic profile, makes it challenging to generalize research findings across different cancer types.

In some cancers such as prostate cancer or

pancreatic cancer, immunogenetic data remain limited and insufficient for drawing strong conclusions.

The cost and accessibility of new technologies such as next generation sequencing and immunoprofiling remain significant barriers in many regions, limiting their availability to patients.

Perspectives

The use of artificial intelligence for analyzing complex immunogenomic data has the potential to reveal new biological patterns that are not detected by conventional methods.

The development of personalized vaccines based on neoantigens may transform future cancer treatment strategies and significantly improve therapeutic outcomes.

The integration of genetic, immunologic, and clinical information will enable the creation of multidimensional models, which can lead to more accurate treatment planning.

Predictive medicine, supported by immunogenetic information, will allow cancer risk assessment in healthy individuals and guide preventive strategies tailored to each person.

Conclusion

As an interdisciplinary field located at the intersection of genetics and immunology,

immunogenetics is playing an increasingly significant role in understanding the etiology, diagnosis, treatment, and prevention of cancer. A review of recent research shows several important findings.

First, in cancer etiology, HLA genes and other immune related polymorphisms can influence a person's susceptibility to different cancer types. The interaction of environmental exposures such as cigarette smoke, air pollution, and dietary factors with genetic predispositions creates molecular pathways that contribute to cancer development.

Second, in cancer diagnosis and classification, immunogenetic biomarkers have improved the accuracy of tumor identification, prognosis, and molecular subtype classification. These advances have enhanced early detection and supported more precise therapeutic decision making.

Third, in cancer treatment, immunogenetics has provided the foundation for new therapeutic approaches such as neoantigen based vaccines, cell therapies including CAR T and TCR T treatments, immune checkpoint inhibitors, and RNA based therapies.

Fourth, in prevention and predictive medicine, the use of genomic information, HLA typing, and microbiome profiles enables the personalized prediction of cancer risk and the implementation of targeted preventive strategies for each

individual.

Overall, immunogenetics is not only essential for understanding the biological mechanisms underlying cancer but also a powerful tool for shaping the future of person centered medicine based on prevention and precise treatment. Achieving these goals requires broad collaboration among experts in genetics, immunology, bioinformatics, epidemiology, and clinical practice.

11. ROLE OF IMMUNOGENETICS IN THE ETIOLOGY, DIAGNOSIS, AND TREATMENT OF OTHER DISEASES

Role of Immunogenetics in the Etiology, Diagnosis, and Treatment of Autoimmune Disorders

Background

Autoimmune disorders comprise a broad and complex category of diseases characterized by inappropriate immune responses directed against self tissues. These conditions affect virtually every organ system in the human body and include systemic diseases such as systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis, as well as organ specific disorders such as type 1 diabetes, autoimmune thyroiditis, multiple sclerosis, celiac disease, vitiligo, autoimmune hepatitis, and inflammatory bowel disease. The global burden of autoimmune diseases has increased significantly in recent decades, making them a major public health concern. Although the reasons behind this increase remain partially understood, rapid changes in environmental exposures, lifestyle factors, microbiome diversity, and infectious patterns are believed to interact with genetic predisposition in driving autoimmunity.

The immune system has evolved to distinguish self from non self and to eliminate pathogens while maintaining tolerance to the body's own tissues. This delicate balance is regulated through mechanisms involving central tolerance, peripheral tolerance, antigen presentation, cytokine signaling, regulatory immune cells, and feedback networks that suppress excessive immune activation. Autoimmune diseases arise when this equilibrium is disrupted. Genetic variation plays a fundamental role in shaping these immune processes. The field of immunogenetics focuses on how inherited genetic differences influence immune responses and predispose individuals to autoimmunity. It explores the role of specific genes, gene complexes, polymorphisms, copy number variations, epigenetic modifications, and molecular pathways that regulate both innate and adaptive immunity.

Advances in genome wide association studies, whole genome sequencing, single cell profiling, epigenomic analysis, and multiomic integration have profoundly expanded knowledge about the genetic basis of autoimmunity. These technologies have identified hundreds of susceptibility loci across various autoimmune disorders. Many of these loci are shared across diseases, suggesting that common immunogenetic mechanisms underlie diverse clinical manifestations. For example, variants within the human leukocyte

antigen region are repeatedly implicated in numerous autoimmune conditions. Other genetic variants regulate cytokine production, immune cell signaling, antigen processing, and immune tolerance pathways. The growing understanding of immunogenetics has transformed the conceptualization of autoimmune disorders from clinically defined diseases to biologically defined conditions shaped by genetic and immune pathways.

Immunogenetics is also increasingly applied in diagnosing autoimmune diseases, refining classification, predicting progression, anticipating therapeutic response, and designing targeted treatments. Innovations in precision medicine have made it possible to use genetic markers to personalize therapeutic strategies, reducing side effects and improving outcomes. As the field continues to progress, immunogenetics promises to play an even greater role in understanding autoimmunity, improving diagnostic accuracy, and guiding individualized therapies.

The following sections examine how immunogenetics contributes to the etiology, diagnosis, and treatment of autoimmune disorders, highlighting both established mechanisms and emerging scientific insights shaping the future of autoimmune medicine.

Etiology of Autoimmune Disorders

from an Immunogenetic Perspective

The etiology of autoimmune disorders is multifactorial and involves the interaction between genetic susceptibility, immune dysregulation, environmental triggers, and stochastic biological events. Immunogenetic research has demonstrated that inherited variations in immune related genes create a predisposition to loss of self tolerance, abnormal antigen recognition, and chronic inflammation. These genetic variations do not act in isolation but instead interact with environmental exposures such as infections, diet, pollutants, stress, and microbiome alterations to initiate autoimmunity.

The human leukocyte antigen region remains the strongest and most consistent immunogenetic determinant across autoimmune diseases. The HLA region encodes molecules responsible for presenting antigenic peptides to T cells, thus playing a central role in immune activation and tolerance. Specific HLA class I and class II alleles significantly increase susceptibility to diseases such as type 1 diabetes, multiple sclerosis, ankylosing spondylitis, rheumatoid arthritis, celiac disease, autoimmune thyroiditis, and autoimmune hepatitis. These associations reflect how particular HLA molecules bind and present self antigens more efficiently or with altered affinity, promoting autoimmune recognition.

Non HLA genes also contribute significantly

to susceptibility. Variants in genes regulating cytokine signaling pathways such as those encoding interleukin 2, interleukin 7, interleukin 23, and interferons influence the balance between pro inflammatory and regulatory responses. Dysregulation of cytokine production or signaling can promote chronic inflammation and loss of immune tolerance. Genetic variants affecting pathways of innate immunity, including Toll like receptors, nod like receptors, and complement components, influence the activation threshold of immune responses to pathogens or self derived molecules. Some variants promote exaggerated innate responses that prime adaptive immune activation.

Genes involved in regulatory T cell development and function are critical for maintaining immune tolerance. Variants in genes encoding transcription factors such as FOXP3, signaling molecules involved in T cell activation, and costimulatory pathways influence the ability of regulatory T cells to suppress autoreactive lymphocytes. Defects in these mechanisms greatly increase susceptibility to autoimmunity.

Epigenetic mechanisms, including DNA methylation, histone modification, and non coding RNA regulation, also contribute to autoimmune pathogenesis. While epigenetic modifications are not strictly genetic, they are influenced by both inherited predisposition and

environmental exposures. Epigenetic alterations can modify gene expression without altering DNA sequence, creating conditions conducive to autoimmunity. These modifications may also explain why autoimmune diseases exhibit variable penetrance even among individuals with identical genetic variants.

Environmental factors interact with immunogenetic susceptibility to trigger autoimmunity. Infectious agents can initiate autoimmunity through molecular mimicry, epitope spreading, bystander activation, or persistent immune activation. Genetic predisposition determines whether immune responses to infection resolve or evolve into chronic autoimmune responses. Microbiome composition plays an important role in shaping immune development, and genetic variation influences the interaction between host immunity and microbial communities. Dysbiosis resulting from genetic or environmental influences may lead to increased intestinal permeability, abnormal immune activation, and systemic autoimmune responses.

Sex related differences in autoimmune disease prevalence are also influenced by immunogenetics. Women exhibit higher rates of many autoimmune disorders due to interactions between genetic and hormonal factors. Genes located on the X chromosome, which carries

numerous immune related genes, contribute to sex differences in susceptibility.

Taken together, immunogenetics provides a comprehensive framework for understanding the etiology of autoimmune disorders. Genetic variation influences antigen presentation, immune cell activation, cytokine signaling, regulatory mechanisms, and interactions with environmental stimuli, all of which contribute to the initiation and progression of autoimmunity.

Diagnosis and Classification of Autoimmune Disorders through Immunogenetics

Diagnosis of autoimmune diseases traditionally relies on clinical evaluation, serological markers, imaging, histopathology, and functional testing. However, many autoimmune disorders present with overlapping symptoms, nonspecific clinical signs, and variable progression. Immunogenetics enhances diagnostic precision by identifying molecular markers associated with susceptibility, early onset, and specific clinical phenotypes. Genetic information supports early diagnosis, disease stratification, and prognostic assessment.

HLA typing is widely used in the diagnosis of autoimmune diseases. In type 1 diabetes, specific HLA class II haplotypes greatly increase disease likelihood and are used to identify at risk individuals before clinical onset. In celiac disease,

the presence of specific HLA alleles is required for disease development, and their absence effectively rules out the diagnosis. In ankylosing spondylitis, HLA B27 typing supports diagnosis, particularly in early disease when imaging may be inconclusive. In autoimmune hepatitis, HLA variants help differentiate autoimmune pathology from viral or metabolic liver disease.

Non HLA genetic markers also contribute to diagnosis. Variants in genes regulating cytokine signaling, T cell activation, or innate immune responses may help distinguish autoimmune diseases with similar symptoms. For example, genetic markers assist in differentiating multiple sclerosis from neuromyelitis optica spectrum disorder. Genetic variants associated with interferon pathways provide diagnostic clues in systemic lupus erythematosus and influence classification of disease subtypes.

Immunogenetics also supports diagnosis of primary immunodeficiencies that present with autoimmune complications. Identifying genetic defects in immune regulation helps differentiate primary autoimmune disorders from immunodeficiency related autoimmunity. This distinction is clinically important because treatment strategies differ significantly.

Classification of autoimmune diseases is enhanced through immunogenetic profiling. Genetic information helps delineate disease

subtypes based on molecular mechanisms rather than solely on clinical presentation. This refined classification improves prediction of disease course and response to therapy. Genetic clustering of autoimmune diseases also reveals shared pathways across conditions, such as the overlap between psoriasis, inflammatory bowel disease, and ankylosing spondylitis, which share pathogenic mechanisms involving interleukin 23 and interleukin 17 pathways.

In rheumatic diseases, immunogenetic markers contribute to classification criteria for systemic lupus erythematosus, rheumatoid arthritis, and juvenile idiopathic arthritis. Genetic markers support redefinition of disease boundaries, helping identify distinct autoimmune syndromes or overlapping conditions that require specialized treatment.

Overall, immunogenetics enhances diagnostic accuracy, refines classification, and supports early detection of autoimmune disorders. Incorporating these insights into clinical practice allows for more personalized and timely medical care.

Treatment of Autoimmune Disorders through Immunogenetic Insights

Immunogenetics has transformed the treatment landscape for autoimmune disorders by enabling the development of targeted therapies,

improving prediction of treatment response, and guiding personalized therapeutic strategies. Traditional treatments for autoimmune diseases include corticosteroids, broad spectrum immunosuppressants, nonsteroidal anti inflammatory drugs, and symptomatic therapies. While effective for some patients, these treatments often produce significant side effects and fail to address underlying immunological mechanisms. Immunogenetic insights have spurred the development of therapies that target specific immune pathways involved in disease pathogenesis.

Biologic therapies represent one of the most important advances in autoimmune treatment. These therapies target cytokines, immune cell receptors, costimulatory molecules, or immune cell populations. Tumor necrosis factor inhibitors, interleukin 6 receptor antagonists, interleukin 1 inhibitors, interleukin 17 inhibitors, and interleukin 23 blockers have profoundly improved outcomes for patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Immunogenetic markers help identify patients most likely to respond to each biologic therapy.

In multiple sclerosis, therapies targeting B cells, T cell migration, and interferon pathways are guided by immunogenetic understanding of disease mechanisms. Genetic markers

may predict treatment response or risk of adverse reactions such as progressive multifocal leukoencephalopathy.

In systemic lupus erythematosus, therapies targeting B cell activation, interferon signaling, and immune complex formation reflect immunogenetic mechanisms identified through genomic studies. Targeted therapies such as B cell depletion agents and interferon blockade therapies offer improved control of disease with fewer side effects.

In type 1 diabetes, immunogenetic understanding has informed strategies aimed at preserving beta cell function through immunomodulation. Therapies targeting T cell pathways or costimulatory signals are being explored as preventive or early intervention strategies.

In autoimmune thyroid disease, genetic insights into immune tolerance have supported the development of therapies aimed at modulating B cell activation or reducing chronic inflammation.

In celiac disease, immunogenetic knowledge has guided research into peptide based immunotherapies designed to induce tolerance to gluten in genetically predisposed individuals.

Gene therapy and gene editing technologies represent future opportunities for correcting immunogenetic defects and restoring immune tolerance. Therapies aimed at modifying

regulatory T cells, enhancing immune checkpoint pathways, or correcting specific genetic mutations are being explored.

Immunogenetics also informs the use of small molecule therapies such as JAK inhibitors and S1P receptor modulators. These treatments target intracellular immune signaling pathways influenced by genetic variation.

Personalized medicine approaches emerging from immunogenetic research allow clinicians to tailor treatment based on genetic risk, predicted therapeutic response, and likelihood of adverse events. Pharmacogenomic testing may optimize dosing of immunomodulatory drugs and reduce toxicity.

Immunogenetics also contributes to regenerative medicine approaches for autoimmune disorders by guiding selection of cell based therapies and identifying immune barriers to tissue regeneration.

Overall, immunogenetics enables a shift from generalized immunosuppression toward precise immunomodulation that targets the root causes of autoimmune disease.

Conclusion

Immunogenetics plays a foundational role in the etiology, diagnosis, and treatment of autoimmune disorders. Genetic variation in immune pathways

shapes susceptibility to autoimmune diseases, influences antigen presentation, modulates immune tolerance, and determines inflammatory responses. Incorporating immunogenetic insights into diagnostic practice enhances accuracy, supports early detection, and refines disease classification. In treatment, immunogenetics has revolutionized management by enabling targeted biologic therapies, personalized immunomodulation, and innovative approaches that address underlying immune dysregulation rather than suppressing immunity globally.

As immunogenetic research continues to expand, autoimmune medicine will increasingly incorporate genomic, immunologic, and clinical data to develop highly individualized therapeutic strategies. Continued collaboration among geneticists, immunologists, clinicians, computational biologists, and translational scientists will be essential for fully integrating immunogenetics into clinical practice. Through these advancements, the future of autoimmune medicine promises to deliver more effective, safer, and more personalized care, ultimately improving outcomes and quality of life for patients worldwide.

REFERENCES

1. Abd El-Fattah EE, Abdelhamid AM. Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung. *Toxicology*. 2021;463:152994.
2. AbdelMassih AF, Fouda R, Kamel A, Mishriky F, Ismail HA, El Qadi L, et al. Single cell sequencing unraveling genetic basis of severe COVID19 in obesity. *Obes Med*. 2020;20:100303.
3. AbdelMassih AF, Menshawey R, Ismail JH, Husseiny RJ, Husseiny YM, Yacoub S, et al. PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature. *J Genet Eng Biotechnol*. 2021;19(1):82.
4. Abedalthagafi M, Barakeh D, Foshay KM. Immunogenetics of glioblastoma: the future of personalized patient management. *NPJ Precis Oncol*. 2018;2:27.
5. Aboulaghras S, Piancatelli D, Oumhani K, Balahbib A, Bouyahya A, Taghzouti K. Pathophysiology and immunogenetics of celiac disease. *Clin Chim Acta*. 2022;528:74-83.
6. Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the

European Research Initiative on CLL. *Leukemia*. 2022;36(8):1961-8.

7. Agathangelidis A, Chatzikonstantinou T, Stamatopoulos K. B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients. *Semin Hematol*. 2024;61(2):91-9.

8. Agathangelidis A, Vlachonikola E, Davi F, Langerak AW, Chatzidimitriou A. High-Throughput immunogenetics for precision medicine in cancer. *Semin Cancer Biol*. 2022;84:80-8.

9. Ahmadi SAY, Shahsavari F, Anbari K, Rezaian J. An introduction to the role of immunology in medical anthropology and molecular epidemiology. *Biomed Pharmacother*. 2019;109:2203-9.

10. Aiello A, Accardi G, Candore G, Caruso C, Colomba C, Di Bona D, et al. Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing. *Int J Mol Sci*. 2019;20(3).

11. Aiello A, Candore G, Accardi G, Caruso C, Colomba C, Duro G, et al. Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases. *Curr Pharm Des*. 2018;24(26):3113-22.

12. Akhtar N, Verma KK, Sharma A. Immunogenetics of cytokine genes in parthenium dermatitis: a review. *Eur Ann Allergy Clin Immunol*. 2018;50(2):59-65.

13. Al-Rashed M, Foshay K, Abedalthagafi M. Recent Advances in Meningioma Immunogenetics. *Front Oncol*. 2019;9:1472.

14. Ali A, Baby B, Vijayan R. From Desert to Medicine: A Review of Camel Genomics and Therapeutic Products. *Front Genet*. 2019;10:17.

15. Aliyu M, Zohora FT, Ceylan A, Hossain F, Yazdani R, Azizi G. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches. *Immunopharmacol Immunotoxicol*. 2024;46(3):355-77.

16. Amoroso A. [Immunogenetics of glomerulopathies]. *G Ital Nefrol*. 2015;32 Suppl 64.

17. Anagnostouli M, Markoglou N, Chrousos G. Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications. *Hormones (Athens)*. 2020;19(4):485-96.

18. Angrand L, Masson JD, Rubio-Casillas A, Nosten-Bertrand M, Crépeaux G. Inflammation and Autophagy: A Convergent Point between Autism Spectrum Disorder (ASD)-Related Genetic and Environmental Factors: Focus on Aluminum Adjuvants. *Toxics*. 2022;10(9).

19. Antony JM, MacDonald KS. A critical analysis of the cynomolgus macaque, *Macaca fascicularis*, as a model to test HIV-1/SIV vaccine efficacy. *Vaccine*. 2015;33(27):3073-83.

20. Aran A, Garrigós L, Curigliano G, Cortés J, Martí M. Evaluation of the TCR Repertoire as

a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? *Cancers (Basel)*. 2022;14(7).

21. Araujo-Ayala F, Béguelin W. Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics. *Blood*. 2025;146(15):1759-69.

22. Arenella M, Matuleviciute R, Tamouza R, Leboyer M, McAlonan G, Bralten J, et al. Immunogenetics of autism spectrum disorder: A systematic literature review. *Brain Behav Immun*. 2023;114:488-99.

23. Armstrong-James D. Future Directions for Clinical Respiratory Fungal Research. *Mycopathologia*. 2021;186(5):685-96.

24. Asgarbeik S, Amoli MM, Vahidi A, Klashami ZN. Genetic research in Immunogenetics Group of Endocrinology and Metabolism Research Institute. *J Diabetes Metab Disord*. 2024;23(2):1553-61.

25. Baliakas P, Strefford JC, Bikos V, Parry M, Stamatopoulos K, Oscier D. Splenic marginal-zone lymphoma: ontogeny and genetics. *Leuk Lymphoma*. 2015;56(2):301-10.

26. Bannister MH, Peng XP. Clinical Genetics and Genomics for the Immunologist: A Primer. *Immunol Allergy Clin North Am*. 2025;45(2):153-71.

27. Bardeskar NS, Mania-Pramanik J. HIV and host immunogenetics: unraveling the role of HLA-C. *Hla*. 2016;88(5):221-31.

28. Barinotti A, Radin M, Cecchi I, Foddai SG,

Rubini E, Roccatello D, et al. Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. *Int J Mol Sci*. 2020;21(24).

29. Berry N, Mee ET, Almond N, Rose NJ. The Impact and Effects of Host Immunogenetics on Infectious Disease Studies Using Non-Human Primates in Biomedical Research. *Microorganisms*. 2024;12(1).

30. Bignucolo A, Scarabel L, Toffoli G, Cecchin E, De Mattia E. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. *Expert Rev Clin Pharmacol*. 2022;15(6):689-713.

31. Bimber BN, Evans DT. The killer-cell immunoglobulin-like receptors of macaques. *Immunol Rev*. 2015;267(1):246-58.

32. Blouin AG, Ye F, Williams J, Askar M. A practical guide to chimerism analysis: Review of the literature and testing practices worldwide. *Hum Immunol*. 2021;82(11):838-49.

33. Borilova Linhartova P, Gachova D, Lipovy B. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. *J Dermatol*. 2020;47(11):1236-48.

34. Bos M, Colucci F. A New Look at Immunogenetics of Pregnancy: Maternal Major Histocompatibility Complex Class I Educates Uterine Natural Killer Cells. *Int J Mol Sci*. 2024;25(16).

35. Bossini-Castillo L, López-Isac E, Martín J. Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways. *J Autoimmun.* 2015;64:53-65.
36. Bravo-Egana V, Monos D. The impact of next-generation sequencing in immunogenetics: current status and future directions. *Curr Opin Organ Transplant.* 2017;22(4):400-6.
37. Brescia C, Audia S, Pugliano A, Scaglione F, Iuliano R, Trapasso F, et al. Metabolic drives affecting Th17/Treg gene expression changes and differentiation: impact on immune-microenvironment regulation. *Apmis.* 2024;132(12):1026-45.
38. Brito-Zerón P, Lower EE, Ramos-Casals M, Baughman RP. Hematological involvement in sarcoidosis: from cytopenias to lymphoma. *Expert Rev Clin Immunol.* 2024;20(1):59-70.
39. Bugoye FC, Torrorey-Sawe R, Biegon R, Dharsee N, Mafumiko F, Kibona H, et al. Exploring therapeutic applications of PTEN, Tmprss2:ERG fusion, and tumour molecular subtypes in prostate cancer management. *Front Oncol.* 2025;15:1521204.
40. Burahmah J, Zheng D, Leslie RD. Adult-onset type 1 diabetes: A changing perspective. *Eur J Intern Med.* 2022;104:7-12.
41. Burek Kamenaric M, Ivkovic V, Kovacevic Vojtusek I, Zunec R. The Role of HLA and KIR Immunogenetics in BK Virus Infection after

- Kidney Transplantation. *Viruses.* 2020;12(12).
42. Burkholder BM. Vogt-Koyanagi-Harada disease. *Curr Opin Ophthalmol.* 2015;26(6):506-11.
43. Callus R, Buttigieg J, Anastasi AA, Halawa A. Basic concepts in kidney transplant immunology. *Br J Hosp Med (Lond).* 2017;78(1):32-7.
44. Caraballo L, Lockey R, Puerta L, Zakzuk J, Acevedo N, Fernández-Caldas E. *Blomia tropicalis*: A 50-Year History. *J Allergy Clin Immunol Pract.* 2025;13(6):1289-97.
45. Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. *Autoimmun Rev.* 2020;19(11):102670.
46. Carvalho-Oliveira M, Valdivia E, Blasczyk R, Figueiredo C. Immunogenetics of xenotransplantation. *Int J Immunogenet.* 2021;48(2):120-34.
47. Ceribelli A, De Santis M, Selmi C. Sex and autoimmune disease: Four mechanisms pointing at women. *Mediterr J Rheumatol.* 2019;30(3):162-6.
48. Cezar-Dos-Santos F, Assolini JP, Okuyama NCM, Viana KF, de Oliveira KB, Itano EN. Unraveling the susceptibility of paracoccidioidomycosis: Insights towards the pathogen-immune interplay and immunogenetics. *Infect Genet Evol.* 2020;86:104586.

49. Chen X, Kang Y, Luo J, Pang K, Xu X, Wu J, et al. Next-Generation Sequencing Reveals the Progression of COVID-19. *Front Cell Infect Microbiol.* 2021;11:632490.
50. Cheng C, Liu S, Yu Z, Zhu K, Liu R, Li X, et al. Frontiers of premature ovarian insufficiency research: an analysis from the top 100 most influential articles in the field. *Gynecol Endocrinol.* 2025;41(1):2470986.
51. Chung BK, Hirschfield GM. Immunogenetics in primary sclerosing cholangitis. *Curr Opin Gastroenterol.* 2017;33(2):93-8.
52. Chyu KY, Dimayuga PC, Shah PK. Immunogenetics of Atherosclerosis-Link between Lipids, Immunity, and Genes. *Curr Atheroscler Rep.* 2020;22(10):53.
53. Clark B, Poulton K. SARS-CoV-2: An immunogenetics call to arms. *Int J Immunogenet.* 2020;47(4):319-23.
54. Colucci F, Traherne J. Killer-cell immunoglobulin-like receptors on the cusp of modern immunogenetics. *Immunology.* 2017;152(4):556-61.
55. Crocchiolo R, Fusco C, Andreani M, Rombolà G, Falco M, Vecchiato C, et al. Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti - AIBT).

- Blood Transfus. 2024;22(4):338-49.
56. D'Avino P, Serena G, Kenyon V, Fasano A. An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications. *Expert Rev Clin Immunol.* 2021;17(3):269-84.
57. Das A, Yilmaz O, Yilmaz O, Deshpande V. SOX17: a new therapeutic target for immune evasion of colorectal cancer. *J Clin Pathol.* 2025;78(10):653-8.
58. Davi F, Langerak AW, de Septenville AL, Kolijn PM, Hengeveld PJ, Chatzidimitriou A, et al. Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. *Leukemia.* 2020;34(10):2545-51.
59. de Lange KM, Barrett JC. Understanding inflammatory bowel disease via immunogenetics. *J Autoimmun.* 2015;64:91-100.
60. Debnath M. The expanding spectrum of infectious risk organisms and immunogenetic susceptibility in neuropsychiatric disorders. *Neurosci Biobehav Rev.* 2025;174:106177.
61. DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. *Curr Gastroenterol Rep.* 2016;18(3):13.
62. Dornburg A, Yoder JA. On the relationship between extant innate immune receptors and the evolutionary origins of jawed vertebrate adaptive

- immunity. *Immunogenetics*. 2022;74(1):111-28.
63. Douillard V, Castelli EC, Mack SJ, Hollenbach JA, Gourraud PA, Vince N, et al. Current HLA Investigations on SARS-CoV-2 and Perspectives. *Front Genet*. 2021;12:774922.
64. Douillard V, Castelli EC, Mack SJ, Hollenbach JA, Gourraud PA, Vince N, et al. Approaching Genetics Through the MHC Lens: Tools and Methods for HLA Research. *Front Genet*. 2021;12:774916.
65. Dourson AJ, Willits A, Raut NGR, Kader L, Young E, Jankowski MP, et al. Genetic and epigenetic mechanisms influencing acute to chronic postsurgical pain transitions in pediatrics: Preclinical to clinical evidence. *Can J Pain*. 2022;6(2):85-107.
66. Doxiadis I, Loeffler-Wirth H, Lachmann N, Lehmann C. A Short History of B-Cell HLA Epitopes. *Transfus Med Hemother*. 2024;51(3):152-7.
67. Dreussi E, Ecça F, Scarabel L, Gagno S, Toffoli G. Immunogenetics of prostate cancer: a still unexplored field of study. *Pharmacogenomics*. 2018;19(3):263-83.
68. Drvar DL, Vlahinić T, Maleš Ž, Turčić P, Čeović R. A modern approach to the treatment of plaque psoriasis. *Acta Pharm*. 2019;69(4):511-23.
69. Dubois V, Amokrane K, Crocchiolo R, Fort M, Guillaume N, Kennel A, et al. [Definition and standardization of histocompatibility requests depending on patient course and donor type:

- Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)]. *Bull Cancer*. 2021;108(12s):S45-s52.
70. Dubreuil L, Chevallier P, Retière C, Gagne K. Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. *Cancers (Basel)*. 2021;13(15).
71. Edgerly CH, Weimer ET. The Past, Present, and Future of HLA Typing in Transplantation. *Methods Mol Biol*. 2018;1802:1-10.
72. Edinur HA, Manaf SM, Che Mat NF. Genetic barriers in transplantation medicine. *World J Transplant*. 2016;6(3):532-41.
73. ElAbd H, Mahdy AKH. Decoding the etiology of immune-mediated inflammatory diseases statistically. *Front Immunol*. 2025;16:1610662.
74. Ellwanger JH, Chies JAB. Host immunogenetics in tick-borne encephalitis virus infection-The CCR5 crossroad. *Ticks Tick Borne Dis*. 2019;10(4):729-41.
75. Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. *Infect Genet Evol*. 2018;66:376-91.
76. Ellwanger JH, Kulmann-Leal B, Kaminski

VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. *Virus Res.* 2020;286:198040.

77. Evans-Molina C, Dor Y, Lernmark Å, Mathieu C, Millman JR, Mirmira RG, et al. The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. *Diabetologia.* 2025;68(9):1859-78.

78. Farajzadeh S, Khalili M, Dehghani S, Babaie S, Fattah M, Abtahi-Naeini B. Top 10 acral skin manifestations associated with COVID-19: A scoping review. *Dermatol Ther.* 2021;34(6):e15157.

79. Farzan R. Artificial intelligence in Immuno-genetics. *Bioinformatics.* 2024;20(1):29-35.

80. Ferreira RR, Waghbi MC, Bailly S, Feige JJ, Hasslocher-Moreno AM, Saraiva RM, et al. The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics. *Front Cell Infect Microbiol.* 2021;11:767576.

81. Fleury H, Tumiotto C, Bellecave P, Recordon-Pinson P. Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients. *AIDS Res Hum Retroviruses.* 2018;34(1):27-30.

82. Floch A, Téletchéa S, Tournamille C, de Brevern AG, Pirenne F. A Review of the Literature

Organized Into a New Database: RHeference. *Transfus Med Rev.* 2021;35(2):70-7.

83. Forconi F, Lanham SA, Chiodin G. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. *Cancers (Basel).* 2022;14(3).

84. Frommer L, Kahaly GJ. Autoimmune Polyendocrinopathy. *J Clin Endocrinol Metab.* 2019;104(10):4769-82.

85. Galigalidou C, Zaragoza-Infante L, Iatrou A, Chatzidimitriou A, Stamatopoulos K, Agathangelidis A. Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. *Front Oncol.* 2021;11:769612.

86. Garraud O, Chiaroni J. An overview of red blood cell and platelet alloimmunisation in transfusion. *Transfus Clin Biol.* 2022;29(4):297-306.

87. Gate D. New Perspectives on Immune Involvement in Parkinson's Disease Pathogenesis. *J Parkinsons Dis.* 2022;12(s1):S5-s11.

88. Gemenetzi K, Agathangelidis A, Zaragoza-Infante L, Sofou E, Papaioannou M, Chatzidimitriou A, et al. B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making. *Front Oncol.* 2020;10:67.

89. Geo JA, Ameen R, Al Shemmari S, Thomas J. Advancements in HLA Typing Techniques and

Their Impact on Transplantation Medicine. *Med Princ Pract.* 2024;33(3):215-31.

90. Georgopoulos AP, James LM. Anthrax Vaccines in the 21st Century. *Vaccines (Basel).* 2024;12(2).

91. Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, et al. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. *Int J Mol Sci.* 2021;22(9).

92. Ghandorah S, Alsawaf B, Alrefai W, Ghazwani A, Almusabi S. Role of HLA typing and chimerism analysis in post-liver transplantation GVHD in pediatrics: A systematic review. *Pediatr Transplant.* 2022;26(8):e14381.

93. Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. *J Autoimmun.* 2015;64:125-36.

94. Giammalva GR, Brunasso L, Paolini F, Costanzo R, Bonosi L, Benigno UE, et al. The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas. *Cancers (Basel).* 2022;14(15).

95. Goldberg JF, Truby LK, Agbor-Enoh S, Jackson AM, deFilippi CR, Khush KK, et al. Selection and Interpretation of Molecular Diagnostics in Heart Transplantation. *Circulation.* 2023;148(8):679-94.

96. Golfinopoulou R, Giudicelli V, Manso T, Kossida S. Delving into Molecular Pathways:

Analyzing the Mechanisms of Action of Monoclonal Antibodies Integrated in IMGT/mAb-DB for Myasthenia Gravis. *Vaccines (Basel).* 2023;11(12).

97. Gonzalez-Galarza FF, McCabe A, Melo Dos Santos EJ, Jones AR, Middleton D. A snapshot of human leukocyte antigen (HLA) diversity using data from the Allele Frequency Net Database. *Hum Immunol.* 2021;82(7):496-504.

98. González-Romo F, Picazo JJ. [Development of new vaccines]. *Enferm Infecc Microbiol Clin.* 2015;33(8):557-68.

99. Goodwin G. Type 1 Diabetes Mellitus and Celiac Disease: Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms. *Horm Res Paediatr.* 2019;92(5):285-92.

100. Goyos A, Fort M, Sharma A, Lebrech H. Current Concepts in Natural Killer Cell Biology and Application to Drug Safety Assessments. *Toxicol Sci.* 2019;170(1):10-9.

101. Grimstad F, Krieg S. Immunogenetic contributions to recurrent pregnancy loss. *J Assist Reprod Genet.* 2016;33(7):833-47.

102. Grixti L, Lane LC, Pearce SH. The genetics of Graves' disease. *Rev Endocr Metab Disord.* 2024;25(1):203-14.

103. Grow DA, McCarrey JR, Navara CS. Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease. *Stem Cell Res.* 2016;17(2):352-66.

104. Grunewald J, Spagnolo P, Wahlström J, Eklund A. Immunogenetics of Disease-Causing Inflammation in Sarcoidosis. *Clin Rev Allergy Immunol.* 2015;49(1):19-35.
105. Guga S, Wang Y, Graham DC, Vyse TJ. A review of genetic risk in systemic lupus erythematosus. *Expert Rev Clin Immunol.* 2023;19(10):1247-58.
106. Gumkowska-Sroka O, Kotyla K, Kotyla P. Immunogenetics of Systemic Sclerosis. *Genes (Basel).* 2024;15(5).
107. Gupta NS, Shrivastav SK, Singh IK, Kumari S, Jha NK, Gupta R. Decoding the molecular and cellular aspects of multiple sclerosis: From diagnosis to therapeutic strategies. *Brain Res.* 2025;1863:149844.
108. Hagberg N, Lundtoft C, Rönnblom L. Immunogenetics in systemic lupus erythematosus: Transitioning from genetic associations to cellular effects. *Scand J Immunol.* 2020;92(4):e12894.
109. Hanaei S, Abdollahzade S, Sadr M, Mirbolouk MH, Fattahi E, Khoshnevisan A, et al. The role of interleukin 4 and IL-4RA in intervertebral disc degeneration: investigation of single nucleotide polymorphisms in genes and a systematic review & meta-analysis of IL-4 expression level. *Br J Neurosurg.* 2020;34(1):66-71.
110. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive

- review. *J Autoimmun.* 2015;64:66-73.
111. Harmer A, Mascaretti L, Petershofen E. Accreditation of histocompatibility and immunogenetics laboratories: Achievements and future prospects from the European Federation for Immunogenetics Accreditation Programme. *Hla.* 2018.
112. Hartono S, Ippoliti MR, Mastroianni M, Torres R, Rider NL. Gastrointestinal Disorders Associated with Primary Immunodeficiency Diseases. *Clin Rev Allergy Immunol.* 2019;57(2):145-65.
113. Hashim O, Dimier-Poisson I. Computational vaccine development against protozoa. *Comput Struct Biotechnol J.* 2025;27:2386-93.
114. Hashim PW, Friedlander P, Goldenberg G. Systemic Therapies for Late-stage Melanoma. *J Clin Aesthet Dermatol.* 2016;9(10):36-40.
115. Haslund MM, Sørensen JK, Graff Stensballe L. Genetics and measles, mumps and rubella vaccine response in childhood and adolescence-A systematic review. *Scand J Immunol.* 2023;97(6):e13266.
116. Hatano H, Ishigaki K. Functional Genetics to Understand the Etiology of Autoimmunity. *Genes (Basel).* 2023;14(3).
117. Haykal M, Matsumori A, Saleh A, Fayez M, Negm H, Shalaby M, et al. Diagnosis and treatment of HCV heart diseases. *Expert Rev Cardiovasc Ther.* 2021;19(6):493-9.

118. Helanterä I, Markkinen S, Partanen J, Hyvärinen K. Novel Aspects of Immunogenetics and Post-Transplant Events in Kidney Transplantation. *Transpl Int.* 2024;37:13317.
119. Hemler JA, Phillips EJ, Mallal SA, Kendall PL. The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy. *Ann Allergy Asthma Immunol.* 2015;115(6):471-6.
120. Hersh AO, Arkin LM, Prahalad S. Immunogenetics of cutaneous lupus erythematosus. *Curr Opin Pediatr.* 2016;28(4):470-5.
121. Hersh AO, Prahalad S. Immunogenetics of juvenile idiopathic arthritis: A comprehensive review. *J Autoimmun.* 2015;64:113-24.
122. Hess JF, Kohl TA, Kotrová M, Rönsch K, Paprotka T, Mohr V, et al. Library preparation for next generation sequencing: A review of automation strategies. *Biotechnol Adv.* 2020;41:107537.
123. Ho S, Hod-Dvorai R, Bravo-Egana V, Kheradmand T, Bishop C, Brown NK, et al. Practical guide to personnel competency assessment in clinical histocompatibility laboratories. *Hum Immunol.* 2025;86(4):111321.
124. Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: A comprehensive review. *J Autoimmun.* 2015;64:13-25.
125. Ibrahim SM, Khalel AM. Using the Immune System for Effective Periodontal

- and Caries Management. *Biomed Res Int.* 2025;2025:6385469.
126. Jacobson G, Muncaster S, Mensink K, Forlenza M, Elliot N, Broomfield G, et al. Omics and cytokine discovery in fish: Presenting the Yellowtail kingfish (*Seriola lalandi*) as a case study. *Dev Comp Immunol.* 2017;75:63-76.
127. Jain M, Mohan S, van Dijk EHC. Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification. *Taiwan J Ophthalmol.* 2022;12(4):381-93.
128. Jiang Y, Lv X, Ge X, Qu H, Zhang Q, Lu K, et al. Wilms tumor gene 1 (WT1)-specific adoptive immunotherapy in hematologic diseases. *Int Immunopharmacol.* 2021;94:107504.
129. Jimenez-Ferrer I, Swanberg M. Immunogenetics of Parkinson's Disease. In: Stoker TB, Greenland JC, editors. *Parkinson's Disease: Pathogenesis and Clinical Aspects.* Brisbane (AU): Codon Publications
- Copyright: The Authors.; 2018.
130. Karassa FB, Pelechas E, Zouzos G. The Immunogenetics of Vasculitis. *Adv Exp Med Biol.* 2022;1367:299-334.
131. Keating BJ, Pereira AC, Snyder M, Piening BD. Applying genomics in heart transplantation. *Transpl Int.* 2018;31(3):278-90.
132. Kelly A, Trowsdale J. Introduction: MHC/KIR and governance of specificity.

- Immunogenetics. 2017;69(8-9):481-8.
133. Khan Mohammad Beigi P. The Immunogenetics of Morphea and Lichen Sclerosus. *Adv Exp Med Biol.* 2022;1367:155-72.
134. Kneiber D, Kowalski EH, Amber KT. The Immunogenetics of Autoimmune Blistering Diseases. *Adv Exp Med Biol.* 2022;1367:173-212.
135. Kocaaga A, Kocaaga M. Psoriasis: An Immunogenetic Perspective. *Glob Med Genet.* 2022;9(2):82-9.
136. Kocaaga A, Kocaaga M. A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Glob Med Genet.* 2025;12(3):100054.
137. Kozek LK, Vavvas DG. The Immunopathogenesis of Adamantiades-Behçet Uveitis: Advances in Understanding of Genetics and Molecular Mechanisms. *Int Ophthalmol Clin.* 2025;65(3):114-24.
138. Kumrah R, Vignesh P, Rawat A, Singh S. Immunogenetics of Kawasaki disease. *Clin Rev Allergy Immunol.* 2020;59(1):122-39.
139. Kung PJ, Elsayed I, Reyes-Pérez P, Bandres-Ciga S. Immunogenetic Determinants of Parkinson's Disease Etiology. *J Parkinsons Dis.* 2022;12(s1):S13-s27.
140. La Nasa G, Vacca A, Littera R, Piras E, Orru S, Greco M, et al. What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught us about Transplant Immunogenetics. *Mediterr J Hematol Infect Dis.* 2016;8(1):e2016048.

141. Lacoma A, Mateo L, Blanco I, Méndez MJ, Rodrigo C, Latorre I, et al. Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections. *Front Immunol.* 2019;10:1013.
142. Lafarge X. What compatibility in 2017 for the haematopoietic stem cell transplantation? *Transfus Clin Biol.* 2017;24(3):124-30.
143. Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. *Lancet.* 2015;385(9984):2297-307.
144. Leal R, Pardinhas C, Martinho A, Sá HO, Figueiredo A, Alves R. Strategies to Overcome HLA Sensitization and Improve Access to Retransplantation after Kidney Graft Loss. *J Clin Med.* 2022;11(19).
145. Leboyer M, Oliveira J, Tamouza R, Groc L. Is it time for immunopsychiatry in psychotic disorders? *Psychopharmacology (Berl).* 2016;233(9):1651-60.
146. Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. *J Autoimmun.* 2015;64:82-90.
147. Lefranc MP, Lefranc G. IMGT(®) and 30 Years of Immunoinformatics Insight in Antibody V and C Domain Structure and Function. *Antibodies (Basel).* 2019;8(2).
148. Lefranc MP, Lefranc G. Immunoglobulins or Antibodies: IMGT(®) Bridging Genes, Structures and Functions. *Biomedicines.* 2020;8(9).
149. Lenz TL. HLA Genes: A Hallmark

of Functional Genetic Variation and Complex Evolution. *Methods Mol Biol.* 2024;2809:1-18.

150. Liberal R, Vergani D, Mieli-Vergani G. Update on Autoimmune Hepatitis. *J Clin Transl Hepatol.* 2015;3(1):42-52.

151. Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The discovery and development of omalizumab for the treatment of asthma. *Expert Opin Drug Discov.* 2015;10(9):1033-42.

152. Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Misra S, et al. Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review. *Indian J Clin Biochem.* 2020;35(3):260-73.

153. Little AM, Green A, Harvey J, Hemmatpour S, Latham K, Marsh SG, et al. BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation. *Int J Immunogenet.* 2016;43(5):263-86.

154. Liu C. A long road/read to rapid high-resolution HLA typing: The nanopore perspective. *Hum Immunol.* 2021;82(7):488-95.

155. Mabelane T, Masekela R, Dandara C, Hadebe S. Immunogenetics and pharmacogenetics of allergic asthma in Africa. *Front Allergy.* 2023;4:1165311.

156. Madden K, Chabot-Richards D. HLA testing in the molecular diagnostic laboratory. *Virchows Arch.* 2019;474(2):139-47.

157. Magnusen AF, Hatton SL, Rani R, Pandey MK. Genetic Defects and Pro-inflammatory

Cytokines in Parkinson's Disease. *Front Neurol.* 2021;12:636139.

158. Maksic M, Corovic I, Maksic T, Zivic J, Zivic M, Zdravkovic N, et al. Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients. *Int J Mol Sci.* 2025;26(15).

159. Mallikarjunappa S, Brito LF, Pant SD, Schenkel FS, Meade KG, Karrow NA. Johne's Disease in Dairy Cattle: An Immunogenetic Perspective. *Front Vet Sci.* 2021;8:718987.

160. Masmoudi H, Abida O, Masmoudi A, Turki H. Update on immunogenetics of Tunisian endemic pemphigus foliaceus. *J Leukoc Biol.* 2019;105(2):257-65.

161. Mavridou M, Pearce SH. Exploring antigenic variation in autoimmune endocrinopathy. *Front Immunol.* 2025;16:1561455.

162. Mazurkiewicz Ł, Czernikiewicz K, Grygiel-Górniak B. Immunogenetic Aspects of Sarcopenic Obesity. *Genes (Basel).* 2024;15(2).

163. McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. *Autoimmun Rev.* 2018;17(11):1115-23.

164. Medlin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. *Semin Arthritis Rheum.* 2016;45(6):691-7.

165. Meesilpavikkai K, Hirankarn N, Dalm V, Hagen PMV, Dik WA, H IJ. Unraveling the Immunogenetics of STAT Proteins: Clinical Perspectives on Gain-of-Function and Loss-of-Function Variants. *Asian Pac J Allergy Immunol.* 2024;42(2):105-22.
166. Menzella F, Lusuardi M, Galeone C, Zucchi L. Tailored therapy for severe asthma. *Multidiscip Respir Med.* 2015;10(1):1.
167. Messemaker TC, Huizinga TW, Kurreeman F. Immunogenetics of rheumatoid arthritis: Understanding functional implications. *J Autoimmun.* 2015;64:74-81.
168. Michielsen LA, van Zuilen AD, Muskens IS, Verhaar MC, Otten HG. Complement Polymorphisms in Kidney Transplantation: Critical in Graft Rejection? *Am J Transplant.* 2017;17(8):2000-7.
169. Milano G, Innocenti F, Ciccolini J. The association between adverse events and outcome under checkpoint inhibitors: Where is the deal? *Transl Oncol.* 2021;14(1):100952.
170. Miller MM, Taylor RL, Jr. Brief review of the chicken Major Histocompatibility Complex: the genes, their distribution on chromosome 16, and their contributions to disease resistance. *Poult Sci.* 2016;95(2):375-92.
171. Misra MK, Damotte V, Hollenbach JA. The immunogenetics of neurological disease. *Immunology.* 2018;153(4):399-414.
172. Monaco DC, Ende Z, Hunter E. Virus-

- Host Gene Interactions Define HIV-1 Disease Progression. *Curr Top Microbiol Immunol.* 2017;407:31-63.
173. Montgomery RA, Tatapudi VS, Leffell MS, Zachary AA. HLA in transplantation. *Nat Rev Nephrol.* 2018;14(9):558-70.
174. Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. *Mol Aspects Med.* 2015;42:42-60.
175. Mortaz E, Moloudizargari M, Varahram M, Movassaghi M, Garssen J, Kazempour Dizagie M, et al. What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections? *Iran J Allergy Asthma Immunol.* 2018;17(2):100-9.
176. Mulas O, Mola B, Caocci G, La Nasa G. Conditioning Regimens in Patients with β -Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review. *J Clin Med.* 2022;11(4).
177. Mulinacci G, Palermo A, Gerussi A, Asselta R, Gershwin ME, Invernizzi P. New insights on the role of human leukocyte antigen complex in primary biliary cholangitis. *Front Immunol.* 2022;13:975115.
178. Murray JS. An old Twist in HLA-A: CDR3 α Hook up at an R65-joint. *Front Immunol.* 2015;6:268.
179. Nabi A, Ebihara A, Shekhar HU. Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation. *World J Virol.* 2023;12(3):151-71.

180. Nadat F, Clark B. Forming a new perspective: Post-structural approaches to determination of donor compatibility and post-transplant assessment of allograft health. *Int J Immunogenet.* 2024;51(4):195-205.
181. Ndong Sima CAA, Smith D, Petersen DC, Schurz H, Uren C, Möller M. The immunogenetics of tuberculosis (TB) susceptibility. *Immunogenetics.* 2023;75(3):215-30.
182. Noble JA. Immunogenetics of type 1 diabetes: A comprehensive review. *J Autoimmun.* 2015;64:101-12.
183. Oder B, Chatzidimitriou A, Langerak AW, Rosenquist R, Österholm C. Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. *Front Oncol.* 2023;13:1143811.
184. Oguz FS. External proficiency testing for histocompatibility and immunogenetics in today and future. *Front Genet.* 2024;15:1294330.
185. Ohlin M, Scheepers C, Corcoran M, Lees WD, Busse CE, Bagnara D, et al. Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming. *Front Immunol.* 2019;10:435.
186. Oliveira J, Oliveira-Maia AJ, Tamouza R, Brown AS, Leboyer M. Infectious and immunogenetic factors in bipolar disorder. *Acta Psychiatr Scand.* 2017;136(4):409-23.
187. Osoegawa K, Mack SJ, Prestegaard M, Fernández-Viña MA. Tools for building, analyzing

- and evaluating HLA haplotypes from families. *Hum Immunol.* 2019;80(9):633-43.
188. Osoegawa K, Vayntrub TA, Wenda S, De Santis D, Barsakis K, Ivanova M, et al. Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop. *Hum Immunol.* 2019;80(4):228-36.
189. Ota M, Umemura T, Kawa S. Immunogenetics of IgG4-Related AIP. *Curr Top Microbiol Immunol.* 2017;401:35-44.
190. Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. *Immunol Rev.* 2020;296(1):205-19.
191. Palmer WH, Norman PJ. The impact of HLA polymorphism on herpesvirus infection and disease. *Immunogenetics.* 2023;75(3):231-47.
192. Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. *Immunol Allergy Clin North Am.* 2017;37(4):785-815.
193. Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, et al. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. *Pharmacol Res.* 2017;120:279-93.
194. Pojero F, Candore G, Caruso C, Di Bona D, Groneberg DA, Ligotti ME, et al. The Role of Immunogenetics in COVID-19. *Int J Mol Sci.* 2021;22(5).

195. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. *Vaccine*. 2018;36(36):5350-7.
196. Poller W, Heidecker B, Ammirati E, Kuss AW, Tzvetkova A, Poller WC, et al. Innate Immunity in Cardiovascular Diseases- Identification of Novel Molecular Players and Targets. *J Clin Med*. 2023;12(1).
197. Poller W, Sahoo S, Hajjar R, Landmesser U, Krichevsky AM. Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets- Recent Insights at Molecular and Cellular Level. *Cells*. 2023;12(22).
198. Poole GD. The Welsh Blood Service - 70 years of continuous change. *Transfus Med*. 2017;27(3):159-66.
199. Prapas P, Anagnostouli M. Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics. *Int J Mol Sci*. 2024;25(13).
200. Raja A, Kuiper JJW. Evolutionary immuno-genetics of endoplasmic reticulum aminopeptidase II (ERAP2). *Genes Immun*. 2023;24(6):295-302.
201. Rajendra S, Sharma P. Transforming human papillomavirus infection and the esophageal transformation zone: prime time for total excision/ablative therapy? *Dis Esophagus*. 2019;32(7).
202. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from

- epidemiology to pathophysiology. *Eur Respir Rev*. 2018;27(147).
203. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: Key regulators of T-cell-mediated drug hypersensitivity. *Hla*. 2018;91(1):3-16.
204. Refae S, Gal J, Brest P, Milano G. Germinal immunogenetics as a predictive factor for immunotherapy. *Crit Rev Oncol Hematol*. 2019;141:146-52.
205. Renac V, Moalic V, Dautin G, Cherel M, Mercier B, Walencik A, et al. Guidelines From the French-Speaking Society for Histocompatibility and Immunogenetics (SFHI) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics. *Hla*. 2025;106(4):e70442.
206. Rodríguez-Vicente AE, Bikos V, Hernández-Sánchez M, Malcikova J, Hernández-Rivas JM, Pospisilova S. Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. *Oncotarget*. 2017;8(41):71234-48.
207. Roosens W, Demeulemeester J, Legius E, Savic S, Schrijvers R. Emerging insights into mosaic errors of immunity. *Trends Immunol*. 2025.
208. Roshan-Zamir M, Khademolhosseini A, Rajalingam K, Ghaderi A, Rajalingam R. The genomic landscape of the immune system in lung cancer: present insights and continuing investigations. *Front Genet*. 2024;15:1414487.

209. Rosser C, Sage D. Approaches for the characterization of clinically relevant pre-transplant human leucocyte antigen (HLA) antibodies in solid organ transplant patients. *Int J Immunogenet.* 2021;48(5):385-402.
210. Rostami A, White K, Rostami K. Pro and anti-inflammatory diets as strong epigenetic factors in inflammatory bowel disease. *World J Gastroenterol.* 2024;30(27):3284-9.
211. Sadiq A, Khumalo NP, Bayat A. Genetics of Keloid Scarring. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG, editors. *Textbook on Scar Management: State of the Art Management and Emerging Technologies.* Cham (CH): Springer Copyright 2020, The Author(s). 2020. p. 61-76.
212. Salvetti M, Landsman D, Schwarz-Lam P, Comi G, Thompson AJ, Fox RJ. Progressive MS: from pathophysiology to drug discovery. *Mult Scler.* 2015;21(11):1376-84.
213. Savoy SKA, Boudreau JE. The Evolutionary Arms Race between Virus and NK Cells: Diversity Enables Population-Level Virus Control. *Viruses.* 2019;11(10).
214. Schmidt AH, Sauter J, Baier DM, Daiss J, Keller A, Klussmeier A, et al. Immunogenetics in stem cell donor registry work: The DKMS example (Part 2). *Int J Immunogenet.* 2020;47(2):139-48.
215. Schmidt AH, Sauter J, Baier DM, Daiss J, Keller A, Klussmeier A, et al. Immunogenetics in stem cell donor registry work: The DKMS example

- (Part 1). *Int J Immunogenet.* 2020;47(1):13-23.
216. Schraven AL, Stannard HJ, Ong OTW, Old JM. Immunogenetics of marsupial B-cells. *Mol Immunol.* 2020;117:1-11.
217. Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M. Genetic aspects of the antiphospholipid syndrome: An update. *Autoimmun Rev.* 2016;15(5):433-9.
218. Selmi C. Autoimmunity in 2015. *Clin Rev Allergy Immunol.* 2016;51(1):110-9.
219. Selmi C. Autoimmunity in 2016. *Clin Rev Allergy Immunol.* 2017;53(1):126-39.
220. Seppälä O, Çetin C, Cereghetti T, Feulner PGD, Adema CM. Examining adaptive evolution of immune activity: opportunities provided by gastropods in the age of 'omics'. *Philos Trans R Soc Lond B Biol Sci.* 2021;376(1825):20200158.
221. Serpen JY, Armenti ST, Prasov L. Immunogenetics of the Ocular Anterior Segment: Lessons from Inherited Disorders. *J Ophthalmol.* 2021;2021:6691291.
222. Sheervalilou M, Ghanei M, Arabfard M. Single-cell RNA sequencing in high-burden viral respiratory infections: Decoding immune cell subsets and immune-related differential gene expression. *Infect Genet Evol.* 2025;135:105834.
223. Shi J, Fu Q, Ma Q, Wei Z, Su X, Li X. Autoimmune complications of tyrosine kinase inhibitors in cancer therapy: Clinical insights, mechanisms, and future perspectives. *Medicine (Baltimore).* 2024;103(40):e39928.

224. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, Brinith L, Martinez-Lavin M, Ikeda S, et al. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. *Clin Immunol.* 2020;214:108384.
225. Sighencea MG, Trifu SC. Unravelling the Viral Hypothesis of Schizophrenia: A Comprehensive Review of Mechanisms and Evidence. *Int J Mol Sci.* 2025;26(15).
226. Silpa-Archa S, Silpa-Archa N, Preble JM, Foster CS. Vogt-Koyanagi-Harada syndrome: Perspectives for immunogenetics, multimodal imaging, and therapeutic options. *Autoimmun Rev.* 2016;15(8):809-19.
227. Silva MJA, Santana DS, de Oliveira LG, Monteiro EOL, Lima L. The relationship between 896A/G (rs4986790) polymorphism of TLR4 and infectious diseases: A meta-analysis. *Front Genet.* 2022;13:1045725.
228. Silva R, Lopes MF, Travassos LH. Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus. *Cancer Pathog Ther.* 2023;1(1):76-86.
229. Silva-Carvalho WH, de Moura RR, Coelho AV, Crovella S, Guimarães RL. Frequency of the CCR5-delta32 allele in Brazilian populations: A systematic literature review and meta-analysis. *Infect Genet Evol.* 2016;43:101-7.
230. Sim S, Hibberd ML. Genomic approaches for understanding dengue: insights from the

- virus, vector, and host. *Genome Biol.* 2016;17:38.
231. Smith JR, Ashander LM, Arruda SL, Cordeiro CA, Lie S, Rochet E, et al. Pathogenesis of ocular toxoplasmosis. *Prog Retin Eye Res.* 2021;81:100882.
232. Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Correia O, et al. HLA and Delayed Drug-Induced Hypersensitivity. *Int Arch Allergy Immunol.* 2016;170(3):163-79.
233. Srivastava A, Hollenbach JA. The immunogenetics of COVID-19. *Immunogenetics.* 2023;75(3):309-20.
234. Steiner G, Toes REM. Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond. *Curr Opin Rheumatol.* 2024;36(3):217-24.
235. Stys PK, Tsutsui S. Recent advances in understanding multiple sclerosis. *F1000Res.* 2019;8.
236. Sullivan HC, Jaramillo A, Gaitonde S, Murphey C, Pandey S, Liu C, et al. Virtual crossmatching: Principles, practices, and the path forward-An American Society for Histocompatibility and Immunogenetics/College of American Pathologists collaborative. *Am J Transplant.* 2025;25(10):2048-56.
237. Süsal C, Seidl C, Schönemann C, Heinemann FM, Kauke T, Gombos P, et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German

Society for Immunogenetics. *Tissue Antigens*. 2015;86(5):317-23.

238. Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. *Semin Cancer Biol*. 2015;34:22-35.

239. Szczawińska-Popłonyk A. Atopic dermatitis in inborn errors of immunity: at the interface of immunodeficiency and immune dysregulation. *Immunol Res*. 2025;73(1):147.

240. Szczawinska-Poplonyk A, Begier K, Dorota A, Dabrowska M, Galecka D, Wawrzeniak K, et al. Syndromic immunodeficiencies: a pediatrician's perspective on selected diseases. *Allergol Immunopathol (Madr)*. 2021;49(4):117-36.

241. Szczawińska-Popłonyk A, Bekalarska J, Jęch K, Knobloch N, Łukasik O, Ossowska A, et al. The Burden of Non-Infectious Organ-Specific Immunopathology in Pediatric Common Variable Immunodeficiency. *Int J Mol Sci*. 2025;26(6).

242. Szczawinska-Poplonyk A, Schwartzmann E, Bukowska-Olech E, Biernat M, Gattner S, Korobacz T, et al. The pediatric common variable immunodeficiency - from genetics to therapy: a review. *Eur J Pediatr*. 2022;181(4):1371-83.

243. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet's disease: A comprehensive review. *J Autoimmun*. 2015;64:137-48.

244. Takeuchi M, Mizuki N, Ohno S.

Pathogenesis of Non-Infectious Uveitis Elucidated by Recent Genetic Findings. *Front Immunol*. 2021;12:640473.

245. Tambur AR, Campbell P, Chong AS, Feng S, Ford ML, Gebel H, et al. Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. *Am J Transplant*. 2020;20(10):2652-68.

246. Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? *Am J Transplant*. 2015;15(5):1148-54.

247. Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. *Brain Behav Immun*. 2021;91:731-9.

248. Thom RP, Keary CJ, Palumbo ML, Ravichandran CT, Mullett JE, Hazen EP, et al. Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder. *Psychopharmacology (Berl)*. 2019;236(10):3045-61.

249. Thom RP, McDougale CJ. Immune Modulatory Treatments for Autism Spectrum Disorder. *Semin Pediatr Neurol*. 2020;35:100836.

250. Torres A, Zaborek-Łyczba M, Łyczba J, Mertowska P, Mertowski S, Grywalska E. The Importance of Immunological Disorders in the Pathogenesis of Lichen Sclerosus in Pediatric Patients: A Systematic Review. *Int J Mol Sci*. 2022;23(22).

251. Trivedi PJ, Hirschfield GM. The Immunogenetics of Autoimmune Cholestasis. *Clin Liver Dis.* 2016;20(1):15-31.
252. Turganbekova A, Abdrakhmanova S, Masalimov Z, Almawi WY. Genetic Diversity and Ethnic Tapestry of Kazakhstan as Inferred from HLA Polymorphism and Population Dynamics: A Comprehensive Review. *Genes (Basel).* 2025;16(3).
253. Turner D, Battle R, Akbarzad-Yousefi A, Little AM. The omission of the "wet" pre-transplant crossmatch in renal transplant centres in Scotland. *Hla.* 2019;94(1):3-10.
254. Valdés-Fernández BN, Duconge J, Espino AM, Rúaño G. Personalized health and the coronavirus vaccines-Do individual genetics matter? *Bioessays.* 2021;43(9):e2100087.
255. van der Walt K, Stein DJ, Zoghbi AW. Genetic evidence for a neuro-immune model of schizophrenia. *Biol Psychiatry.* 2025.
256. Van Drongelen V, Holoshitz J. A reciprocal HLA-Disease Association in Rheumatoid Arthritis and Pemphigus Vulgaris. *Front Biosci (Landmark Ed).* 2017;22(5):909-19.
257. Van Horebeek L, Dubois B, Goris A. Somatic Variants: New Kids on the Block in Human Immunogenetics. *Trends Genet.* 2019;35(12):935-47.
258. Van Rhijn I, Moody DB. CD1 and mycobacterial lipids activate human T cells. *Immunol Rev.* 2015;264(1):138-53.
259. Verdu EF, Schuppan D. Co-factors,

- Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment. *Gastroenterology.* 2021;161(5):1395-411.e4.
260. Vinkler M, Fiddaman SR, Těšický M, O'Connor EA, Savage AE, Lenz TL, et al. Understanding the evolution of immune genes in jawed vertebrates. *J Evol Biol.* 2023;36(6):847-73.
261. Vlachonikola E, Sofou E, Chatzidimitriou A, Stamatopoulos K, Agathangelidis A. The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications. *Hematol Oncol Clin North Am.* 2021;35(4):687-702.
262. Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: A comprehensive review. *J Autoimmun.* 2015;64:42-52.
263. Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. *Expert Rev Vaccines.* 2015;14(7):935-47.
264. Wilks DJ, Clark B, Kay SPJ. The histocompatibility and immunogenetics of hand transplantation. *Int J Immunogenet.* 2020;47(1):24-7.
265. Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: Latest advances. *Best Pract Res Clin Rheumatol.* 2017;31(4):535-57.
266. Wu XY, Liu ZQ, Wang Y, Chen WF, Gao PT, Li QL, et al. The etiology of achalasia: An immune-

- dominant disease. *J Dig Dis*. 2021;22(3):126-35.
267. Xu X, Zhang HY. The Immunogenetics of Psoriasis and Implications for Drug Repositioning. *Int J Mol Sci*. 2017;18(12).
268. Yazdanparast S, Bakhtiyaridovvombaygi M, Mikanik F, Ahmadi R, Ghorbani M, Mansoorian MR, et al. Spotlight on contributory role of host immunogenetic profiling in SARS-CoV-2 infection: Susceptibility, severity, mortality, and vaccine effectiveness. *Life Sci*. 2023;328:121907.
269. Yeung HY, Dendrou CA. Pregnancy Immunogenetics and Genomics: Implications for Pregnancy-Related Complications and Autoimmune Disease. *Annu Rev Genomics Hum Genet*. 2019;20:73-97.
270. Yokoda RT, Rodriguez EA. Review: Pathogenesis of cholestatic liver diseases. *World J Hepatol*. 2020;12(8):423-35.
271. Younes N, Younes S, Alsharabasi OA, El Zowalaty ME, Mustafa I, Jahromi M, et al. Immunogenetics of Celiac Disease: A Focus on Arab Countries. *Curr Mol Med*. 2020;20(4):275-85.
272. Yu JE, Orange JS, Demirdag YY. New primary immunodeficiency diseases: context and future. *Curr Opin Pediatr*. 2018;30(6):806-20.
273. Zheng B, Artin MG, Chung H, Chen B, Sun S, May BL, et al. Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans. *J Gastroenterol Hepatol*. 2022;37(6):973-82.
274. Ziemann M, Suwelack B, Banas B, Budde

- K, Einecke G, Hauser I, et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients. *Hla*. 2022;100(1):3-17.
275. Tahavvori A, Chelan RJ, Aminoleslami S, Moghadam OF, Haghighi L, Abdian Y, et al. Large Language Models and ChatGPT in Medical Sciences: Foundations, Capabilities, and Challenges. *Kindle*. 2025;5(1):1-222.
276. Ramezani M, Benis DS, Nikakhtar R, Gorjizadeh N, Asadi F, Bagherianlemraski M, et al. Artificial Intelligence in Genomic Medicine: Improving Diagnostic Accuracy and Treatment Outcomes. *Kindle*. 2025;5(1):1-215.
277. Rahmani E, Farrokhi M, Aghajan A, Gholampour G, Ghoojani E, Shemshadigolafzani R, et al. AI-Driven Strategies for Improving Patient Quality of Life. *Kindle*. 2025;5(1):1-214.
278. Rahaeimehr R, Babakhani Z, Moghadam OF, Nasir SM, Safaei P, Abdollahi MAA, et al. Application of AI in Research and Data Science. *Kindle*. 2025;5(1):1-362.
279. Niakosari V, Mosaddeghi-Heris R, Hezarani HB, Farrokhi M, Safaei P, Nikseresht H, et al. AI in Medical Imaging and Early Disease Detection. *Kindle*. 2025;5(1):1-203.
280. Louia S, Mosaddeghi-Heris R, Kamvar R, Zahmatkesh N, Damiri M, Esfahani MA, et al. Artificial Intelligence in Cancer Genomics: Transforming Diagnosis, Treatment, and Precision Medicine. *Kindle*. 2025;5(1):1-234.
281. Javadzadeh A, Shafiei D, Amlash RS,

- Mehrvar R, Sepehrian S, Shafiee A, et al. The Brain-Body Connection: Neuroscience's Role Across Medical Sciences Disciplines. *Kindle*. 2025;5(1):1-210.
282. Hedayati F, Chelan RJ, Alijaniha M, Koma KK, Irajian P, Rajabi N, et al. Explainable Artificial Intelligence for Reducing the Global Cancer Burden. *Kindle*. 2025;5(1):1-195.
283. Harati K, Tahernejad M, Saddam SMS, Farshi M, Saeedfar M, Gheibi M, et al. The Future of Prosthetics and Organ Transplantation: A Therapeutic Approach Across Various Medical Disciplines. *Kindle*. 2025;5(1):1-193.
284. Harati K, Mosaddeghi-Heris R, Kiani K, Saligheh Rad M, Morovatshoar R, Kamali M, et al. The AI Revolution: Predicting and Managing the Next Global Health Challenges and Emerging Disease Outbreaks. *Kindle*. 2025;5(1):1-326.
285. Harati K, Abbasmofrad H, Ebrahimi M, Hashemlu L, Chelan RJ, Hashemzadeh A, et al. Intelligent Patient Engagement: Education and Follow-Up through AI and Telemedicine. *Kindle*. 2025;5(1):1-185.
286. Gheibi M, Rajabloo Y, Alipour-Khabir Y, Azami P, Louia S, Bojnordi TE, et al. Artificial Intelligence in Biomarker Discovery: Applications Across Medical Specialties. *Kindle*. 2025;5(1):1-209.
287. Farrokhi M, Ghalamkarpour N, Nouri S, Babaei M, Rajabloo Y, Sattari M, et al. Innovative Vaccination: A New Era in Cancer Prevention.

- Kindle*. 2025;5(1):1-194.
288. Babaheidarian P, Soltanattar A, Sajadi SK, Rostamian L, Foroutani L, Soleymannpourshamsi T, et al. Robotics in Healthcare. *Kindle*. 2025;5(1):1-178.
289. Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. *Kindle*. 2024;4(1):1-240.
290. Taheri F, Farrokhi M, Fard AM, Rahmani E, Soltani R, Shamsedanesh S, et al. Role of Micronutrients and Nutrition in Prevention and Treatment of Cancers. *Kindle*. 2023;3(1):1-102.
291. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Rabiei S, Farahmandsadr M, et al. Sex and gender differences in the pathogenesis and treatment of diseases. *Kindle*. 2023;3(1):1-168.
292. Farrokhi M, Taheri F, Farrokhi M, Tosi YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. *Kindle*. 2024;4(1):1-196.
293. Motavaselian M, Farrokhi M, Khouzani PJ, Fard AM, Daeizadeh F, Pourrahimi M, et al. Diagnostic performance of ultrasonography for identification of small bowel obstruction; a systematic review and meta-analysis. *Archives of Academic Emergency Medicine*. 2024;12(1):e33.
294. Rahmani E, Amani-Beni R, Hekmatnia Y, Yaseri AF, Ahadiat S-A, Boroujeni PT, et al. Diagnostic accuracy of ultrasonography for detection of intussusception in children; a systematic review and Meta-Analysis. *Archives of*

Academic Emergency Medicine. 2023;11(1):e24.

295. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Khodashenas M, Babaei M, et al. AI-assisted Screening and Prevention Programs for Diseases. *Kindle*. 2023;3(1):1-209.

296. Shayganfar A, Farrokhi M, Shayganfar S, Ebrahimian S. Associations between bone mineral density, trabecular bone score, and body mass index in postmenopausal females. *Osteoporosis and sarcopenia*. 2020;6(3):111-4.

297. Rahmani E, Bayat Z, Farrokhi M, Karimian S, Zahedpasha R, Sabzehie H, et al. Monkeypox: a comprehensive review of virology, epidemiology, transmission, diagnosis, prevention, treatment, and artificial intelligence applications. *Archives of Academic Emergency Medicine*. 2024;12(1):e70.

Proof